




- (51) International Patent Classification:  
A61K 49/10 (2006.01)
- (21) International Application Number:  
PCT/US2012/053813
- (22) International Filing Date:  
5 September 2012 (05.09.2012)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
61/533,198 10 September 2011 (10.09.2011) US
- (71) Applicants (for all designated States except US): **H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.** [US/US]; 12902 Magnolia Drive, Tampa, FL 33612-9497 (US). **ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA** [US/US]; 888N Euclid Avenue, Room 204, Tucson, AZ 85721-0158 (US).
- (72) Inventors; and  
(75) Inventors/Applicants (for US only): **MORSE, David, L.** [US/US]; 14317 Brentwood Drive, Tampa, FL 33618 (US). **GILLIES, Robert, J.** [US/US]; 450 Knights Run Avenue, Tampa, FL 33602 (US). **HUYNH, Amanda** [US/US]; 18030 Glastonbury Lane, Land O Lakes, FL 34638 (US). **VAGNER, Josef** [CZ/US]; 9291 N. Camino Del Fierro, Tucson, AZ 85742 (US).
- (74) Agents: **PABST, Patrea, L.** et al.; Pabst Patent Group LLP, 1545 Peachtree Street, N.E., Suite 320, Atlanta, GA 30309 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,

[Continued on next page]

(54) Title: MOLECULAR IMAGING OF CANCER CELLS IN VIVO

Figure 25



(57) Abstract: Cellular targets on cancer cells have been identified that can be used with targeted molecular imaging to detect the cancer cells *in vivo*. Non-invasive methods for detecting cancer cells, such as metastasized cancer cells, are therefore provided. Also provided are compositions and kits for use in the disclosed methods.

WO 2013/036543 A2



TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**(84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

**Published:**

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*

**MOLECULAR IMAGING OF CANCER CELLS IN VIVO****CROSS REFERENCE TO RELATED APPLICATIONS**

This application claims benefit of U.S. Provisional Application No. 61/533,198,  
5 filed September 10, 2011. U.S. Provisional Application No. 61/533,198, filed September  
10, 2011, is hereby incorporated herein by reference in its entirety.

**STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH**

This invention was made with Government Support under Agreements R01  
CA97360, R01 CA123547, R01 CA103921, and R01 CA136828 awarded by the  
10 National Institutes of Health (NIH). The Government has certain rights in the invention.

**REFERENCE TO SEQUENCE LISTING**

The Sequence Listing submitted September 5, 2012, as a text file named  
“MOF\_11MB064\_PCT\_AMD\_AFD\_Sequence\_Listing.txt,” created on September 5,  
2012, and having a size of 3,273 bytes is hereby incorporated by reference pursuant to 37  
15 C.F.R. § 1.52(e)(5).

**FIELD OF THE INVENTION**

This invention is generally related to cancer screening. More specifically, this  
invention relates to the use of targeted molecular imaging to detect cancer *in vivo*.

**BACKGROUND OF THE INVENTION**

20 Around most small cancers there is an area where microscopic sized cancers cells  
have spread out or migrated. Normally a surgeon tries to remove the tumor with a rim of  
normal tissue so that he is sure of removing these small cells as well. If cancer cells are  
found right up to the edge of the resected tissue, this is referred to as having cancer at the  
margin (or positive margins). Cancer patients have a reduced chance of cancer  
25 recurrence if resection margins are negative. Current techniques to assess surgical  
margins involve post-operative evaluation of pathology specimens collected during  
surgery. If the pathology specimen is positive, additional surgery may be required.  
Therefore, a method to intraoperative assess the resection margin prior to actual resection  
will minimize the chance of a positive microscopic margin and minimize the need for  
30 additional surgery.

In addition, determining the presence or absence of axillary lymph nodal  
metastasis is critical to the pathologic staging, prognostication and guidance of treatment  
in patients with certain cancers, such as breast cancer (Stacker, S.A., et al. *Nat Rev*

*Cancer* 2:573-583 (2002); Tafreshi, N.K., et al. *Cancer Control* 17:143-155 (2010)). The sentinel lymph node (SLN) is the axillary node that first receives drainage from the breast parenchyma in the area of the primary tumor and, therefore has the highest probability of containing metastatic cells. SLNs can be identified by a surgical application referred to as intraoperative lymphatic mapping (ILM or SLN mapping). ILM helps trace the lymphatic drainage patterns in a cancer patient to evaluate potential tumor drainage and cancer spread in lymphatic tissue. The ILM technique does not detect cancer; rather it helps surgeons identify the lymph node(s) to which a tumor is likely to drain and spread. ILM involves peritumoral injection of a radioactive tracing agent to identify SLNs, which are then biopsied for pathological examination (Albertini, J.J., et al. *JAMA* 276:1818-1822 (1996); Giuliano, A.E. et al. *Annals of Surgery* 220:391-401 (1994); Krag, D.N. et al. *Surg Oncol* 2:335-340 (1993)). The sulfur colloid of technetium 99m (<sup>99m</sup>Tc) is a radioactive tracing agent particularly suited for ILM. Moreover, the radioactive tracing agent Lymphoseek® (Tilmanocept) described in U.S. Patent No. 6,409,990 is designed to accumulate in lymphatic tissue by specifically binding to mannose binding receptor (MBR; CD206) proteins that reside on the surface of resident dendritic cells and macrophages. If biopsied SLNs are negative for cancer, then complete axillary lymph node dissection can be avoided (Douglas-Jones, A.G. et al. *Histopathology* 55:107-113 (2009)).

However, a limitation of ILM techniques is the lack of biomarkers for targeting these agents to cancer cells. Instead, such agents distribute non-specifically across SLNs providing only an anatomic and non-functional map (Galanzha, E.I. et al. *J Biophotonics* 2:528-539 (2009); McElroy, M. et al. *J Surg Res* 151:68-73 (2009)). As a result, SLN biopsy is required to identify potential cancer cells. SLN biopsy is an invasive surgical procedure, requiring a multidisciplinary team with specialized imaging and surgical equipment (Douglas-Jones, A.G. et al. *Histopathology* 55:107-113 (2009); Krag, D. et al. *N Engl J Med* 339:941-946 (1998); McMasters, K.M. et al. *J Clin Oncol* 18:2560-2566 (2000); Ung, O.A. et al. *Asian J Surg* 27:284-290 (2004)), and may have postoperative complications, such as lymphedema, seroma formation, sensory nerve injury, and limitation in range of motion (Purushotham, A.D. et al. *J Clin Oncol* 23:4312-4321 (2005)). The majority of breast cancer patients (74%) who undergo SLN biopsy are pathologically negative (Krag, D.N. et al. *Lancet Oncol* 8:881-888 (2007)). Moreover, biopsies fail to identify axillary disease in 5-10% of patients (McMasters, K.M. et al. *J*

*Clin Oncol* 18:2560-2566 (2000); Ung, O.A. et al. *Asian J Surg* 27:284-290 (2004)).

Therefore, a non-invasive method for detecting cancer with improved sensitivity and specificity and eliminating unnecessary surgeries is warranted.

5 It is an object of the invention to provide compositions and methods for non-invasive detection of cancer in a subject.

It is a particular object of the invention to provide compositions and methods for *in vivo* molecular imaging of cancer cells, such as metastatic cancer cells and pancreatic cancer cells, in a subject.

10 It is a further object of the invention to provide compositions and methods for label-guided surgery for cancer.

It is a particular object of the invention to provide compositions and methods for label-guided surgery for pancreatic cancer.

It is a further object of the invention to provide cell-surface markers that can be used to detect cancer cells *in vivo*.

15 It is a particular object of the invention to provide cell-surface markers that can be used to detect pancreatic cancer cells *in vivo*.

### SUMMARY OF THE INVENTION

20 A non-invasive method for detecting cancer cells in a subject *in vivo* has been developed. The method generally involves administering to the subject one or more targeted imaging probes that each specifically binds a cellular target selected from the group consisting of carbonic anhydrase 9 (CAIX), carbonic anhydrase 12 (CA XII), mammaglobin-A, carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), C-X-C motif chemokine 10 (CXCL10), and matrix metalloproteinase 9 (MMP-9). The subject can then be imaged with a molecular imaging device to detect the  
25 targeted imaging probe(s) in the subject. With this method, detection of the targeted imaging probe(s) in an organ or tissue of a subject can be an indication of cancer cells in the organ.

30 The cancer cells can be primary tumors or metastasized cancer cells. Therefore, in some embodiments, the method involves administering targeted imaging probes to a subject diagnosed with a primary tumor to identify metastasized cancer cells. In other embodiments, the method involves administering targeted imaging probes to a subject at risk of cancer to detect primary or occult tumors. Non-limiting examples of cancer cells

that can be detected by the disclosed methods include breast cancer cells and non small-cell carcinoma cells.

In preferred embodiments, the cellular target can be CAIX and CAXII. The combination of these cellular targets has been shown to identify 100% of lymph node metastasis from patients with breast cancer. In these embodiments, the method can  
5 involve administering to the subject a first targeted imaging probe that specifically binds CAIX and a second targeted imaging probe that specifically binds CAXII, wherein detection of either the first targeted imaging probe or the second targeted imaging probe in an organ of a subject is an indication of cancer cells in the organ.

10 Mammaglobin-A has also been shown to identify malignant breast cancer cells in breast and lymph nodes. Therefore, in some embodiments, the cellular target is mammaglobin-A. In these embodiments, the method can involve administering to the subject a targeted imaging probe that specifically binds mammaglobin-A, wherein detection of the targeted imaging probe that specifically binds mammaglobin-A in an  
15 organ of a subject is an indication of breast cancer cells in the organ.

Devices for use in molecular imaging are known in the art and include, for example, devices for magnetic resonance imaging (MRI), optical imaging, computed tomography (CT), and nuclear medicine imaging. Such devices can be used in the disclosed methods. In preferred embodiments, the molecular imaging device is an optical  
20 imaging device that can detect near-infrared light.

In preferred embodiments, the antibodies can be monoclonal antibodies, or fragments thereof that bind the cellular targets. Monoclonal antibodies that specifically bind CAIX, CAXII, mammaglobin-A, CEACAM6, CXCL10, and MMP-9 *in vivo* are known and commercially available. Moreover, additional antibodies suitable for *in vivo*  
25 detection can be produced using routine methods. In some embodiments, the antibodies or antibody fragments can be chimeric, humanized, human, recombinant, etc.

The targeted imaging probe that specifically binds CAIX preferably contains an antibody having the idiotype of monoclonal antibody clone 303123 linked to a detectable label. The targeted imaging probe that specifically binds CAXII preferably contains an  
30 antibody having the idiotype of monoclonal antibody clone 315602 linked to a detectable label. The targeted imaging probe that specifically binds mammaglobin-A preferably contains an antibody having the idiotype of monoclonal antibody clone 304-1A5 or clone 31A5 linked to a detectable label. Therefore, in some embodiments, the targeted imaging

probe contains monoclonal antibody clone 303123, clone 315602, clone 304-1A5, or clone 31A5.

The targeted imaging probe is preferably an antibody linked to a detectable label. Suitable detectable labels can be selected based upon the devices used in molecular  
5 imaging. In preferred embodiments, the detectable label is a near-infrared (NIR) fluorophore for use with optical imaging. Therefore, the method preferably involves, for example, a first antibody having the idiotype of monoclonal antibody clone 303123 linked to a first NIR fluorophore and a second antibody having the idiotype of monoclonal antibody clone 315602 linked to a second NIR fluorophore.

10 Also provided is a composition containing a first antibody having the idiotype of monoclonal antibody clone 303123 linked to a first NIR fluorophore and a second antibody having the idiotype of monoclonal antibody clone 315602 linked to a second NIR fluorophore. The composition can further contain a third antibody having the idiotype of monoclonal antibody clone 304-1A5 or clone 31A5 linked to a third NIR  
15 fluorophore. Therefore, the composition can contain monoclonal antibody clone 303123, clone 315602, clone 304-1A5, clone 31A5, or any combination thereof. The detectable labels on different targeted imaging probes, for example, can be, the same or different, can have the same, similar, or different excitation and/or emission frequencies, or a combination. For example, different targeted imaging probes that specifically bind  
20 different cellular targets can have detectable labels that allow the different targeted imaging probes to be distinguished when imaged, not distinguished when imaged, or a combination (when, for example, three or more targeted imaging probes are used).

A kit is also provided that contains two or more antibodies that specifically bind a cellular target selected from the group consisting of CAIX, CAXII, mammaglobin-A,  
25 CEACAM6, CXCL10, and MMP-9 in two or more containers, wherein at least a first antibody is linked to a first NIR fluorophore and at least a second antibody is linked to a second NIR fluorophore. In preferred embodiments, light in either the absorption or emission spectrum of the first NIR fluorophore does not excite the second NIR fluorophore. At least one of the two or more antibodies is preferably monoclonal  
30 antibody clone 303123, 315602, or a combination thereof. The kit can also contain monoclonal antibody clone 304-1A5 or clone 31A5.

### BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A and 1B are bar graphs showing *CA9* (Fig. 1A) and *CA12* (Fig. 1B) mRNA expression ( $\log_{10}$  of normalized expression) in breast cancer, lymph node positive, breast, lymph node, spleen, lung, heart, kidney, and liver samples. Data are represented as mean  $\pm$  s.d.

Figures 2A and 2B are graphs showing mean surface radiance (photons/sec/cm<sup>2</sup>/steradian) as a function of time (hrs) for CA9Ab-680 (Fig. 2A) and CA12Ab-680 (Fig. 2B) antibodies in positive (●) and negative (■) mammary fat pad (MFP) tumors. Note that the peak signal in the positive Carbonic anhydrases 9 (CAIX) and 12 (CAXII) tumors is 24-hours post-injection, and that the agents are nearly cleared after 8 days. Data represent mean  $\pm$  s.d. Figures 2C and 2D are bar graphs showing biodistribution (relative count) of CA9Ab-680 (Fig. 2C) and CA12Ab-680 (Fig. 2D) in tumors (Fig. 2C) or positive and negative tumors (Fig. 2D), liver, kidney, spleen, heart, lung, stomach, intestine, skin, bladder, brain, and bone 24 hours (solid bars) and 48 hours (open bars) post-injection. The values were normalized as percentage of the highest signal.

Figures 3A and 3B are graphs showing bioluminescence (average radiance (photons/sec/cm<sup>2</sup>/steradian)) of MDA-mb-231 cells expressing CAIX (Fig. 3A) or CAXII (Fig. 3B) four hours after injection into ALN of 6-8 weeks old female *nu/nu* mice as a function of the number of cells injected (1,000,000, 100,000, 10,000, 5,000, 1,000, or 0). Figures 3C and 3D are graphs showing fluorescence (average radiance (photons/sec/cm<sup>2</sup>/steradian)) 24 hours after injection of CA9Ab-680 (Fig. 3C) or CA12Ab-680 (Fig. 3D) into MFP of the mice of Figures 3A and 3B as a function of the number (1,000,000, 100,000, 10,000, 5,000, 1,000, or 0) of MDA-mb-231 cells expressing CAIX or CAXII injected into ALN. All data represent mean  $\pm$  s.d. of pixel values within the ROIs.

Figures 4A to 4D are bar graphs showing *CEACAM6* (Fig. 4A), *CXCL9*, (Fig. 4B), *CXCL10* (Fig. 4C), and *MMP9* (Fig. 4D) mRNA expression (Log 10 of normalized expression) in breast cancer, lymph node positive, breast, lymph node, spleen, lung, heart, kidney, and liver samples. Data are represented as mean  $\pm$  s.d. Note the Log 10 scale.

Figures 5A and 5B are plots showing CAIX (Fig. 5A) and CAXII (Fig. 5B) expression ( $\log_2$  normalized expression) in normal lung (samples 1-60) and adjacent non-small-cell lung cancer (NSCLC) (samples 61-147) samples.

Figure 6 is a bar graph showing *Mammaglobin-A* mRNA expression ( $\log_{10}$  of normalized expression) in breast cancer, lymph node positive, breast, lymph node, spleen, lung, heart, kidney, and liver samples. Data are represented as mean  $\pm$  s.d.

Figure 7A is a graph showing mean surface radiance (photons/sec/cm<sup>2</sup>/steradian) as a function of time (hrs) for Mammaglobin-A antibodies (MamAb-680) in positive (●) and negative (■) mammary fat pad (MFP) tumors. Data represent mean  $\pm$  s.d. Figure 7B is a bar graph showing biodistribution (relative count) of MamAb-680 in Mammaglobin-A positive and negative tumors, stomach, skin, bone, intestine, liver, lung, spleen, bladder, brain, kidney, and heart 24 hours post-injection.

Figures 8A is a graphs showing bioluminescence (average radiance (photons/sec/cm<sup>2</sup>/steradian)) of ZR-75.1/luc cells injection into MFP of ALN estrogen-pelleted mice as a function of the number of cells injected (1,000,000, 100,000, 10,000, 5,000, 1,000, or 0). Figures 8B is a graph showing fluorescence (average radiance photons/sec/cm<sup>2</sup>/steradian) 24 hours after injection of MamAb-680 into MFP of the mice of Figure 8A as a function of the number (1,000,000, 100,000, 10,000, 5,000, 1,000, or 0) of ZR-75.1/luc cells injected into ALN. All data represent mean  $\pm$  s.d. of pixel values within the ROIs.

Figure 9 is a bar graph showing Toll-like receptor 2 (TLR2) activity (luciferase bioluminescence) in HEK293 controls cells (first set of bars) or HEK293/hTLR2 cells (transfected with expression vector (TLR2-NF- $\kappa$ B-luc) containing the luciferase gene under control of an NF- $\kappa$ B activatable promoter) (second set of bars) that were either untreated (open bars) or treated with Pam3CSK4 (solid bars). n = 6, p < 0.001 by t-test.

Figure 10 is a bar graph showing TLR2 activity (luciferase bioluminescence) in HEK293/hTLR2 cells treated with no ligand, control ligand Pam3CSK2 or Pam3CSK4, or one of seven X-Dhp(Pam2)-peptide MALP2 compounds (357, 358, 359, 360, 361, 362, 363). n=3 assays with quadruplicate wells, p value<0.0003

Figure 11 is a bar graph showing TLR2 activity (luciferase bioluminescence) in HEK293/hTLR2 cells treated with no ligand, TNF- $\alpha$ , Pam3CSK4, serum amyloid A (SAA) (1  $\mu$ g/mL), SAA (10  $\mu$ g/ml), or one of three TLR2 agonist analog derived peptide library (T-02, T-03, T-05). n=3 assays with quadruplicate wells, p value<0.001.

Figures 12A-12F are dose-response curves (% response as a function of concentration (Log nm)) generated by measuring the TLR2 agonistic activity of HEK293/hTLR2 cells treated with 359 (Fig. 12A), T-02 (Fig. 12B), T-03 (Fig. 12C), T-05 (Fig. 12D), Pam2CSK4 (Fig. 12E) and Pam3CSK4 (Fig. 12F). Data points represent the mean  $\pm$  SEM, n=6 assays using quadruplicate wells for 359, T-02, T-03, T-05 compounds and n=3 assays using quadruplicate wells for Pam2CSK4 and Pam3CSK4.

Figure 13A is a plot showing antigen-specific CD8 T cells (% cells with Trp1455/9M /H-2Db tetramer staining) in peripheral blood as a function of time (7, 21 and 34 days) in B6 mice (n=3) immunized i.v. with a mixture of Trp1455/9M peptide, anti-CD40 mAb plus one of the following TLR2 agonists: T-02 (●), Pam2CSK4 (◆), or Pam3CSK4 (▲). Figure 13B is a graph showing mean maximum response of antigen-specific CD8 T cells in peripheral blood for up to 34 days post-immunization (n=3).

Figure 14 is the chemical structure of the T-02 compound conjugated to the LiCor IRDye800CW.

Figures 15A, 15B, and 15C show graphs of binding fluorescence and tissue retention. A) Competitive binding assay of T-02 bound with 25 nM  $K_i$ . B) A version of the T-02 conjugated to the LiCor IRDye800CW bound with a comparable 10 nM  $K_i$  affinity. C) The LiCor IRDye800CW/T-02 conjugate was injected into an animal bearing a TLR2 expressing SU.86.86 pancreatic cancer cell xenograft and was shown to be retained in the tumor at 24 h post injection while the agent had cleared from the animal except for the kidneys.

Figures 16A-16D show screening of A) X-Cys(S-[2,3-bis(palmitoyl)oxy-(R)-propyl])-MALP-2 derived peptide library (compounds 1-7) and B) compound analogs (8-10) with an acetylated-PEGOX-Cys(S-[2,3-bis(palmitoyl)oxy-(R)-propyl])-Y for TLR2 agonist activity determined using the functional bioassay. All compounds exhibit high luminescence intensities similar to the TLR2 agonist controls, Pam2CSK4 and Pam3CSK4, using the HEK-293/hTLR2 cells (n=3 assays with quadruplicate wells, p value<0.0003). Dose-response curves generated by measuring the TLR2 agonistic activity for C) compound 10 and D) compound 13. Performed by serially adding (0.001 ng/mL to 10  $\mu$ g/mL) compound to HEK-293/hTLR2 expressing cells (n>3 assays with quadruplicate wells, R2 >0.98).

Figures 17A, 17B, and 17C show mean binding analysis curves generated by *in cyto* TRF binding assays. A) Saturation binding curve shows the specific binding (total –

nonspecific) curve of Eu-DTPA-labeled compound **11** to TLR2 using HEK-293/hTLR2 cells with a  $K_d$  of 34 nM and  $B_{max}$  of 114,271 AFU ( $n=3$  assays,  $R^2$  values  $>0.97$ ). Competition binding analysis, in which increasing concentrations of test compound were added in the presence of 90 nM **11** using HEK-293/hTLR2 cells. B) Compound **10** had a  
5  $K_i$  of 25 nM ( $n=5$  assays,  $R^2=0.90$ ). C) Compound **13** had a  $K_i$  of 11 nM ( $n=4$  assays,  $R^2=0.87$ ).

Figure 18 shows mean maximum response of antigen-specific CD8 T cells in peripheral blood for up to 34 days post-immunization ( $n=3$ ). Results represent the mean and SD (error bars) of three mice per experimental group. B6 mice were immunized i.v.  
10 with a mixture of Trp1455/9M peptide, anti-CD40 monoclonal antibody plus one of the following TLR2 agonists: **10**, Pam<sub>2</sub>CSK<sub>4</sub>, or Pam<sub>3</sub>CSK<sub>4</sub>.

Figure 19 shows comparison of representative fluorescence images of nude mice bearing TLR2-expressing tumor xenografts (SU.86.86 cells) acquired at 24 h, where the unblocked mice were administered 100 nmol/kg **13** and blocked mice were administered  
15 a co-injection of 100 nmol/kg **13** plus 2  $\mu$ mol/kg Pam<sub>2</sub>CSK<sub>4</sub> (20-fold excess). The graphed results show a significant reduction in the *in vivo* fluorescence signal was measured in the blocked tumors compared to the tumors that were not blocked ( $n=8$ ,  $p<0.001$ ), the mean increase in signal (unblocked tumor/ blocked tumor) of **13** in the tumor was 1.94 fold.

Figures 20A-20G show dose-response curves generated by measuring the TLR2 agonistic activity of the following compounds: A) **3**, B) **8**, C) **9**, D) **11**, E) **12** and TLR2 reference controls F) Pam<sub>2</sub>CSK<sub>4</sub> and G) Pam<sub>3</sub>CSK<sub>4</sub>. The TLR2 functional bioassay was performed by serially adding (0.001 ng/mL to 10  $\mu$ g/mL) compound to HEK-293/hTLR2  
20 expressing cells ( $n\geq 3$  assays with quadruplicate wells). The  $EC_{50}$  values are reported in Table 7.  
25

Figures 21A and 21B show saturation binding analysis of Eu-DTPA-labeled compound **11** to TLR2. The saturation binding curves show TLR2 specific binding (total-nonspecific) curves of **11** to TLR2 using the following TLR2-expressing cancer cell lines: A) SU.86.86 with a  $K_d$  of 74 nM and  $B_{max}$  of 269,878 AFU ( $n=3$  assays,  $R^2$   
30 values  $>0.99$ ) and B) Capan-I with a  $K_d$  of 78 nM and  $B_{max}$  of 951,170 AFU ( $n=3$  assays,  $R^2$  values  $>0.96$ ).

Figures 22A-22C show competition binding analysis, in which increasing concentrations of test compound were added in the presence of 90 nM compound **11**

using SU.86.86 cells to determine TLR2 binding activity. A) Compound **10** had a  $K_i$  of 91 nM (n=3 assays,  $R^2=0.95$ ). B) Compound **12** had a  $K_i$  of 25 nM (n=4 assays,  $R^2=0.90$ ). C) Compound **13** had a  $K_i$  of 67 nM (n=4 assays,  $R^2=0.78$ ).

Figure 23 shows structures for the X-MALP-2 peptide derived compounds **1-7**.

5 Figure 24 shows Scheme 1, the synthetic route for Eu-DTPA Ligand **11** and IRDye800CW Ligand **13**. i Fmoc/tBu synthesis continued as follows: a) Fmoc-aa-OH (3eq), HOBt (3eq), DIEA (6eq), and HBTU (3eq) in DMF for amino acid couplings; b) Piperidine/DMF (1:4) for Fmoc deprotection; ii The DTPA was attached as follows: a) DTPA anhydride (3 eq) and HOBt (3 eq) were dissolved in dry DMSO (0.5M), heated to 10 60oC for 3 minutes then stirred at room temperature for 30 min, b) preformed DTPA-OBt diester mixture reacts with the resin overnight; iii TFA-scavengers cocktail (90% trifluoroacetic acid, 5% water, 5% triisopropylsilane) for 2 hrs; iv Eu(III)Cl<sub>3</sub> (3.0 eq.) in 0.1 ammonium acetate buffer pH 8.0 overnight; vi. IRDye800CW maleimide (1 eq) in DMF.

15 Figure 25 shows the structure of compound **13**, IRDye800CW-Mpr- PEGO-Cys(S-[2,3-bis(palmitoyl)oxy-(R)-propyl])-Gly-DSer-PEGO-NH<sub>2</sub> (T-02).

## DETAILED DESCRIPTION OF THE INVENTION

### I. Definitions

20 The term “targeted molecular imaging” refers to the *in vivo* detection of a biological process, such as biodistribution, at the cellular and molecular level. The *in vivo* detection is accomplished using a targeted imaging probe that specifically binds a molecular or cellular target and an imaging device that detects the probe *in vivo*.

The term “targeted imaging probe” refers to a molecule that specifically binds to 25 a molecular or cellular target *in vivo* that can be detected using *in vivo* imaging techniques. Detection is generally accomplished by linking the binding molecule to a detectable label. Preferred binding molecules include antibodies, peptides, peptidomimetics, and small molecules.

The term “antibody” refers to a polyclonal, monoclonal, recombinant, or 30 synthetic immunoglobulin molecule that specifically binds a target antigen. The term includes intact immunoglobulin molecules, fragments or polymers of those immunoglobulin molecules, chimeric antibodies containing sequences from more than one species, class, or subclass of immunoglobulin, and human or humanized versions of

immunoglobulin molecules or fragments thereof containing a least the idiotype of an immunoglobulin that specifically binds the target antigen.

The term “idiotype” refers to the portion of an immunoglobulin molecule that confers the molecule’s ability to bind an antigen. The idiotype of an antibody is  
5 determined by the complementarity determining regions (CDRs) of the immunoglobulin variable domains ( $V_L$  and  $V_H$ ).

The term “peptide” can be used to refer to a natural or synthetic molecule comprising two or more amino acids linked by the carboxyl group of one amino acid to the alpha amino group of another. The peptide is not limited by length; thus “peptide”  
10 can include polypeptides and proteins.

The term “peptidomimetic” refers to a mimetic of a peptide which includes some alteration of the normal peptide chemistry. Peptidomimetics typically enhance some property of the original peptide, such as increase stability, increased efficacy, enhanced delivery, increased half life, etc.

The term “aptamer” refers to oligonucleic acid molecules that specifically bind to  
15 a target molecule.

As used herein, the term “small molecule” refers to a compound having a molecular weight of less than 1000 Daltons, and typically between 300 and 700 Daltons. The term may include monomers or primary metabolites, secondary metabolites, a  
20 biological amine, a steroid, or synthetic or natural, non-peptide biological molecule(s). In the context of targeted imaging probes that are small molecules, the small molecule can specifically bind the molecular or cellular target.

The term “specifically binds” refers to the binding of a molecule to a target molecule, such as an antibody to its cognate antigen, while not significantly binding to  
25 other molecules. Preferably, a molecule “specifically binds” to a target molecule with an affinity constant ( $K_a$ ) greater than about  $10^5 \text{ mol}^{-1}$  (e.g.,  $10^6 \text{ mol}^{-1}$ ,  $10^7 \text{ mol}^{-1}$ ,  $10^8 \text{ mol}^{-1}$ ,  $10^9 \text{ mol}^{-1}$ ,  $10^{10} \text{ mol}^{-1}$ ,  $10^{11} \text{ mol}^{-1}$ , and  $10^{12} \text{ mol}^{-1}$  or more) with the target molecule.

The term “neoplasm” refers to a cell undergoing abnormal cell proliferation. The growth of neoplastic cells exceeds and is not coordinated with that of the normal tissues  
30 around it. The growth typically persists in the same excessive manner even after cessation of the stimuli, and typically causes formation of a tumor. Neoplasms may be benign, premalignant, or malignant.

The term “cancer” or “malignant neoplasm” refers to a cell that displays uncontrolled growth, invasion upon adjacent tissues, and often metastasizes to other locations of the body.

The term “metastatic” or “metastasized” refer to cancer cells that have spread  
5 from the site of origin (primary site) to a distant location (metastatic site) in the body.

The term “occult tumor” refers to metastasized cancer cells with unknown primary origin.

The term “subject” or “patient” refers to any individual who is the target of administration. The subject can be a vertebrate, for example, a mammal. Thus, the  
10 subject can be a human. The subject can be domesticated, agricultural, or zoo- or circus-maintained animals. Domesticated animals include, for example, dogs, cats, rabbits, ferrets, guinea pigs, hamsters, pigs, monkeys or other primates, and gerbils. Agricultural animals include, for example, horses, mules, donkeys, burros, cattle, cows, pigs, sheep, and alligators. Zoo- or circus-maintained animals include, for example, lions, tigers,  
15 bears, camels, giraffes, hippopotamuses, and rhinoceroses. The term does not denote a particular age or sex.

The term “effective amount” refers to an amount of targeted imaging probes sufficient for *in vivo* detection of the probes in an organ or a tissue by an imaging device. The exact amount required will vary from subject to subject, depending on the age, and  
20 general condition of the subject, the organ or tissue that is being imaged, the particular probes used, and its mode of administration. An appropriate “effective amount” can be determined by one of ordinary skill in the art using only routine experimentation.

The term “detectable label” as used herein refers to any molecule that can be detected by *in vivo* imaging techniques, such as a fluorescent molecule, a metal (e.g.,  
25 gold), or a radioactive isotope.

The term “near-infrared (NIR) fluorophore” refers to a molecule that has an absorption and emission wavelength in the NIR spectrum between 680 and 900 nm. NIR molecular probes work in a preferential wave range for *in vivo* fluorescence imaging called “biological window.” These molecules can be detected deeper while minimizing  
30 the absorption of the fluorescence by tissues.

The terms “label-guided surgery,” “fluorescent-guided surgery,” and the like, refer to surgery where the location of relevant tissue and/or cells is marked by a label, such a fluorescent label, where the label is visible during surgery (this is intraoperative

imaging). Label-guided surgery where the label is visualized via an image of tissue and/or cells can be referred to as image-guided-surgery.

## II. Compositions

### A. Targeted Imaging Probes

5 Targeted imaging probes for detecting cancer cells are provided that specifically bind cellular targets on cancer cells *in vivo*. In general, the cellular targets can be proteins exposed on the surface of cancer cells and the imaging probes are able to access and bind these targets *in vivo*. The disclosed targeted imaging probes preferably do not bind normal (non-cancerous) tissue. In some embodiments, the targeted imaging probes bind  
10 metastasized cancer cells or cells about to undergo metastasis from the primary tumor.

Probes that specifically bind carbonic anhydrase 9 (CAIX), carbonic anhydrase 12 (CAXII), mammaglobin-A, carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), C-X-C motif chemokine 10 (CXCL10), and matrix metalloproteinase 9 (MMP-9) *in vivo* are disclosed for use in detecting cancer cells, such as metastasized  
15 cancer cells. Targeted imaging probes preferably bind the cellular targets in regions that are accessible from the circulation (e.g., blood or lymph) *in vivo*.

Targeted imaging probes specifically binding CAIX and CAXII are preferably used together to detect cancer cells expressing either or both of these proteins. These probes can also be used in combination with other tissue specific probes to enhance  
20 specificity. For example, CAIX and CAXII probes are preferably used in combination with probes that specifically bind mammaglobin-A to detect metastasized breast cancer cells.

Probes that specifically bind Toll-like receptor 2 (TLR2) *in vivo* are disclosed for use in detecting cancer cells, such as pancreatic cancer, pancreatic cancer cells, and  
25 metastasized pancreatic cancer cells.

In some embodiments, the disclosed targeted imaging probes are used in combination with other targeting agents, such as other cancer-specific targeting imaging probes. As an example, a targeting agent that specifically binds tumor-associated glycoprotein-72 (TAG-72) is disclosed for use in combination with the disclosed targeted  
30 imaging probes. TAG-72 is a glycoprotein found on the surface of many cancer cells, including breast, colon, and pancreatic cells. Murine monoclonal antibody (CC49 MAb, Minretumomab) specifically binds TAG-72 and has strong reactivity with both LS-174T colon cancer extract and to a breast cancer extract.

The targeted imaging probes generally can contain a cellular target binding domain and a detectable label. The cellular target binding domain and detectable label can be linked using routine methods.

In some embodiments, the cellular target binding domain and detectable label can be chemically crosslinked using protein cross-linking agents. Commercially available labels, such as fluorophores generally contain crossing linking agents (such as a succinimidyl ester) for conjugation to proteins, such as antibodies. Non-limiting examples of suitable protein crosslinkers include DSS (Disuccinimidylsuberate), DSP (Dithiobis(succinimidylpropionate)), DTSSP (3,3'-Dithiobis(sulfosuccinimidylpropionate)), SULFO BSO COES (Bis[2-(sulfosuccinimidocarbonyloxy) ethyl]sulfone), BSO COES (Bis[2-(succinimidocarbonyloxy)ethyl]sulfone), SULFO DST (Disulfosuccinimidyltartrate), DST (Disuccinimidyltartrate), SULFO EGS (Ethylene glycolbis(succinimidylsuccinate)), EGS (Ethylene glycolbis(sulfosuccinimidylsuccinate)), DPDPB (1,2-Di[3'-(2'-pyridyldithio) propionamido]butane), BSSS (Bis(sulfosuccinimidyl) suberate), SMPB (Succinimidyl-4-(p-maleimidophenyl) butyrate), SULFO SMPB (Sulfosuccinimidyl-4-(p-maleimidophenyl) butyrate), MBS (3-Maleimidobenzoyl-N-hydroxysuccinimide ester), SULFO MBS (3-Maleimidobenzoyl-N-hydroxysulfosuccinimide ester), SIAB (N-Succinimidyl(4-iodoacetyl) aminobenzoate), SULFO SIAB (N-Sulfosuccinimidyl(4-iodoacetyl)aminobenzoate), SMCC (Succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate), SULFO SMCC (Sulfosuccinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate), NHS LC SPDP (Succinimidyl-6-[3-(2-pyridyldithio) propionamido] hexanoate), SULFO NHS LC SPDP (Sulfosuccinimidyl-6-[3-(2-pyridyldithio) propionamido] hexanoate), SPDP (N-Succinimidyl-3-(2-pyridyldithio) propionate), NHS BROMOACETATE (N-Hydroxysuccinimidylbromoacetate), NHS IODOACETATE (N-Hydroxysuccinimidyliodoacetate), MPBH (4-(N-Maleimidophenyl) butyric acid hydrazide hydrochloride), MCCH (4-(N-Maleimidomethyl) cyclohexane-1-carboxylic acid hydrazide hydrochloride), MBH (m-Maleimidobenzoic acid hydrazide hydrochloride), SULFO EMCS (N-(epsilon-Maleimidocaproyloxy) sulfosuccinimide), EMCS (N-(epsilon-Maleimidocaproyloxy) succinimide), PMPI (N-(p-Maleimidophenyl) isocyanate), KMUH (N-(kappa-Maleimidoundecanoic acid) hydrazide), LC SMCC (Succinimidyl-4-(N-maleimidomethyl)-cyclohexane-1-carboxy(6-amidocaproate)), SULFO GMBS (N-

(gamma-Maleimidobutyryloxy) sulfosuccinimide ester), SMPH (Succinimidyl-6-(beta-maleimidopropionamidohexanoate)), SULFO KMUS (N-(kappa-Maleimidoundecanoyloxy)sulfosuccinimide ester), GMBS (N-(gamma-Maleimidobutyryloxy) succinimide), DMP (Dimethylpimelimidate hydrochloride), DMS  
5 (Dimethylsuberimidate hydrochloride), MHBH(Wood's Reagent) (Methyl-p-hydroxybenzimidate hydrochloride, 98%), and DMA (Dimethyladipimidate hydrochloride).

In other embodiments, the targeted imaging probe can be a fusion peptide or protein containing the cellular target binding domain and a detectable label. Fusion are  
10 proteins created through the joining of two or more genes or coding regions that originally coded (and/or were designed to code for) for separate peptides or proteins. Translation of this fusion gene or coding region results in a single peptide or polypeptide with functional properties derived from each of the original peptide or proteins. Recombinant fusion peptide or proteins can be created artificially by recombinant DNA  
15 technology. This typically involves removing the stop codon from a cDNA sequence coding for the first peptide or protein, then appending the cDNA sequence of the second peptide or protein in frame through ligation or overlap extension PCR. Alternatively, the coding regions can be synthesized and then joined or can even be synthesized as a fusion coding region. The resulting fusion DNA sequence can then be expressed by a cell as a  
20 single peptide or protein. The protein can be engineered to include the full sequence of both original peptides or proteins, or only a portion of either. If the two entities are proteins, often linker (or "spacer") peptides can also be added that make it more likely that the proteins fold independently and behave as expected. Alternatively, internal ribosome entry sites (IRES) elements can be used to create multigene, or polycistronic,  
25 messages. IRES elements are able to bypass the ribosome scanning model of 5' methylated Cap dependent translation and begin translation at internal sites. Multiple open reading frames can be transcribed together, each separated by an IRES, creating polycistronic messages. By virtue of the IRES element, each open reading frame is accessible to ribosomes for efficient translation. IRES sequences are known in the art and include those from encephalomyocarditis virus (EMCV) (Ghattas, I. R. et al., Mol.  
30 Cell. Biol., 11:5848-5849 (1991); BiP protein (Macejak and Sarnow, Nature, 353:91 (1991)); the Antennapedia gene of drosophila (exons d and e) [Oh et al., Genes & Development, 6:1643-1653 (1992)]; those in polio virus [Pelletier and Sonenberg,

Nature, 334:320325 (1988); see also Mountford and Smith, TIG, 11:179-184 (1985)). Numerous other recombinant and fusion techniques are known and can be adapted for producing the disclosed peptides and proteins.

Also disclosed are compositions including a first antibody comprising the  
5 idiotype of monoclonal antibody clone 303123 linked to a first near-infrared (NIR) fluorophore and a second antibody comprising the idiotype of monoclonal antibody clone 315602 linked to a second NIR fluorophore.

The composition can further include a third antibody comprising the idiotype of monoclonal antibody clone 304-1A5 or clone 31A5 linked to a third NIR fluorophore.  
10 The first antibody can consists essentially of monoclonal antibody clone 303123. The second antibody can consists essentially of monoclonal antibody clone 315602. The third antibody can consists essentially of monoclonal antibody clone 304-1A5 or clone 31A5.

## 1. Cellular Target Binding Domain

### 15 a. Antibodies

In preferred embodiments, the targeted imaging probes are antibodies that specifically bind the cellular targets. Therefore, antibodies that specifically bind CAIX, CAXII, mammaglobin-A, CEACAM6, CXCL10, and MMP-9 are disclosed for use in the disclosed compositions and methods.

20 The anti-CAIX antibody preferably specifically binds human CAIX protein (Accession No. NP\_001207). In some embodiments, the anti-CAIX antibody specifically binds the N-terminus and the extracellular domain of human CAIX. In particularly preferred embodiments, the anti-CAIX antibody specifically binds amino acids 59 – 414 of human CAIX protein. As an example, the anti-CAIX antibody can be the monoclonal  
25 antibody (mAb) clone 303123 (R&D systems) or can have the idiotype of this clone. In addition, suitable anti-CAIX antibody can be identified that bind the same epitope as this clone.

The anti-CAXII antibody preferably specifically binds human CAXII protein (Accession No. NP\_001209). In some embodiments, the anti-CAXII antibody  
30 specifically binds the N-terminus and the extracellular domain of human CAXII. In particularly preferred embodiments, the anti-CAXII antibody specifically binds amino acids 25 – 291 of human CAXII protein. As an example, the anti-CAXII antibody can be the monoclonal antibody (mAb) clone 315602 (R&D systems) or can have the idiotype

of this clone. In addition, suitable anti-CAXII antibody can be identified that bind the same epitope as this clone.

The anti-Mammaglobin-A antibody preferably specifically binds human Mammaglobin-A (Accession No. NP\_002402.1). As an example, the anti-  
5 Mammaglobin-A antibody can be the monoclonal antibody (mAb) clone 304-1A5 or 31A5 (Zeta Corp., California, Sierra Madre) or can have the idiotype of one of these clones. In addition, suitable anti-Mammaglobin-A antibody can be identified that bind the same epitope as this clone.

Antibodies that can be used in the disclosed compositions and methods include  
10 whole immunoglobulin (i.e., an intact antibody) of any class, fragments thereof, and synthetic proteins containing at least the antigen binding variable domain of an antibody. The variable domains differ in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen. However, the variability is not usually evenly distributed through the variable domains of antibodies. It  
15 is typically concentrated in three segments called complementarity determining regions (CDRs) or hypervariable regions both in the light chain and the heavy chain variable domains. The more highly conserved portions of the variable domains are called the framework (FR). The variable domains of native heavy and light chains each comprise four FR regions, largely adopting a beta-sheet configuration, connected by three CDRs,  
20 which form loops connecting, and in some cases forming part of, the beta-sheet structure. The CDRs in each chain are held together in close proximity by the FR regions and, with the CDRs from the other chain, contribute to the formation of the antigen binding site of antibodies.

Antibodies for use in the disclosed compositions and methods can be of any  
25 isotype, including IgG, IgA, IgE, IgD, and IgM. IgG isotype antibodies can be further subdivided into IgG1, IgG2, IgG3, and IgG4 subtypes. IgA antibodies can be further subdivided into IgA1 and IgA2 subtypes.

Also disclosed are fragments of antibodies which have bioactivity. The  
fragments, whether attached to other sequences or not, include insertions, deletions,  
30 substitutions, or other selected modifications of particular regions or specific amino acids residues, provided the activity of the fragment is not significantly altered or impaired compared to the nonmodified antibody or antibody fragment. Fab is the fragment of an antibody that contains a monovalent antigen-binding fragment of an antibody molecule.

A Fab fragment can be produced by digestion of whole antibody with the enzyme papain to yield an intact light chain and a portion of one heavy chain. Fab' is the fragment of an antibody molecule can be obtained by treating whole antibody with pepsin, followed by reduction, to yield an intact light chain and a portion of the heavy chain. Two Fab' fragments are obtained per antibody molecule. Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxyl terminus of the heavy chain CH1 domain including one or more cysteines from the antibody hinge region. (Fab')<sub>2</sub> is the fragment of an antibody that can be obtained by treating whole antibody with the enzyme pepsin without subsequent reduction. F(ab')<sub>2</sub> is a dimer of two Fab' fragments held together by two disulfide bonds. Fv is the minimum antibody fragment that contains a complete antigen recognition and binding site. This region consists of a dimer of one heavy and one light chain variable domain in a tight, non-covalent association (V<sub>H</sub>-V<sub>L</sub> dimer). It is in this configuration that the three CDRs of each variable domain interact to define an antigen-binding site on the surface of the V<sub>H</sub>-V<sub>L</sub> dimer. Collectively, the six CDRs confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.

Techniques can also be adapted for the production of single-chain antibodies specific for the cellular targets. Single chain antibody ("SCA"), defined as a genetically engineered molecule containing the variable region of the light chain (V<sub>L</sub>), the variable region of the heavy chain (V<sub>H</sub>), linked by a suitable polypeptide linker as a genetically fused single chain molecule. Such single chain antibodies are also referred to as "single-chain Fv" or "sFv" antibody fragments. Generally, the Fv polypeptide further comprises a polypeptide linker between the V<sub>H</sub> and V<sub>L</sub> domains that enables the sFv to form the desired structure for antigen binding. Methods for the production of single-chain antibodies are well known to those of skill in the art. A single chain antibody can be created by fusing together the variable domains of the heavy and light chains using a short peptide linker, thereby reconstituting an antigen binding site on a single molecule. Single-chain antibody variable fragments (scFvs) in which the C-terminus of one variable domain is tethered to the N-terminus of the other variable domain via a 15 to 25 amino acid peptide or linker have been developed without significantly disrupting

antigen binding or specificity of the binding. The linker is chosen to permit the heavy chain and light chain to bind together in their proper conformational orientation.

Divalent single-chain variable fragments (di-scFvs) can be engineered by linking two scFvs. This can be done by producing a single peptide chain with two V<sub>H</sub> and two V<sub>L</sub> regions, yielding tandem scFvs. ScFvs can also be designed with linker peptides that are too short for the two variable regions to fold together (about five amino acids), forcing scFvs to dimerize. This type is known as diabodies. Diabodies have been shown to have dissociation constants up to 40-fold lower than corresponding scFvs, meaning that they have a much higher affinity to their target. Still shorter linkers (one or two amino acids) lead to the formation of trimers (triabodies or tribodies). Tetrabodies have also been produced. They exhibit an even higher affinity to their targets than diabodies.

Preferably, if the antibody is to be administered to humans, the antibody is a human antibody or is a “humanized” antibody derived from a non-human animal. Methods for humanizing non-human antibodies are known in the art and have been described in, for example, U.S. Patent Nos. 5,530,101; 5,585,089; 5,693,762; 6,180,370; and 6,407,213.

*b. Peptides*

In some embodiments, the targeted imaging probe can contain a peptide that binds the cellular target CAIX, CAXII, mammaglobin-A, CEACAM6, CXCL10, or MMP-9. In some embodiments, the peptide comprises the idiotype of an antibody, such as those described above. In other embodiments, the peptide can be identified by screening a library of peptides against the cellular target.

*c. Peptidomimetics*

In some embodiments, the targeted imaging probe can contain a peptidomimetic that binds CAIX, CAXII, mammaglobin-A, CEACAM6, CXCL10, or MMP-9. A peptidomimetic is a small protein-like chain designed to mimic a peptide. They typically arise either from modification of an existing peptide, or by designing similar systems that mimic peptides, such as peptoids and  $\beta$ -peptides. Irrespective of the approach, the altered chemical structure is designed to advantageously adjust the molecular properties such as, stability or biological activity. This can have a role in the development of drug-like compounds from existing peptides. These modifications involve changes to the peptide that will not occur naturally (such as altered backbones and the incorporation of nonnatural amino acids).

Methods of making peptidomimetics based upon a known polypeptide sequence is described, for example, in U.S. Patent Nos. 5,631,280; 5,612,895; and 5,579,250. Peptidomimetics can have a non-amino acid residue with non-amide linkages at a given position. Some non-limiting examples of unnatural amino acids which may be suitable amino acid mimics include  $\beta$ -alanine, L- $\alpha$ -amino butyric acid, L- $\gamma$ -amino butyric acid, L- $\alpha$ -amino isobutyric acid, L- $\epsilon$ -amino caproic acid, 7-amino heptanoic acid, L-aspartic acid, L-glutamic acid, N- $\epsilon$ -Boc-N- $\alpha$ -CBZ-L-lysine, N- $\epsilon$ -Boc-N- $\alpha$ -Fmoc-L-lysine, L-methionine sulfone, L-norleucine, L-norvaline, N- $\alpha$ -Boc-N- $\delta$ CBZ-L-ornithine, N- $\delta$ -Boc-N- $\alpha$ -CBZ-L-ornithine, Boc-p-nitro-L-phenylalanine, Boc-hydroxyproline, and Boc-L-thioprolin

*d. Aptamers*

In some embodiments, the targeted imaging probe can contain an aptamer that binds CAIX, CAXII, mammaglobin-A, CEACAM6, CXCL10, or MMP-9. Aptamers are single-stranded RNA or DNA oligonucleotides 15 to 60 base in length that bind with high affinity to specific molecular targets. Most aptamers to proteins bind with Kds (equilibrium constant) in the range of 1 pM to 1 nM, similar to monoclonal antibodies. These nucleic acid ligands bind to nucleic acid, proteins, small organic compounds, and even entire organisms.

Aptamers can be selected by incubating the target molecule in a large (e.g., 1010 to 1020) pool of oligonucleotide (usually 40 to 60mers). The large pool size of the oligonucleotide ensures the selection and isolation of the specific aptamer. Aptamers can distinguish between closely related but non-identical members of a protein family, or between different functional or conformational states of the same protein. The protocol called systematic evolution of ligands by exponential enrichment (SELEX) is generally used with modification and variations for the selection of specific aptamers. Using this process, it is possible to develop new aptamers in as little as two weeks.

*e. Sulfonamide-based Inhibitors*


In some embodiments, the targeted imaging probe can contain a carbonic anhydrase inhibitor that binds CAIX and/or CAXII. Carbonic anhydrase inhibitors are a class of pharmaceuticals that suppress the activity of carbonic anhydrase by binding to its catalytic site. Suitable carbonic anhydrase inhibitors generally contain a sulfonamide group. Non-limiting examples of carbonic anhydrase inhibitors include Acetazolamide, Brinzolamide, Methazolamide, Dorzolamide, and Topiramate.

*f. Natural Ligands and Synthetic Analogues*


In some embodiments, the targeted imaging probe can contain a natural ligand of the cellular targets on cancer cells, or a fragment or analogue thereof.

For example, Toll-like receptor 2 (TLR2) recognizes cell-wall components such as peptidoglycan, lipoteichoic acid and lipoprotein from gram-positive bacteria, lipoarabinomannan from mycobacteria, and zymosan from yeast cell wall. Therefore, in some embodiments, the natural ligand is a cell-wall component of a microorganism, such as bacteria or yeast.

In other embodiments, the targeted imaging probe contains a synthetic analogue of a natural ligand. For example, synthetic diacylated lipoprotein corresponding to N-terminal partial structures of bacterial lipoproteins have also been developed that bind TLR2. In some embodiments, the targeted imaging probe contains the TLR2 ligand dipalmitoyl-S-glycerol-L-Cys-Ser-(Lys)<sub>4</sub> (Pam<sub>2</sub>CSK<sub>4</sub>), which has the following structure:




In some embodiments, the targeted imaging probe contains the TLR2 ligand tripalmitoyl-S-glycerol-L-Cys-Ser-Lys-Lys-Lys-Lys (Pam<sub>3</sub>CSK<sub>4</sub>), which has the following structure:



In some embodiments, the targeted imaging probe contains the lipolanthionine peptide (2R,6R)-Pam<sub>2</sub>LanHda-Ser-(Lys)<sub>4</sub>-NH<sub>2</sub> (lipolan).

5 In some embodiments, the targeted imaging probe contains MALP-2, which is a diacylated lipopeptide isolated from *Mycoplasma Fermentans*.


In some embodiments, the targeted imaging probe contains a cellular target binding domain having the formula:



10 where "X" represents the addition of: Palmitoyl, Fluorescein, Ac-PEGO20, Ac-Aha, Adapaleneyl, Ac-Aun, or Tretinoyl. Ac = acetyl; Dhc = 1,2-dihydroxypropylcysteine; Aha = epsilon-aminohexanoic acid; Aun = epsilon-aminoundecanoic acid; PEGO20 = 20 atoms long polyethelene glycol (4 Peg units); Pam<sub>2</sub> = dipalmitoyl-S-glyceryl; Pam<sub>3</sub> = tripalmitoyl-S-glyceryl.

15 In some embodiments, the targeted imaging probe contains a PEGO group. For example, the TLR2 agonist analog T-02 (Ac-PEGO-Dhc (Pam)<sub>2</sub>-Gly-Ser-PEGO-NH<sub>2</sub>) was derived from synthetic origin based on the scaffold of MALP2 with manipulation of N terminal PEGO (see Figure 14 for the structure of T-02 labeled with Licor IR® 800CW Maleimide dye). T-03 (Ac-PEGO-Dhc(Pam)<sub>2</sub>-Ser-Arg-Phe-Asp-Glu-Asp-Asp-  
20 Leu-Glu-NH<sub>2</sub>, SEQ ID NO:5) was derived from CD14 peptide origin manipulation of N-terminal PEGO. T-05 (Ac-PEGO-Dhc(Pam)<sub>2</sub>-Gly-Ser-Gln-Asn-Leu-Ala-Ser-Leu-Glu-Glu-NH<sub>2</sub>, SEQ ID NO:6) was derived from *S. aureus* peptide origin.

In some embodiments, the targeted imaging probe can have the structure



where  $R_1$  is  $-\text{CO}-R_6$  or H, wherein  $R_6$  is  $C_{12}$  to  $C_{18}$  alkyl or alkenyl;

where  $R_2$  is  $-\text{CH}_2-\text{O}-\text{CO}-R_7$ ,  $-\text{CH}_2-\text{OH}$ , or  $-\text{H}$ , wherein  $R_7$  is any  $C_{12}$  to  $C_{18}$  alkyl, alkenyl, amine, alkyl amine, alkenyl amine, alkyl ether, polyether, wherein  $R_7$  is  
 5 optionally substituted with one or more functional group(s) selected from the group consisting of alkyl, alkenyl, ether, polyether, or alkyl amine;

where  $R_3$  is  $R_8$ -label, wherein  $R_8$  is acetyl-PEGO- (Ac-PEGO), palmitoyl-, fluorescein-, acetyl-6-aminohexanoyl- (Ac-Aha), adapalenoil-, acetyl-11-aminoundecanoyl- (Ac-Aun), or tretinoyl-;

10 where  $R_4$  is  $-\text{Gly}-\text{D}\text{Ser}-\text{PEGO}-\text{NH}_2$ ,  $-\text{Gly}-\text{D}\text{Ser}-\text{NH}_2$ ,  $-\text{Cys}-\text{Ser}-(\text{Lys})_4-\text{NH}_2$ ,  $-\text{Gly}-\text{Asn}-\text{Asn}-\text{Asp}-\text{Glu}-\text{Ser}-\text{Asn}-\text{Ile}-\text{Ser}-\text{Phe}-\text{Lys}-\text{Glu}-\text{Lys}-\text{NH}_2$ ,  $-\text{Ser}-\text{Arg}-\text{Phe}-\text{Asp}-\text{Glu}-\text{Asp}-\text{Asp}-\text{Leu}-\text{Glu}-\text{NH}_2$ ,  $-\text{Gly}-\text{Ser}-\text{Gln}-\text{Asn}-\text{Leu}-\text{Ala}-\text{Ser}-\text{Leu}-\text{Glu}-\text{Glu}-\text{NH}_2$ , or  $-\text{serine methyl ester}$ ; and

where  $R_5$  is  $-\text{S}-$  or  $-\text{Se}-$ .

15 In some embodiments, if  $R_1$  is H, then  $R_2$  is  $-\text{CH}_2-\text{O}-\text{CO}-R_7$  wherein  $R_7$  is any  $C_{12}$  to  $C_{18}$  alkyl or alkenyl.

In some embodiments,  $R_1$  can be  $-\text{CO}-R_6$ , wherein  $R_6$  is  $C_{12}$  to  $C_{18}$  alkyl;  $R_2$  can be  $-\text{CH}_2-\text{O}-\text{CO}-R_7$ , wherein  $R_7$  is any  $C_{12}$  to  $C_{18}$  alkyl;  $R_3$  can be  $R_8$ -label, wherein  $R_8$  is acetyl-PEGO- (Ac-PEGO), palmitoyl-, fluorescein-, acetyl-6-aminohexanoyl- (Ac-Aha),  
 20 adapalenoil-, acetyl-11-aminoundecanoyl- (Ac-Aun), or tretinoyl-;  $R_4$  can be  $-\text{Gly}-\text{D}\text{Ser}-\text{PEGO}-\text{NH}_2$ ,  $-\text{Gly}-\text{D}\text{Ser}-\text{NH}_2$ ,  $-\text{Cys}-\text{Ser}-(\text{Lys})_4-\text{NH}_2$ ,  $-\text{Gly}-\text{Asn}-\text{Asn}-\text{Asp}-\text{Glu}-\text{Ser}-\text{Asn}-\text{Ile}-\text{Ser}-\text{Phe}-\text{Lys}-\text{Glu}-\text{Lys}-\text{NH}_2$ ,  $-\text{Ser}-\text{Arg}-\text{Phe}-\text{Asp}-\text{Glu}-\text{Asp}-\text{Asp}-\text{Leu}-\text{Glu}-\text{NH}_2$ ,  $-\text{Gly}-\text{Ser}-\text{Gln}-\text{Asn}-\text{Leu}-\text{Ala}-\text{Ser}-\text{Leu}-\text{Glu}-\text{Glu}-\text{NH}_2$ , or  $-\text{serine methyl ester}$ ; and  $R_5$  can be  $-\text{S}-$ .

## 25 2. Detectable Labels

The disclosed targeted imaging probes are preferably linked to a detectable label. Substances suitable for detectably labeling imaging agents include fluorescent molecules (a.k.a. fluorochromes and fluorophores), chemiluminescent reagents (e.g., luminol), bioluminescent reagents (e.g., luciferin and green fluorescent protein (GFP)), metals  
 30 (e.g., gold nanoparticles), and radioactive isotopes (radioisotopes). Suitable detectable



a reconstitution medium; emulsions, such as water-in-oil (w/o) emulsions, oil-in-water (o/w) emulsions, and microemulsions thereof, liposomes, or emulsomes.

The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, one or more polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), oils, such as vegetable oils (e.g., peanut oil, corn oil, sesame oil, etc.), and combinations thereof.

Solutions and dispersions of the active compounds as the free acid or base or pharmacologically acceptable salts thereof can be prepared in water or another solvent or dispersing medium suitably mixed with one or more pharmaceutically acceptable excipients including, but not limited to, surfactants, dispersants, emulsifiers, pH modifying agents, and combination thereof.

Suitable surfactants may be anionic, cationic, amphoteric or nonionic surface active agents. Suitable anionic surfactants include, but are not limited to, those containing carboxylate, sulfonate and sulfate ions. Examples of anionic surfactants include sodium, potassium, ammonium of long chain alkyl sulfonates and alkyl aryl sulfonates such as sodium dodecylbenzene sulfonate; dialkyl sodium sulfosuccinates, such as sodium dodecylbenzene sulfonate; dialkyl sodium sulfosuccinates, such as sodium bis-(2-ethylthioxyl)-sulfosuccinate; and alkyl sulfates such as sodium lauryl sulfate. Cationic surfactants include, but are not limited to, quaternary ammonium compounds such as benzalkonium chloride, benzethonium chloride, cetrimonium bromide, stearyl dimethylbenzyl ammonium chloride, polyoxyethylene and coconut amine. Examples of nonionic surfactants include ethylene glycol monostearate, propylene glycol myristate, glyceryl monostearate, glyceryl stearate, polyglyceryl-4-oleate, sorbitan acylate, sucrose acylate, PEG-150 laurate, PEG-400 monolaurate, polyoxyethylene monolaurate, polysorbates, polyoxyethylene octylphenylether, PEG-1000 cetyl ether, polyoxyethylene tridecyl ether, polypropylene glycol butyl ether, Poloxamer<sup>®</sup> 401, stearyl monoisopropanolamide, and polyoxyethylene hydrogenated tallow amide. Examples of amphoteric surfactants include sodium N-dodecyl- $\beta$ -alanine, sodium N-lauryl- $\beta$ -iminodipropionate, myristoamphoacetate, lauryl betaine and lauryl sulfobetaine.

The formulation can contain a preservative to prevent the growth of microorganisms. Suitable preservatives include, but are not limited to, parabens,

chlorobutanol, phenol, sorbic acid, and thimerosal. The formulation may also contain an antioxidant to prevent degradation of the active agent(s).

The formulation is typically buffered to a pH of 3-8 for parenteral administration upon reconstitution. Suitable buffers include, but are not limited to, phosphate buffers, acetate buffers, and citrate buffers.

Water soluble polymers are often used in formulations for parenteral administration. Suitable water-soluble polymers include, but are not limited to, polyvinylpyrrolidone, dextran, carboxymethylcellulose, and polyethylene glycol.

Sterile injectable solutions can be prepared by incorporating the active compounds in the required amount in the appropriate solvent or dispersion medium with one or more of the excipients listed above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those listed above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. The powders can be prepared in such a manner that the particles are porous in nature, which can increase dissolution of the particles. Methods for making porous particles are well known in the art.

## 2. Dosage

Targeted imaging probes are preferably administered in a dose equivalent to parenteral administration of about 0.1 ng to about 100 g per kg of body weight, such as about 10 ng to about 50 g per kg of body weight, about 100 ng to about 1 g per kg of body weight, from about 1 µg to about 100 mg per kg of body weight, from about 1 µg to about 50 mg per kg of body weight, from about 1 mg to about 500 mg per kg of body weight, and from about 1 mg to about 50 mg per kg of body weight. For example, the amount of targeted imaging probes administered to achieve an effective dose for imaging can be about 0.1 ng, 1 ng, 10 ng, 100 ng, 1 µg, 10 µg, 100 µg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 500 mg per kg of body weight or greater.

### C. Kits

One or more of the compositions described herein can be assembled in kits. Printed instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and/or guidelines for mixing the  
5 components, can also be included in the kit. Kits of the invention can optionally include pharmaceutically acceptable carriers and/or diluents.

The disclosed kit can contain, for example, antibodies that specifically bind one, two, three, or more of CAIX, CAXII, mammaglobin-A, CEACAM6, CXCL10, and MMP-9. In preferred embodiments, the disclosed kit can contain antibodies that  
10 specifically bind CAIX and CAXII. In some embodiments, the disclosed kit can contain antibodies that specifically bind CAIX, CAXII, and mammaglobin-A. In these embodiments, the antibodies that specifically bind different cellular targets can in some embodiments be linked to the same detectable label, or to a different label that is indistinguishable by the imaging device. In preferred embodiments, the antibodies that  
15 specifically bind different cellular targets can be linked to different detectable labels that are distinguishable by the imaging device. For example, where the detectable label is a near-infrared (NIR) fluorophore, the NIR fluorophores preferably absorb and emit at different wavelengths.

In preferred embodiments a pharmaceutical composition can be provided in the  
20 kit as a liquid or solution. The kit can also include means of administration, such as one or more of a syringe (*e.g.*, a barrel syringe or a bulb syringe), intravenous (IV) bag, IV line, IV needle, and/or cannula. In some embodiments, the kit can comprise an ampoule or syringe containing a pharmaceutical compositions in liquid or solution form

Kits can include one or more containers containing a one or more targeted  
25 imaging probes disclosed herein. Containers of the kit can be of any suitable material, *e.g.*, glass, plastic, metal, *etc.*, and of any suitable size, shape, or configuration.

Also disclosed are kits including two or more antibodies that specifically bind a cellular target selected from the group consisting of carbonic anhydrase 9 (CAIX), carbonic anhydrase 12 (CAXII), mammaglobin-A, carcinoembryonic antigen-related cell  
30 adhesion molecule 6 (CEACAM6), C-X-C motif chemokine 10 (CXCL10), and matrix metalloproteinase 9 (MMP-9) in two or more containers, wherein at least one antibody is linked to a first near-infrared (NIR) fluorophore and at least a second antibody is linked to a second near-infrared (NIR) fluorophore.

In some embodiments, light in either the absorption or emission spectrum of the first NIR fluorophore does not excite the second NIR fluorophore. In some embodiments, at least one of the two or more antibodies consists essentially of monoclonal antibody clone 303123. In some embodiments, at least one of the two or more antibodies consists essentially of monoclonal antibody clone 315602. In some  
5 more antibodies consists essentially of monoclonal antibody clone 304-1A5 or clone 31A5. In some embodiments, at least one of the two or more antibodies consists essentially of monoclonal antibody clone 304-1A5 or clone 31A5.

### III. Methods

#### A. Detecting Cancer In Vivo

10 The disclosed targeted imaging probes can be used in combination with molecular imaging to detect cancer cells, such as those that have metastasized and therefore spread to another organ or tissue of the body, using an *in vivo* imaging device. A non-invasive method is therefore provided for detecting cancer cells in a subject that involves administering a pharmaceutical composition containing targeted imaging probes  
15 to the subject and then detecting the biodistribution of the targeted imaging probes using an imaging device. In some embodiments, the pharmaceutical composition is injected into the parenchyma. In other embodiments, the pharmaceutical composition is injected into the circulation.

The disclosed targeted imaging probes can also be used for intraoperative  
20 detection of cancer cells. For example, the disclosed targeted imaging probes can be used for intraoperative lymphatic mapping (ILM) to trace the lymphatic drainage patterns in a cancer patient to evaluate potential tumor drainage and cancer spread in lymphatic tissue. In these embodiments, the targeted imaging probes are injected into the tumor and their movement through the lymphatic system is traced using a molecular  
25 imaging device. As another example, the disclosed targeted imaging probes can be used for intraoperative assessment of, for example, tumor margins and tumor proximal tissues for the presence of cancer cells. This can be useful, for example, in effectively resecting tumors and detecting the spread of cancer proximal to the tumor.

The disclosed methods of imaging to detect cancer cells are referred to herein as  
30 non-invasive. By non-invasive is meant that the targeted imaging probes can be detected from outside of the subject's body. By this it is generally meant that the signal detection device is located outside of the subject's body. It is understood, however, that the disclosed targeted imaging probes can also be detected from inside the subject's body or

from inside the subject's gastrointestinal tract or from inside the subject's respiratory system and that such methods of imaging are also specifically contemplated. For example, for intraoperative detection, the signal detection device can be located either outside or inside of the subject's body. From this it should be understood that the a non-  
5 invasive method of imaging can be used along with, at the same time as, or in combination with an invasive procedure, such as surgery.

In some embodiments, the method can be used to diagnose cancer in a subject or detect cancer in a particular organ of a subject. A particularly useful aspect of this method is the ability to search for metastatic cancer cells in secondary tissues or organs,  
10 such as lymph nodes, or at or near tumor margins. Therefore, the disclosed methods can be used for assessing lymph node status in patients that have or are suspected of having cancer, such as breast cancer. This avoids the need to biopsy the tissue or organ, e.g., remove a lymph node. In some embodiments, the method involves administering to the patient targeted imaging probes and detecting whether the probes have bound to cells in  
15 a lymph node. In some of these embodiments, the lymph node can be an axillary lymph node (ALN). In other embodiments, the lymph node can be a sentinel lymph node. In further embodiments, both axillary and sentinel lymph nodes can be assessed for binding of the agent to cells in the lymph node.

In some embodiments, the method can be used for intraoperative imaging, such  
20 as in label-guided surgery. An example of fluorescence-guide surgery is described in Example 18.

The method can also be used with other therapeutic or diagnostic methods. For example, the method can also be used during an operation to, for example, guide cancer removal, which is referred to herein as "intraoperative guidance" or "image guided  
25 surgery." In a particular embodiment, the method can be used for therapeutic treatment to remove or destroy cancer cells in a patient's lymph nodes. For example, targeted imaging probes can be administered to a patient, and the location of cancerous tissue (e.g., lymph nodes) can be determined and removed using image guided surgery. In another preferred embodiment, the method can be used for therapeutic treatment to  
30 prevent positive microscopic margins after tumor resection. For example, targeted imaging probes can be administered to a patient, the location of cancer cells around a tumor can be determined, and the complete tumor removed using image guided surgery. In these embodiments, the physician administers targeted imaging probes to the patient

and uses an imaging device to detect the cancer cells, guide resection of tissue, and assure that all of the cancer is removed, i.e., negative cancer margins. In addition, the imaging device can be used post-operatively to determine if any cancer remains or reoccurs.

5           In some embodiments, the targeted imaging probes can be linked to a therapeutic compound. The therapeutic compound or moiety can be one that kills or inhibits cancer cells directly (*e.g.*, cisplatin) or it can be one that can kill or inhibit a cancer cell indirectly (*e.g.*, gold nanoparticles that kill or destroy cancer cells when heated using a light source). If the therapeutic compound or moiety is one that kills or inhibits a cancer cell indirectly, then the method further comprises a step of taking appropriate action to “activate” or otherwise implement the anti-cancer activity of the compound or moiety. In a specific embodiment, the therapeutic compound or moiety attached to the agent can be a gold nanoparticle and following administration to the patient and binding of the agent to cancer cells, the gold nanoparticles are heated, *e.g.*, using a laser light, to kill or destroy the nearby cancer cells (photothermal ablation). For example, in some 10           embodiments, the method involves image guided surgery using targeted imaging probes to detect and resect cancer from a subject followed by the use of the same or different targeted imaging probes linked to a therapeutic compound to kill remaining cancer cells. 15

          Disclosed are non-invasive methods for *in vivo* detection of cancer cells in a subject, the method including administering to the subject a targeted imaging probe that specifically binds a cellular target selected from the group consisting of carbonic anhydrase 9 (CAIX), carbonic anhydrase 12 (CAXII), mammaglobin-A, carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), C-X-C motif chemokine 10 (CXCL10), and matrix metalloproteinase 9 (MMP-9); and imaging the subject with a molecular imaging device to detect the targeted imaging probe in the subject, wherein detection of the targeted imaging probe in an organ of a subject is an indication of cancer cells in the organ. 20           25

          The cellular target can be CAIX, CAXII, mammaglobin-A, or a combination thereof. The method can include administering to the subject a first targeted imaging probe that specifically binds CAIX, a second targeted imaging probe that specifically binds CAXII, or a combination thereof, wherein detection the first targeted imaging probe or the second targeted imaging probe in an organ of a subject is an indication of cancer cells in the organ. The method can include administering to the subject a targeted 30

imaging probe that specifically binds mammaglobin-A, wherein detection of the targeted imaging probe that specifically binds mammaglobin-A in an organ of a subject is an indication of breast cancer cells in the organ.

The molecular imaging device can include a gamma radiation detector. The targeted imaging probe can include an antibody linked to a detectable label. The targeted imaging probe that specifically binds CAIX is an antibody can include the idiotype of monoclonal antibody clone 303123. The targeted imaging probe that specifically binds CAXII is an antibody can include the idiotype of monoclonal antibody clone 315602. The targeted imaging probe that specifically binds mammaglobin-A is an antibody can include the idiotype of monoclonal antibody clone 304-1A5 or clone 31A5.

The antibody can consist essentially of monoclonal antibody clone 303123, clone 315602, clone 304-1A5, or clone 31A5. The detectable label can be a near-infrared (NIR) fluorophore. The targeted imaging probe can include a first antibody having the idiotype of monoclonal antibody clone 303123 linked to a first NIR fluorophore and a second antibody having the idiotype of monoclonal antibody clone 315602 linked to a second NIR fluorophore.

The cancer cells can be metastasized cancer cells. The cancer cells can be breast cancer cells. The cancer cells can be non small-cell carcinoma cells.

### 1. Cancers

In some embodiments, the cancer of the disclosed methods can be any cell in a subject undergoing unregulated growth. In preferred embodiments, the cancer is any cancer cell capable of metastasis. For example, the cancer can be a sarcoma, lymphoma, leukemia, carcinoma, blastoma, or germ cell tumor. A representative but non-limiting list of cancers that the disclosed compositions can be used to detect include lymphoma, B cell lymphoma, T cell lymphoma, mycosis fungoides, Hodgkin's Disease, myeloid leukemia, bladder cancer, brain cancer, nervous system cancer, head and neck cancer, squamous cell carcinoma of head and neck, kidney cancer, lung cancers such as small cell lung cancer and non-small cell lung cancer, neuroblastoma/glioblastoma, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, liver cancer, melanoma, squamous cell carcinomas of the mouth, throat, larynx, and lung, colon cancer, cervical cancer, cervical carcinoma, breast cancer, epithelial cancer, renal cancer, genitourinary cancer, pulmonary cancer, esophageal carcinoma, head and neck carcinoma, large bowel

cancer, hematopoietic cancers; testicular cancer; colon and rectal cancers, prostatic cancer, and pancreatic cancer.

In preferred embodiments, the cancer is breast cancer. Breast cancers originating from ducts are known as ductal carcinomas, and those originating from lobules that supply the ducts with milk are known as lobular carcinomas. Common sites of breast cancer metastasis include bone, liver, lung and brain.

In other preferred embodiments, the cancer is non-small-cell lung carcinoma (NSCLC). NSCLC is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). The most common types of NSCLC are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma, but there are several other types that occur less frequently, and all types can occur in unusual histologic variants and as mixed cell-type combinations.

In other preferred embodiments, the cancer is pancreatic cancer. The most common type of pancreatic cancer, accounting for 95% of these tumors is adenocarcinoma, which arises within the exocrine component of the pancreas. A minority arises from the islet cells and is classified as a neuroendocrine tumor.

## 2. Molecular Imaging

Methods are disclosed for *in vivo* detection of cancer cells using the disclosed targeted imaging probes in combination with a molecular imaging device. Molecular imaging differs from traditional imaging in that probes known as biomarkers are used to help image particular targets or pathways. There are many different modalities that can be used for noninvasive molecular imaging. Each have their different strengths and weaknesses and some are more adept at imaging multiple targets than others.

### a. Magnetic resonance imaging (MRI)

MRI has the advantages of having very high spatial resolution and is very adept at morphological imaging and functional imaging. However, MRI has a sensitivity of around  $10^{-3}$  mol/L to  $10^{-5}$  mol/L which, compared to other types of imaging, can be very limiting. This problem stems from the fact that the difference between atoms in the high energy state and the low energy state is very small. For example, at 1.5 tesla, a typical field strength for clinical MRI, the difference between high and low energy states is approximately 9 molecules per 2 million. Improvements to increase MR sensitivity include hyperpolarization by increasing magnetic field strength, optical pumping, or

dynamic nuclear polarization. There are also a variety of signal amplification schemes based on chemical exchange that increase sensitivity.

*b. Optical imaging*

There are a number of approaches used for optical imaging. The various methods  
5 depend upon fluorescence, bioluminescence, absorption or reflectance as the source of contrast. Optical imaging's most valuable attribute is that it does not have strong safety concerns like the other medical imaging modalities. The downside of optical imaging is the lack of penetration depth, especially when working at visible wavelengths. Depth of penetration is related to the absorption and scattering of light, which is primarily a  
10 function of the wavelength of the excitation source. Light is absorbed by endogenous chromophores found in living tissue (e.g. hemoglobin, melanin, and lipids). In general, light absorption and scattering decreases with increasing wavelength. Below ~700 nm (e.g. visible wavelengths), these effects result in shallow penetration depths of only a few millimeters. Thus, in the visible region of the spectrum, only superficial assessment of  
15 tissue features is possible. Above 900 nm, water absorption can interfere with signal-to-background ratio. Because the absorption coefficient of tissue is considerably lower in the near infrared (NIR) region (680-900 nm), light can penetrate more deeply, to depths of several centimeters.

Fluorescent probes and labels are an important tool for optical imaging. A  
20 number of near-infrared (NIR) fluorophores have been employed for *in vivo imaging*, including Kodak X-SIGHT Dyes and Conjugates, DyLight 750 and 800 Fluors, Cy 5.5 and 7 Fluors, Alexa Fluor 680 and 750 Dyes, IRDye 680 and 800CW Fluors. In some embodiments, the detectable label is a Quantum dot.

*c. Nuclear Medicine Imaging*

25 Nuclear medicine imaging involves the use and detection of radioisotopes in the body. Nuclear medicine imaging techniques include scintigraphy, single photon emission computed tomography (SPECT), and positron emission tomography (PET). In these techniques, radiation from the radioisotopes is captured by a gamma camera to form two-dimensional images (scintigraphy) or 3-dimensional images (SPECT and PET).

30 Suitable gamma-emitting radioisotopes for scintigraphy and SPECT include  $^{99m}\text{Tc}$ ,  $^{111}\text{In}$ ,  $^{123}\text{I}$ ,  $^{133}\text{Xe}$ ,  $^{201}\text{Tl}$ . Suitable radioisotopes have relatively long half lives (a few hours to a few days) making them easy to produce and relatively cheap. This represents a major advantage, since it is significantly cheaper than either PET or MRI. However it

lacks good spatial resolution. Additionally, due to the radioactivity of the contrast agent, there are safety aspects concerning the administration of radioisotopes to the subject, especially for serial studies.

Radionuclides used in PET scanning are typically isotopes with short half-lives. Typical isotopes include  $^{11}\text{C}$ ,  $^{13}\text{N}$ ,  $^{15}\text{O}$ ,  $^{18}\text{F}$ ,  $^{64}\text{Cu}$ ,  $^{62}\text{Cu}$ ,  $^{124}\text{I}$ ,  $^{76}\text{Br}$ ,  $^{82}\text{Rb}$  and  $^{68}\text{Ga}$ , with  $^{18}\text{F}$  being the most clinically utilized. One of the major disadvantages of PET is that most of the probes must be made with a cyclotron. Most of these probes also have a half life measured in hours, forcing the cyclotron to be on site. PET imaging is, however, very sensitive. A typical PET scanner can detect between  $10^{-11}$  mol/L to  $10^{-12}$  mol/L concentrations.

Gamma radiation from radioisotopes is detected using a gamma particle detection device. In some embodiments, the gamma particle detection device is a Gamma Finder® device (SenoRx, Irvine CA). In some embodiments, the gamma particle detection device is a neoprobe® GDS gamma detection system (Dublin, OH).

#### 15           **B.       Administration**

The disclosed pharmaceutical compositions are preferably administered parenterally into the parenchyma or into the circulation so that the targeted imaging probes reach target tissues where cancer cells may be located. In some preferred embodiments, the pharmaceutical composition is administered directly into or adjacent to a tumor mass. In other preferred embodiments, the pharmaceutical composition is administered intravenously. In still other embodiments, the pharmaceutical composition is administered intraperitoneally, intramuscularly, subcutaneously, intracavity, or transdermally.

Parenteral administration of the composition, if used, is generally characterized by injection. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. A revised approach for parenteral administration involves use of a slow release or sustained release system such that a constant dosage is maintained.

#### 25           **C.       Actions Based on Imaging and Identifications**

The disclosed methods include the determination, identification, indication, correlation, diagnosis, prognosis, etc. (which can be referred to collectively as “identifications”) of subjects, diseases, conditions, states, etc. based on imagings, measurements, detections, comparisons, analyses, assays, screenings, etc. For example,

the disclosed imaging methods allow identification of patients, organs, tissues, etc. having cancer cells, metastasized cancer cells, cancer cells beyond tumor margins, etc. Such identifications are useful for many reasons. For example, and in particular, such identifications allow specific actions to be taken based on, and relevant to, the particular  
5 identification made. For example, diagnosis of a particular disease or condition in particular subjects (and the lack of diagnosis of that disease or condition in other subjects) has the very useful effect of identifying subjects that would benefit from treatment, actions, behaviors, etc. based on the diagnosis. For example, treatment for a particular disease or condition in subjects identified is significantly different from  
10 treatment of all subjects without making such an identification (or without regard to the identification). Subjects needing or that could benefit from the treatment will receive it and subjects that do not need or would not benefit from the treatment will not receive it.

Accordingly, also disclosed herein are methods comprising taking particular actions following and based on the disclosed identifications. For example, disclosed are  
15 methods comprising creating a record of an identification (in physical—such as paper, electronic, or other—form, for example). Thus, for example, creating a record of an identification based on the disclosed methods differs physically and tangibly from merely performing a imaging, measurement, detection, comparison, analysis, assay, screen, etc. Such a record is particularly substantial and significant in that it allows the  
20 identification to be fixed in a tangible form that can be, for example, communicated to others (such as those who could treat, monitor, follow-up, advise, etc. the subject based on the identification); retained for later use or review; used as data to assess sets of subjects, treatment efficacy, accuracy of identifications based on different imagings, measurements, detections, comparisons, analyses, assays, screenings, etc., and the like.  
25 For example, such uses of records of identifications can be made, for example, by the same individual or entity as, by a different individual or entity than, or a combination of the same individual or entity as and a different individual or entity than, the individual or entity that made the record of the identification. The disclosed methods of creating a record can be combined with any one or more other methods disclosed herein, and in  
30 particular, with any one or more steps of the disclosed methods of identification.

As another example, disclosed are methods comprising making one or more further identifications based on one or more other identifications. For example, particular treatments, monitorings, follow-ups, advice, etc. can be identified based on the

other identification. For example, identification of a subject as having a disease or condition with a high level of a particular component or characteristic can be further identified as a subject that could or should be treated with a therapy based on or directed to the high level component or characteristic. A record of such further identifications can be created (as described above, for example) and can be used in any suitable way. Such further identifications can be based, for example, directly on the other identifications, a record of such other identifications, or a combination. Such further identifications can be made, for example, by the same individual or entity as, by a different individual or entity than, or a combination of the same individual or entity as and a different individual or entity than, the individual or entity that made the other identifications. The disclosed methods of making a further identification can be combined with any one or more other methods disclosed herein, and in particular, with any one or more steps of the disclosed methods of identification.

As another example, disclosed are methods comprising treating, monitoring, following-up with, advising, etc. a subject identified in any of the disclosed methods. Also disclosed are methods comprising treating, monitoring, following-up with, advising, etc. a subject for which a record of an identification from any of the disclosed methods has been made. For example, particular treatments, monitorings, follow-ups, advice, etc. can be used based on an identification and/or based on a record of an identification. For example, a subject identified as having a disease or condition with a high level of a particular component or characteristic (and/or a subject for which a record has been made of such an identification) can be treated with a therapy based on or directed to the high level component or characteristic. Such treatments, monitorings, follow-ups, advice, etc. can be based, for example, directly on identifications, a record of such identifications, or a combination. Such treatments, monitorings, follow-ups, advice, etc. can be performed, for example, by the same individual or entity as, by a different individual or entity than, or a combination of the same individual or entity as and a different individual or entity than, the individual or entity that made the identifications and/or record of the identifications. The disclosed methods of treating, monitoring, following-up with, advising, etc. can be combined with any one or more other methods disclosed herein, and in particular, with any one or more steps of the disclosed methods of identification.

The disclosed imagings, measurements, detections, comparisons, analyses, assays, screenings, etc. can be used in other ways and for other purposes than those disclosed. For example, imaging of cancer cells can be used to identify areas of organs of tissues or margins of cancer-affected organs or tissues. Thus, the disclosed imagings, measurements, detections, comparisons, analyses, assays, screenings, etc. do not encompass all uses of such imagings, measurements, detections, comparisons, analyses, assays, screenings, etc.

## EXAMPLES

### Example 1: Microarray and TMA studies on patient tissue samples

#### 10 Materials and Methods

*DNA microarray analysis:* A list of 3,800 cell surface genes was compiled from Gene Bank and used to filter Affymetrix® expression microarray data from 304 breast cancer samples of which 37 were noted as being from LN positive patients; and from normal tissues including 116 normal breast, 23 lymph node, 4 spleen, 5 lung, 4 heart, 8 kidney and 4 liver samples. The Affymetrix® CEL files for the tumor samples were downloaded from the Gene Expression Omnibus (GEO) database (www.ncbi.nlm.nih.gov/projects/geo/index.cgi), data series GSE2109. This is the Expression Project for Oncology carried out by the International Genomics Consortium (IGC). Normal tissue data were from the GEO data series GSE7307, Human Body Index, which was a transcriptional profiling project carried out by Neurocrine Biosciences, Inc. The CEL files were analyzed using the MAS 5.0 algorithm (Affymetrix Corp.) and then screened through a rigorous quality control panel to remove samples with low percentages of probe sets called present by the MAS 5 algorithm, indicating problems with the amplification process; high scaling factors, indicating poor transcript abundance during hybridization; and poor 3'/5' ratios, indicating RNA degradation either prior to or during processing. The remaining samples were normalized to the trimmed average of 500 in the MAS 5 algorithm.

*Immunohistochemistry (IHC) of tissue microarray (TMA):* A TMA was constructed at the Tissue Core of Moffitt Cancer Center containing human breast tissue samples of formalin-fixed and paraffin-embedded (FFPE) specimens. The TMA contains 50 normal breast tissue, 50 ductal carcinoma in situ, 50 invasive ductal carcinomas without metastasis, 50 invasive ductal carcinomas with metastasis, and 50 lymph node with macrometastases of breast. The procedure of the TMA construction and the protocol

were described previously (Schlauder, S.M. et al. *Fetal Pediatr Pathol* 27:83-97 (2008)). For the current project, a 1:500 dilution of anti-CAXII antibody (Prestige Antibodies Powered by Atlas Antibodies, Sigma-Aldrich) was used as a primary antibody for CAXII staining and a 1:500 dilution of anti-CAIX rabbit polyclonal antibody (Abcam plc) was used for CAIX staining.

*Statistics:* Data are represented as mean  $\pm$  s.d. and Student's t-test was used to determine significance.

### Results

CAIX and CAXII were identified and validated as cell-surface markers for breast cancer lymph node (LN) metastasis. CAIX expression is observed in a variety of cancer types including breast cancer (Brennan, D.J. et al. *Clin Cancer Res* 12:6421-6431 (2006); Chia, S.K. et al. *J Clin Oncol* 19:3660-3668 (2001); Colpaert, C.G. et al. *Breast Cancer Res Treat* 81:137-147 (2003); Hussain, S.A. et al. *Br J Cancer* 96:104-109 (2007); Lancashire, L.J. et al. *Breast Cancer Res Treat* 120:83-93 (2010); Span, P. N. et al. *Br J Cancer* 89:271-276 (2003); Trastour, C. et al. *Int J Cancer* 120:1451-1458 (2007)), but is relatively absent from corresponding normal tissues (Supuran, C.T. et al. *ioorg Med Chem* 15:4336-4350 (2007)). CAIX expression is correlated with high tumor grade and increased tumor size in breast cancer (Chia, S.K. et al. *J Clin Oncol* 19:3660-3668 (2001); Span, P. N. et al. *Br J Cancer* 89:271-276 (2003)).

To identify additional targets, a list of 3800 cell surface and secreted genes was curated from Gene Bank and used to filter DNA microarray data from 304 breast tumor samples (37 node positive), 111 normal breast tissue samples, 15 unaffected lymph node, and 189 samples from 6 unaffected organ sites in the area surrounding the axillary nodes and those involved in clearance and toxicity. Five genes, *CAI2*, *CEACAM6*, *CXCL9*, *CXCL10* and *MMP9*, were identified with high expression in breast cancer including lymph node positive tumors, but low expression in the normal tissues surveyed (Figs. 1A-1B, 4A-4D). Since *CXCL9*, *CXCL10* and *MMP9* products are secreted, and *CEACAM6* had significant expression in the lung, CAXII was selected for validation. Also, CAXII was intriguing because of the potential for development of probes targeting the carbonic anhydrase catalytic site using sulfonamide-based inhibitors as imaging probes, which would target both CAXII and CAIX.

For validation of protein expression, immunohistochemistry (IHC) of CAIX and CAXII was performed on a tissue microarray (TMA) containing 50 normal breast tissue

samples, 50 ductal carcinoma in situ, 50 invasive ductal carcinomas without metastasis, 50 invasive ductal carcinoma with metastasis, and 50 lymph node macrometastases. As shown in Table 1, positive staining of CAIX and CAXII was observed in the ductal epithelium of 73.9 % and 100% of normal breast tissue samples, respectively. These markers were not present in normal breast stroma. CAIX and CAXII staining was distributed in the cell membranes of tumor tissues. Lymph node metastases samples (44%) were positive for both CAIX and CAXII and all of the positive lymph nodes were found to express either CAIX or CAXII. Tumor heterogeneity was found in 28.6% and 35% for CAIX and CAXII, respectively.

10

Table 1. Expression of CAIX and CAXII in normal breast and breast cancer patients

	CA9	CA12	Combination
Normal	73.9%	100%	100% (n=7)
DCIS	71.4%	81.3%	100% (n=9)
IDC without Mets	55.8%	78.7%	100% (n=28)
IDC with Mets	56.5%	80.4%	93% (n=26)
LN Macro Mets	71.4%	75.5%	100% (n=31)

Mammaglobin A is expressed in 45% of LN macrometastases on breast TMA.

An analysis of expression of all three of these markers on our TMA shows that 100% of the samples LN macrometastases express at least one of the three markers, 31% express only one, 51% express two, and 18% express all three markers. Therefore, a combination of CAIX, CAXII and mammaglobin markers can be used as suitable targets for imaging agents for early diagnosis of metastatic breast cancer in lymph nodes.

### Example 2: Cell models and *in vitro* studies

#### Materials and Methods

*Cell Culture:* A breast cancer cell line that expresses luciferase, MDA-mb-231-luc, (Baggett, B. et al. *Mol Imaging* 3:324-332 (2004)) was grown in RPMI 1640 containing 10% fetal bovine serum (Life Technologies), 0.03% L-glutamine, 100 units/mL penicillin, 100  $\mu$ g/mL streptomycin and 300  $\mu$ g/ml G418 (Mediatech) in 5% CO<sub>2</sub> at 37 °C.

*Generation of stably transfected MDA-mb-231 cells bearing the CA12 gene:* pCMV6-XL5 containing *homo sapiens CA12* was purchased (Origene) and it was subcloned to pCDNA3.1-Zeo (Invitrogen) containing Zeocin™ as a selectable marker for mammalian cells. Briefly, pCMV6-XL5 and pCDNA3.1-Zeo were digested by NotI and XbaI (Invitrogen) and the digested fragment was inserted into NotI/XbaI restriction

sites of digested pCDNA3.1-Zeo vector and the ligated mixture was transformed into competent cells of *E. coli* DH5 $\alpha$ .

To identify the optimal concentration for selection, a range (50-1000  $\mu\text{g/ml}$ ) of Zeocin<sup>TM</sup> (Invitrogen) was tested on MDA-mb-231 cells. MDA-mb-231 cells expressing luciferase were transfected with 5  $\mu\text{g}$  of pCDNA3.1-Zeo containing *CA12*. In response to zeocin, massive cell death was observed after ~5 days. After 2 weeks, resistant colonies appeared. Large colonies were selected and transferred to individual plates. The clone with the highest expression of *CA12* was determined using qRT-PCR as previously described (Morse, D.L. et al. *Anal Biochem* 342:69-77 (2005)). RNA was extracted from each clone using an RNA extraction kit (Qiagen). *CA12* specific primer sets were designed using Gene Runner Software for Windows version 3.05: forward, 5'-CTGGCATCATGTATTTAGGGGC-3' (SEQ ID NO:1) and reverse, 5'-GAGTTGCGCCTGTCAGAAAC-3' (SEQ ID NO:2).  $\beta$ -actin was used for normalization. A clone with the highest expression was selected and maintained in medium containing 300  $\mu\text{g/ml}$  of G418 and 800  $\mu\text{g/ml}$  of zeocin.

*Immunocytochemistry (ICC) and fluorescence microscopy:* To verify expression of CAXII in engineered cells, two sets of MDA-mb-231 (as a negative control) and MDA-mb-231/CAXII cells (each  $1 \times 10^4$ ) were plated onto glass coverslips placed at the bottom of culture wells and incubated for 16 h. Cells were fixed with a 1:1 mixture of cold methanol and acetone, air dried for 20 min, blocked with 3% BSA and 0.2% saponin in PBS for 1 hour at room temperature and incubated with 1:50 CAXII antibody (Sigma-Aldrich) for 1 h. Plates were then washed (3 times, 5 min each) with PBS containing 0.2% saponin, and incubated with 1:2000 secondary antibody (Alexa-Fluor 488 goat anti-mouse IgG, Invitrogen). After three washes, coverslips were mounted using mounting medium with DAPI, 4, 6-diamidino-2-phenylindole (Vector Laboratories, Inc.). Samples were viewed in the Analytic Microscopy Core Facility at Moffitt Cancer Center using an automated Zeiss Observer Z.1 inverted microscope with 40x /1.3NA oil immersion objectives through narrow bandpass DAPI, FITC /A488 Chroma filter cubes, Nomarski Differential Interference Contrast polarizing, and analyzing prisms. Images were produced using the AxioCam MRm CCD camera and Axiovision version 4.6 software suite (Carl Zeiss Inc.).

*Conjugation of antibodies to dye and fluorescence microscopy studies:* A mixture of 10  $\mu\text{g}$  anti-human CAIX monoclonal antibody (mAb) (Clone 303123, R&D systems)

was incubated with 10 µg VivoTag-S® 680 (VisEn Medical) at room temperature for 1 hour. The immunogen for this antibody is rhCA9; accession # NP\_001207; aa 59 – 414, which corresponds to the N-terminus and the extracellular domain. The conjugate was purified with a Sephadex® G25 column (Roche) and eluted into a sterile tube. Protein (A280) and dye (A680) absorbance was determined using an ND-1000 spectrophotometer (NanoDrop) and used to confirm the number of fluorophore molecules conjugated to each antibody molecule. The conjugate was termed CA9Ab-680.

The same procedure was used for conjugation of CAXII mAb (Clone 315602, R&D system) to the dye. The immunogen for this antibody is rhCA12; accession # NP\_001209; aa 25 – 291, which corresponds to the N-terminus and the extracellular domain. The conjugate was termed CA12Ab-680.

To verify that CA9Ab-680 and CA12Ab-680 retained binding specificity,  $1 \times 10^4$  MDA-mb-231 cells (constitutively expressing CAIX and not expressing CAXII) and the same number of MDA-mb-231/CAXII (engineered cells to express CAXII) were seeded and incubated for 16 hours, then fixed as described above. The fixed cells that constitutively express CAIX were incubated with 0.5 µg/µl CA9Ab-680, and both cell lines were incubated with 0.5 µg/µl CA12Ab-680. Cells were also incubated with 5.0 µg/mL of wheat germ agglutinin (WGA), Oregon Green 488 conjugate (Invitrogen) for 30 min. After three washes, coverslips were mounted using mounting medium with DAPI. Micrographs were acquired at 200 Hz in the Analytic Microscopy Core at Moffitt Cancer Center using a Leica DMI6000 inverted microscope and TCS SP5 tandem confocal scanner, through a 63X/1.40NA Plan Apochromat oil immersion objective lens (Leica Microsystems) with triple photomultiplier tube detectors. Lasers, 405 diode (DAPI/ Lysotracker Blue), 488 tunable argon (Green dye) and 543 diode (Rhodamine), were applied to excite the samples and a tunable emission filter was used to eliminate crosstalk between fluorochromes. LAS AF software version 2.1.0 (Leica Microsystems) was used to acquire and save the images using no compression of the original files.

*Statistics:* Data are represented as mean ± s.d. and Student's t-test was used to determine significance.

### Results

Cells were needed that express CAIX and CAXII for *in vitro* as well as *in vivo* studies. MDA-mb-231 breast cancer cells constitutively express CAIX (Brennan, D.J. et

al. *Clin Cancer Res* 12:6421-6431 (2006); Robey, I.F. et al. *Neoplasia* 7:324-330 (2005); Li, Y. et al. *Cancer Invest* 27:613-623 (2009)), but do not express the *CA12* gene (and presumably the protein) as determined by qRT-PCR. Therefore, MDA-mb-231-luc cells were engineered to stably express CAXII as confirmed by qRT-PCR and ICC.

5            Monoclonal antibodies (mAbs) from R&D Systems that bind to the extracellular domain of CAIX and CAXII, respectively, were determined to be highly target specific by Western analysis and ICC, and were conjugated to a near-infrared (NIR) fluorescent dye (VivoTag-S® 680, VisEn). To verify the selectivity of the CAIX antibody-dye conjugate (CA9Ab-680), ICC was performed using the molecular probe on the CAIX  
10            constitutively expressing MDA-mb-231 cells and MCF-7 cells which do not express CAIX in normoxia condition as a negative control (Robey, I.F. et al. *Neoplasia* 7:324-330 (2005)). For CA12Ab-680, ICC was performed using MDA-mb-231 cells engineered to express CAXII (MDA-mb-231/CAXII) and the parental cells as a negative control. CA12Ab-680 bound only to expressing cells. Hence, the conjugated agents  
15            retained specificity for CAIX and CAXII proteins.

### **Example 3: *In vivo* and *ex vivo* selectivity studies**

#### Materials and Methods

*Tumor xenograft studies:* To study selectivity of the CA9Ab-680 imaging probe, female *nu/nu* mice 6-8 weeks old (Harlan Sprague Dawley, Inc.) were implanted with 5  
20             $\times 10^6$  MDA-mb-231 (as CAIX expressing cells) in the right mammary fat pad (MFP). To study CA12Ab-680, the same procedure was done, except that MDA-mb-231/CAXII (as CAXII expressing cells) were implanted in the right MFP and MDA-mb-231 (as non-expressing cells) in the left MFP. Tumor volume was determined with calipers using the formula: volume = (length  $\times$  width<sup>2</sup>)/2. Once tumors reached 500-800 mm<sup>3</sup>, 50  $\mu$ g  
25            CA9Ab-680 in 100  $\mu$ L sterile saline, was injected into the tail vein. *In vivo* fluorescence images were acquired using an IVIS 200 small animal imaging system (Caliper LifeSciences) using a 615-665 nm excitation filter and a 695-770 nm emission filter. According to the manufacturer, the excitation maxima of unconjugated VivoTag-S® 680 dye is 673  $\pm$ 5 nm and the emission maxima is 691  $\pm$ 5. Living Image 3.2 Software was  
30            used to draw regions of interest (ROIs) over the tumors to determine the mean tumor surface radiance (photons/sec/steradian/cm<sup>2</sup>). Autofluorescence background was subtracted by determining the mean tumor fluorescence signal prior to injection.

*Ex vivo studies:* One half of each excised tumor from animals was fixed in formalin and embedded in paraffin, the other half placed in Tissue-Tek Optical Cutting Temperature (OCT) cryoembedding media (Sakura Finetek) and snap frozen in liquid nitrogen. For histology, formalin fixed sections (5  $\mu\text{m}$ ) were stained with hematoxylin and eosin (H&E). Frozen sections were stained with the CA9Ab-680 and CA12Ab-680 using the ICC protocol described above. Sections were also stained with mammaglobin-A primary antibody as described above for TMAs.

*Statistics:* Data are represented as mean  $\pm$  s.d. and Student's t-test was used to determine significance.

## 10 Results

To study the selectivity of the CA9Ab-680 *in vivo*, MDA-mb-231 cells that constitutively express CAIX were used to form a positive MFP tumor in nude mice. Since CAIX is expressed under hypoxic conditions, all tumors may express CAIX, including small metastases which may not have established vasculature. Therefore, a blocking experiment was used to determine specificity, where unlabeled CAIX mAb was added prior to CA9Ab-680.

For CA12Ab-680, MDA-mb-231/CAXII cells were used for generating the positive tumor in the right MFP, and parental cells were used for the negative left MFP tumor. After tumor growth to approximately 500-800  $\text{mm}^3$  in volume, agent was intravenously (i.v.) injected. CA9Ab-680 was retained in the CAIX positive MDA-mb-231 tumor 24 hours after injection, and that after blocking with unlabeled CAIX mAb, the amount of probe retained in the tumor was decreased. After blocking, the probe-related fluorescence signal decreased by 1.7 times relative to the unblocked tumor. The MDA-mb-231/CAXII tumor also retained high levels of the CA12Ab-680 compared to the CAXII negative xenograft. Expression in the CAXII positive tumor was quantified as having a  $7.0 \pm 1.0$  s.d. ( $n=3$ ,  $p<0.001$ ) fold greater fluorescence compared to the negative tumor. These results demonstrate the *in vivo* targeting specificity of the molecular probes.

For further confirmation, an *ex vivo* analysis was performed. Sections of flash-frozen tumors were stained with the probes, a nuclear stain, (DAPI), and a cell-surface/cytoplasmic stain, wheat germ agglutinin (WGA), and were imaged using confocal microscopy. CAIX staining was observed in the positive tumor, and was reduced by blocking with unlabeled mAb. CAXII staining was only observed in tumors

from the positively expressing cell line but not in the negative line. *Ex vivo* images of the corresponding center sections of the tumors confirmed the *in vivo* results and allow comparison of probe signal relative to target expression in adjacent sections by IHC and histology.

#### 5 **Example 4: Pharmacokinetics and biodistribution studies**

##### Materials and Methods

*Pharmacodynamics and biodistribution studies:* Pharmacodynamics studies were performed by imaging at various time points. For biodistribution studies, mice were imaged and euthanized at 24 h and 48 h post-injection, tissues excised, rinsed with PBS, 10 blotted dry, and then imaged *ex vivo* in the IVIS-200. A center slice cut from the tumor was imaged and the remaining halves were formalin fixed and fresh frozen, respectively, as described below. Mean surface radiance was determined for each tumor and organ. Autofluorescence background was subtracted using measurements from comparable tissues from an untreated animal.

15 *Statistics:* Data are represented as mean  $\pm$  s.d. and Student's t-test was used to determine significance.

##### Results

To evaluate the pharmacodynamics of probe uptake and clearance in the tumors, CA9Ab-680 and CA12Ab-680 were intravenously (i.v.) injected and images acquired at 20 intervals from 5 minutes to 8 days post injection (Fig. 2A and 2B). Fluorescence signal in positive tumors increased to a maximum at 24 hours following injection of both probes, and signal slowly cleared until approximately 7 days post-injection. Fluorescence signal in CAXII negative tumors increased slightly for about 24 hours and slowly cleared over the following 5 days.

25 For biodistribution studies, mice bearing tumors were injected with probe, and tissue distribution of fluorescence signal determined after removing tumors and organs at 24-hours and 48-hours post-administration (Fig. 2C and 2D). Twenty four hours post-injection, CA9Ab-680 and CA12Ab-680 retained at relatively high levels in the positive tumor relative to a corresponding negative tumor and other organs. However, the CAIX 30 probe was elevated in liver, kidney and stomach and the CAXII probe was elevated in the liver and stomach. After 48 hours, probe had nearly cleared from all tissues except for positive tumors.

**Example 5: Detection of malignant cells in ALNs using CA9Ab-680 and CA12Ab-680 imaging probes**Materials and Methods

*Metastases to ALNs of mouse model:* For the CA9Ab-680 study,  $5 \times 10^6$  luciferase expressing MDA-mb-231 cells were implanted into the right MFP of 6-8 weeks old female *nu/nu* mice. Eight to nine weeks later, bioluminescence imaging was used to follow metastasis formation in the ALN. Animals were anesthetized and 300  $\mu$ l of D-luciferin potassium salt (GoldBio) was introduced via intraperitoneal (i.p.) injection. Five minutes after the injection, a bioluminescence image was acquired using standard bioluminescence settings on the IVIS 200. The same protocol was used for CA12Ab-680, except that MDA-mb-231 cells that express both luciferase and CAXII were used.

To determine agent sensitivity, precise numbers of cells were injected into ALNs using ultrasound image guidance. Female *nu/nu* mice (6-8 weeks old) were anesthetized with 3-4% isoflurane using a nose-cone manifold and restrained on the stage of a VEVO® 770 high-resolution small animal ultrasound imaging system (VisualSonics) using tape; ultrasound gel was applied to the area over the right axillary node; the 40MHz ultrasound probe was placed in the probe guide and the node located by mechanically adjusting the probe guide to resolve the nodes; and a 1 cc syringe with a 29 gauge needle was loaded with 500 to 100,000 cells in a 20  $\mu$ L volume of 1:1 matrigel and sterile PBS and positioned in the needle guide so that the end of the needle could be moved into the node and cells injected. Ultrasound images were acquired at the time of each injection. Four hours after injection of cells, animals were imaged using bioluminescence as described above. Twenty-four hour after injection of cells, 30  $\mu$ g of agent was injected into the mammary fat pad proximal to axillary nodes, and fluorescence imaging was performed using the IVIS-200 as described above for pharmacodynamics and biodistribution studies.

*Statistics:* Data are represented as mean  $\pm$  s.d. and Student's t-test was used to determine significance.

Results

To investigate whether the CAIX and CAXII molecular imaging probes can be delivered through the lymphatics and are selectively retained in positive ALNs, the MDA-mb-231-luc spontaneous metastasis model was used. After injecting cells in the

MFP, ALN metastases were observed after 6-8 weeks by bioluminescence imaging. Probe was then injected peritumorally into the MFP and observed to traverse through the MFP into the lymph node within 4 hours. At 24 h post-injection, a strong fluorescence signal was obtained from the area of the ALN corresponding to a metastasis positive for the marker, and the probe had mostly cleared from the MFP. A specific and durable fluorescence signal was observed in target positive metastases out to at least 48 hours post-injection, long after completely clearing from the MFP. Probe was not retained in ALN metastases that did not express the target marker.

Agent selectivity and sensitivity for positive lymph nodes was also measured using an orthotopic model of lymph node metastasis. A range in number of MDA-mb-231/Luc cells that constitutively express CAIX but do not express CAXII, and a range of MDA-mb-231/Luc/CAXII cells (500 to 1 million) were directly injected into the ALN using ultrasound image guidance. For confirmation of successful cell implantation, cells were detected by bioluminescence imaging four hours after implantation. Twenty four hours after cell implantation, CA9Ab-680 and CA12Ab-680 were delivered by MFP injection and fluorescence images were acquired 24 hours after injection. Bioluminescence and fluorescence signals were quantified by drawing a region-of-interest (ROI) surrounding the tumor cells in the ALN. As expected, signal intensities for both bioluminescence and fluorescence decreased with cell number (Figs. 3A-3D). With fluorescence, the CA12Ab-680 probe detected as few as 500 cells above background and CA9Ab-680 detected as few as 1000 cells (Fig. 3C-3D). When CA12Ab-680 was injected into the MFP of animals that were sham injected into the axillary lymph node with matrigel and PBS, probe was not retained at the 24 hour time point.

In conclusion, either CAIX or CAXII are expressed in 100% of lymph node metastasis from patients with breast cancer. CAIX and CAXII targeted molecular imaging probes were developed for non-invasive *in vivo* imaging and detection of breast cancer metastases in ALNs using small animal models. These imaging probes detected tumor cells in ALNs with high sensitivity. This targeted imaging strategy has potential for future translation into the clinic for ALN assessment and intraoperative surgical guidance as well as monitoring alteration in CAIX/CAXII expression as an indicator of treatment response. In the future, the agents may be improved by development of small targeting peptides and agents with theragnostic capability.

**Example 6: CAIX and CAXII are cell-surface markers for non small-cell lung cancer (NSCLC).**

Expression profiling of CAIX and CAXII in 147 NSCLC patient samples, 87 from NSCLC tumors and 60 from adjacent normal lung, are shown in Figure 5A and 5B. NCBI Gene Expression Omnibus (GEO) dataset GSE19188, shows that CAIX is expressed higher in 45% of NSCLC tumors compared to the highest expression observed in any adjacent normal tissue in the dataset, and that CAXII is expressed higher in 39% of NSCLC tumors (Figures 5A and 5B). Hence, these markers may be general markers for cancer and imaging probes against these markers may be used for detection of cancer of the lung as well as breast, and possibly other cancer types as well.

**Example 7: Mammaglobin-A expression in patient tissue samples**Materials and Methods

*DNA microarray analysis:* Affymetrix expression data for the mammaglobin-A gene (SCGB2A2) in patient tissue samples were compiled from publicly available datasets. The CEL files for the tumor samples were downloaded from the Gene Expression Omnibus (GEO) database (<http://www.ncbi.nlm.nih.gov/projects/geo/index.cgi>), data series GSE2109. Normal tissue data were from the GEO data series GSE7307, Human Body Index. The CEL files were processed using the MAS 5.0 algorithm (Affymetrix, Santa Clara, California) and screened through a rigorous quality control panel to remove samples with a low percentage of probesets called present by the MAS 5 algorithm, indicating problems with the amplification process or poor sample quality; high scaling factors, indicating poor transcript abundance during hybridization; and poor 3'/5' ratios, indicating RNA degradation either prior to or during processing. The remaining samples were normalized to the trimmed average of 500 in the MAS 5 algorithm before comparison of the expression values across tumors and normal samples.

*Immunohistochemistry (IHC) of Tissue Microarray (TMA):* A TMA was constructed at the Moffitt Tissue Core, containing 50 normal breast tissue, 50 ductal carcinoma in situ, 50 invasive ductal carcinomas without metastasis, 50 invasive ductal carcinomas with metastasis and 50 lymph node with macrometastases of breast carcinoma. The same method was previously reported by our group for construction of a Ewing sarcoma TMA (Sharma, P. et al. *Chem Mater* 20:6087-6094 (2008)), except the breast TMA has only one sample per case. Mouse anti-mammaglobin-A mAb, 1:50,

(Clone 304-1 A5, Thermo Scientific, Rockford, Illinois) was used for staining. Positive staining was arbitrarily set as membranous (partial or complete) and cytoplasmic immunoreactivity in greater than or equal to 5% of tumor cells. Results were recorded as positive or negative.

5            *Statistics:* Data are represented as mean  $\pm$  s.d. and the t-test was used to determine significance.

### Results

Several studies have demonstrated high expression of mammaglobin-A in breast cancer (Span, P. N. et al. *Br J Cancer* 89:271-276 (2003)). For further confirmation and  
10 to characterize mRNA expression in patient tissue samples, including lymph node metastases and normal tissues, publicly available DNA microarray data sets were analyzed. *Mammaglobin-A* mRNA was highly and generally expressed in breast tumors, breast cancer lymph node metastases and in normal breast (Fig. 6). A high percentage (83%) of lymph node metastases expressed mammaglobin-A. In contrast,  
15 mammaglobin-A was not expressed in normal lymph nodes. Also, other organs involved in toxicity or drug clearance, *i.e.*, liver, kidney, heart, lung and spleen did not express mammaglobin-A mRNA.

To determine mammaglobin-A protein expression in patient samples, immunohistochemistry (IHC) was performed on a breast cancer tissue microarray  
20 containing 250 samples. Positive staining was observed in the ductal epithelium of 63% of normal breast tissues, 80% DCIS, 53% invasive ductal carcinoma without metastasis, 43% invasive ductal carcinoma with metastasis and 45% lymph node with macrometastasis of breast cancer.

### **Example 8: ZR-75.1 breast cancer cells express mammaglobin-A**

25            Materials and Methods

*Stable transfection of ZR-75.1 cells:* The cells were transfected with 5  $\mu$ g of pLenti PGK Blast V5-LUC luciferase containing vector (Addgene, Cambridge, Massachusetts) using the ViraPower lentiviral expression system (Invitrogen, Carlsbad, California). In response to blasticidin (5  $\mu$ g/ml), resistant colonies appeared. Clones were  
30 screened by adding medium containing 150  $\mu$ g/ml D-luciferin potassium salt (GoldBioTechnology, St. Louis, Missouri) to the cells and the light detected by a Victor X4 2030 multiple plate reader (PerkinElmer, Waltham, Massachusetts).

*Cell culture:* Mammaglobin-A expressing ZR-75.1 (Robey, I.F. et al. *Neoplasia* 7:324-330 (2005); Goonewardene, T. I. et al. *Microsc Res Tech* 59:41-48 (2002); Ivanov, S. et al. *Am J Pathol* 158:905-919 (2001)) and non-expressing MDA-mb-231 (Ivanov, S. et al. *Am J Pathol* 158:905-919 (2001)) were obtained from and cultured according to  
5 ATCC recommendations.

*Quantitative real-time RT-PCR:* Mammaglobin-A primers were designed using Gene Runner Software for Windows version 3.05: forward, 5'-  
CTTCTTCAAGAGTTCATAGACGAC-3' (SEQ ID NO:3) and reverse, 5'-  
TGCTCAGAGTTTCATCCGTTTG-3' (SEQ ID NO:4).  $\beta$ -actin was used for  
10 normalization as described in our previous study (Sevick-Muraca, E.M. et al. *Radiology* 246:734-741 (2008)).

### Results

ZR-75.1 breast cancer cells endogenously express mammaglobin-A (Robey, I.F. et al. *Neoplasia* 7:324-330 (2005); Goonewardene, T. I. et al. *Microsc Res Tech* 59:41-48  
15 (2002); Ivanov, S. et al. *Am J Pathol* 158:905-919 (2001)) and MDA-mb-231 cells do not (Ivanov, S. et al. *Am J Pathol* 158:905-919 (2001)). To confirm this, mammaglobin-A mRNA expression was quantified by qRT-PCR in ZR-75.1 and MDA-mb-231 cells. As expected, mammaglobin-A was expressed in ZR-75.1 but not MDA-mb-231 cells. Western blot and immunocytochemistry (ICC) also confirmed protein expression.

### 20 **Example 9: Antibody and MamAb-680 characterization**

#### Materials and Methods

*Conjugation of antibody to dye:* Fifteen  $\mu$ g human Mammaglobin-A specific mouse mAb (Zeta Corp., California, Sierra Madre) was incubated with 10  $\mu$ g VivoTag-S 680 (VisEn Medical, Bedford, Massachusetts) and purified with a Sephadex G25 column  
25 (Roche, Indianapolis, Indiana). Protein (A280) and dye (A680) absorbance was determined using an ND-1000 spectrophotometer (NanoDrop, Wilmington, Delaware) and used to confirm the number of fluorophore molecules conjugated to each antibody molecule.

#### Results

30 The specificities of three different mammaglobin-A monoclonal antibodies were evaluated for sensitivity and specificity by Western blot and ICC. A highly specific mAb (Zeta Corp.) was selected for conjugation to near-infrared dye (VivoTag-S 680). The mAb conjugated with near-infrared dye is referred to herein as MamAb-680. To

evaluate the antibody-dye conjugation and to verify that MamAb-680 retained binding specificity, ICC was performed using only the dye-labeled primary antibody on the endogenously expressing ZR-75.1 cells, MDA-mb-231 cells engineered to express mammaglobin-A and the non-expressing MDA-mb-231 cells. MamAb-680 bound only to mammaglobin-A expressing cells. Hence, the conjugated agent retained specificity for mammaglobin-A protein.

**Example 10: Mammaglobin-A is expressed on the cell-surface**

Mammaglobin-A is directly associated with the surface of breast cancer cells (Supuran, C.T. et al. *Bioorg Med Chem* 15:4336-4350 (2007)). As described above, permeabilized fixed cells were used for ICC. To verify cell-surface expression, ZR-75.1 cells were incubated with MamAb-680 at 4°C. Agent was observed at the cell surface co-localized with agglutinin dye. Western blots of membrane protein extracts of mammaglobin-A positive cells stained positive for mammaglobin-A protein.

**Example 11: MamAb-680 selectively accumulates in positive tumors**

Materials and Methods

*Microscopic studies:* Cells and tissues from positive and negative xenograft tumors were fixed with cold methanol:acetone and incubated with 1 µg/µl MamAb-680 and 5.0 µg/mL of WGA (Invitrogen, Carlsbad, California) for 30 min. After washing, coverslips were mounted. Micrographs were acquired using a Leica DMI6000 inverted microscope and TCS SP5 tandem confocal scanner (Leica Microsystems, Germany).

*Statistics:* Data are represented as mean ± s.d. and the t-test was used to determine significance.

Results

To determine the specificity of MamAb-680 targeting *in vivo*, ZR-75.1 and MDA-mb-231 cells were implanted in the right and left mammary fat pads (MFP) of female nude mice. After tumor growth to approximately 500-800 mm<sup>3</sup> in volume, MamAb-680 was intravenously (i.v.) injected.

ZR-75.1 tumors retained higher levels of the agent signal compared to MDA-mb-231. Fluorescence signal in the positive tumor was 8.6 ± 0.8 s.d. (*n*=4, *p*<0.001) fold higher relative to the negative tumor. These results demonstrate the *in vivo* targeting specificity of MamAb-680.

To confirm the presence of mammaglobin-A protein *in vivo*, sections from flash-frozen tumors were stained with MamAb-680, a nuclear stain, 4',6-diamidino-2-

phenylindole (DAPI), and a cell-surface/cytoplasmic stain, wheat germ agglutinin (WGA), and analyzed using confocal microscopy. Mammaglobin-A staining was observed in tumors from the positively expressing cell line but not in the negative line. *Ex-vivo* images of the corresponding center sections of the tumors confirmed MamAb-680 localization to the positive tumor relative to the negative tumor.

### **Example 12: Pharmacodynamics and biodistribution of MamAb-680**

#### Materials and Methods

*Tumor xenograft studies:* Female *nu/nu* mice 6-8 weeks old (Harlan Sprague Dawley, Inc., Indianapolis, Indiana) were implanted subcutaneously with 0.72 mg of estradiol (Innovative Research of America, Sarasota, Florida). After two days,  $5 \times 10^6$  cells were implanted in the mammary fat pad. Once tumors reached 500-800 mm<sup>3</sup>, 50 µg MamAb-680, in 100 µL saline, was injected into the tail vein. In vivo fluorescence images were acquired using an IVIS-200 small animal imaging system (Caliper LifeSciences, Hopkinton, Massachusetts) using a 615-665 nm excitation and a 695-770 nm emission filter. Living Image 3.2 Software was used to draw regions of interest (ROIs) over the tumors to determine the mean tumor surface radiance. Autofluorescence background was subtracted by determining the mean tumor fluorescence signal prior to injection. Pharmacodynamics studies were performed by imaging at various time points. For biodistribution studies, mice were euthanized at 24 h post-injection, tissues excised and imaged *ex vivo* in the IVIS-200.

*Statistics:* Data are represented as mean  $\pm$  s.d. and the t-test was used to determine significance.

#### Results

To assess the pharmacodynamics of tumor uptake and clearance, MamAb-680 was injected intravenously (i.v.) and images acquired at intervals from 5 min to 12 d post injection. Fluorescence signal increased for 24 h and then slowly decreased at later time-points (Fig. 7A). Elevation of fluorescence in the positive tumor relative to the negative tumor was detected from 4 h to 10 days after injection.

For biodistribution studies, MamAb-680 was i.v. injected into mammaglobin-A positive and negative tumor-bearing mice and, 24 h later, the tumors and organs were removed and imaged *ex vivo*. Fluorescence was present in the positive tumor but agent was largely cleared from the negative tumor and other organs (Fig. 7B).

**Example 13: MamAb-680 detects tumor cells in axillary lymph nodes**Materials and Methods

*Tumor xenograft studies:* see description in Example 12.

*Orthotopic implantation of cells into ALN:* A range of 100 to 100,000 ZR-75.1/Luc cells in a 20  $\mu$ L volume of 1:1 matrigel and PBS were injected into the axillary lymph node using image guidance by a VEVO 770 ultrasound imaging system (VisualSonics, Toronto, Canada). Four h after injection of cells, 300  $\mu$ L of 15 mg/ml D-luciferin potassium salt was introduced via intraperitoneal injection and bioluminescence images were acquired using an IVIS-200. Twenty-four h after injection of cells, 50  $\mu$ g MamAb-680 was injected into the mammary fat pad proximal to ALN, and fluorescence imaging was performed.

*Statistics:* Data are represented as mean  $\pm$  s.d. and the t-test was used to determine significance.

Results

ZR-75.1 cells have not been reported to form ALN metastases. To determine this,  $5 \times 10^6$  ZR-75.1/Luc cells were implanted into the right MFP of estrogen-pelleted mice. Three weeks after implantation, tumors were surgically removed. Two weeks later, the tumor had re-grown and bioluminescence imaging showed metastasis to the ALN. Hence, ZR-75.1 cells are a suitable model for ER+ breast cancer lymph node metastasis.

To investigate whether MamAb-680 can be delivered through the lymphatics to selectively bind positive nodes, the agent was injected peritumorally into the MFP. At 24 h post-injection, the area of the ALN showed a strong fluorescence signal, which co-localized with the bioluminescence image of the luciferase expressing metastases. After imaging, the metastases was removed and the presence of cancer cells confirmed by H & E staining and pathological examination.

Agent selectivity was also determined for positive lymph nodes using an orthotopic model of lymph node metastasis. ZR-75.1/luc cells were directly injected into the ALN using ultrasound image guidance and were detected by bioluminescence. MamAb-680 was delivered by MFP injection and was observed to have traversed to the lymph node within 4 h. Fluorescence signal was retained in lymph nodes implanted with mamoglobin-A positive cells long after clearance from the MFP and negative lymph nodes. Positive lymph nodes were resolved as early as 4 h and were detected up to at least 7 days post-injection. These results show that *in vivo* lymphatic imaging using

MamAb-680 provided a specific and durable signal in mammaglobin-A expressing lymph node metastases.

As a control, animals were injected with PBS and Matrigel (no cells) into the ALN using the same method and amounts used above, then injected MamAb-680 into the MFP and imaged. Minimal signal was detected in the draining lymphatics at 4 h post-injection and no signal was observed at 24 h. At 48 h, agent was cleared from the animal.

To determine the sensitivity of the agent, a range in number of ZR-75.1/luc (1000 to 1 million) were injected into ALN via ultrasound guidance. For confirmation of successful cell implantation, bioluminescence images were acquired and as few as 1,000 cells (Fig. 8A) detected. Four hours after cell injection, MamAb-680 were injected into mammary fat pad proximal to the ALN and acquired fluorescence images 24 h after injection (Fig. 8B) and bioluminescent and fluorescent signals quantified by drawing a region-of-interest (ROI) encompassing the tumor cells in the ALN. Signal intensity decreased with cell number and at least 1,000 cells were detectable above background (Fig. 8B).

Mammaglobin is expressed in malignant breast tissues and is not expressed in normal lymph node (LN) or skin, as determined by DNA and tissue microarray. A mammaglobin targeted imaging probe has therefore been developed. Three monoclonal antibodies (mAbs) were compared by immunostaining of cells, tissues and Western analysis. One highly specific mAb was conjugated to a near-infrared dye (VivoTag 680, VisEn) and intravenously injected into nude mice bearing bilateral mammary fat pad (MFP) tumors of mammaglobin-positive (ZR-75.1) and mammaglobin-negative (MDA-mb-231) cells. *In vivo* fluorescence imaging showed agent was retained only in ZR-75.1 tumors. Selectivity for positive LNs was determined by implanting ZR-75.1/luc cells in the axillary LN using ultrasound guidance and monitoring by bioluminescence Labeled mAb was delivered by MFP injection and traversed to LN. Label was retained in mammaglobin-positive LNs long after clearance from the MFP and negative LNs.

#### **Example 14: Combination with other Antibodies**

##### Materials and Methods

*DNA microarray analysis:* Affymetrix expression data for the mammaglobin-A gene (SCGB2A2) in patient tissue samples were compiled from publicly available datasets. The CEL files for the tumor samples were downloaded from the Gene Expression Omnibus (GEO) database

(<http://www.ncbi.nlm.nih.gov/projects/geo/index.cgi>), data series GSE2109. Normal tissue data were from the GEO data series GSE7307, Human Body Index. The CEL files were processed using the MAS 5.0 algorithm (Affymetrix, Santa Clara, California) and screened through a rigorous quality control panel to remove samples with a low  
5 percentage of probesets called present by the MAS 5 algorithm, indicating problems with the amplification process or poor sample quality; high scaling factors, indicating poor transcript abundance during hybridization; and poor 3'/5' ratios, indicating RNA degradation either prior to or during processing. The remaining samples were normalized to the trimmed average of 500 in the MAS 5 algorithm before comparison of the  
10 expression values across tumors and normal samples.

*Immunohistochemistry (IHC) of Tissue Microarray (TMA):* A TMA was constructed at the Moffitt Tissue Core, containing 50 normal breast tissue, 50 ductal carcinoma in situ, 50 invasive ductal carcinomas without metastasis, 50 invasive ductal carcinomas with metastasis and 50 lymph node with macrometastases of breast  
15 carcinoma. The same method was previously reported by our group for construction of a Ewing sarcoma TMA (Sharma, P. et al. *Chem Mater* 20:6087-6094 (2008)), except the breast TMA has only one sample per case. Mouse anti-mammaglobin-A mAb, 1:50, (Clone 304-1 A5, Thermo Scientific, Rockford, Illinois) was used for staining. Positive staining was arbitrarily set as membranous (partial or complete) and cytoplasmic  
20 immunoreactivity in greater than or equal to 5% of tumor cells. Results were recorded as positive or negative.

*Statistics:* Data are represented as mean  $\pm$  s.d. and the t-test was used to determine significance.

### Results

25 To identify more targets, 3800 cell surface genes were curated from Gene Bank and used to filter DNA microarray data from 304 breast tumors (38 node positive), 111 normal breast tissues, 15 LNs, and 189 samples from 6 unaffected organ sites in the area surrounding the LNs and involved in clearance and toxicity. Of all genes, *CA-9* and *CA-12* were seen to be highly expressed in breast and LN-positive cancers but not in the  
30 normal tissues. Immunohistochemistry was performed on 50 normal breast tissues, 50 DCIS, 50 IDCs without metastasis, 50 IDCs with metastasis and 50 LN macrometastases. Nearly all (95%) of LN metastases expressed either CAIX or CAXII (Table 2). Thus, these CAs are valid targets for imaging of LN status for breast cancer.

Table 2. Coverage of breast cancer samples in the Moffitt breast cancer tissue microarray, including LN metastases, by three cell-surface markers, individually and in combination.

	Mammaglobin	CA9	CA12	Combination
DCIS	80.0%	71.4%	81.3%	100% (n=9)
IDC without Mets	53.1%	55.8%	78.7%	100% (n=28)
IDC with Mets	42.9%	56.5%	80.4%	93% (n=26)
LN Macro Mets	45.2%	71.4%	75.5%	100% (n=31)

Note that the three markers, mammaglobin, CA9 and CA12 cover 100% of the lymph node metastases (n = 51) on the tissue microarray

### Example 15: In vitro Identification and Functional Characterization of TLR2

#### ligands

#### 5 Materials and Methods

##### *Peptides, Antibodies, and Tetramers*

The test compounds (359, 360, 361, 362, 363, T-02, T-03, T-05) were synthesized and prepared with high purity. Lyophilized compounds were dissolved in DMSO at a 1 mg/mL concentration as stock solutions stored at -20 °C. For biological experimental use, 10 µg/mL working solutions of the compounds were prepared from stock solutions in sterilized, deionized water and used immediately. Commercially available synthetic TLR-2 agonists were used as references: Pam2CSK4 and Pam3CSK4 were purchased from InvivoGen (San Diego, CA) and recombinant human apo-SAA1 was purchased from Peprotech (Rocky Hill, NJ).

#### 15 *Cell Culture*

For the *in vitro* TLR2 bioassay, the parental HEK293 cells (ATCC, Manassas, VA) were cultured in DMEM/F12 media (Invitrogen, Carlsbad, CA) supplemented with 10% normal calf serum (Atlanta Biologicals, Lawrenceville, GA) and 1% penicillin/streptomycin solution (Sigma, St. Louis, MO). The commercially purchased HEK293/hTLR2 cells (InvivoGen, San Diego, CA), which are HEK293 cells stably transfected with pUNO-hTLR2 plasmid expressing the human TLR2 gene (Zuany-Amorim, C., J., et al. *Nat Rev Drug Discov*, 2002. 1(10):797-807), were cultured in DMEM/F12 media supplemented with 10% normal calf serum, 1% penicillin/streptomycin solution, 10 µg/mL blasticidin (InvivoGen). All cells were grown at 37°C and 5% CO<sub>2</sub>.

#### 25 *RT-PCR*

HEK293/hTLR2 and the parental HEK293 cells were seeded in T-25 flasks and grown to approximately 80% confluency. RNA was extracted from the cells using the GenElute Mammalian Total RNA Mini Prep kit (Sigma Aldrich). The RNA was treated with DNASE (Applied Biosystems Ambion, Austin, TX) then the RNA concentration  
5 was determined using the Nanodrop. Next, the RT-PCR was run using Superscript First-strand Synthesis System kit for RT-PCR (Invitrogen) and a Biorad PCR machine. The sequence for the forward TLR2 primer was TCTCCCAGTGTTTGGTGTG (SEQ ID NO:7); while the sequence for the reverse TLR2 primer was  
10 TGGTGTTTCATTATCTTCCGCAG (SEQ ID NO:8). The DNA samples were run on a 1% agarose gel with ethidium bromide and a 1 kb ladder.

#### *Western blot*

Western blot was performed under standard denatured and reduced conditions. The samples, HEK293 cells and HEK293/hTlr2 p3 cells, were prepared by growing up cells on 10cm petri dishes until 90% confluency was reached. The cells were lysed using  
15 RIPA Lysis and Extraction Buffer (Thermo Fisher Scientific Pierce) with Halt Protease Inhibitor Cocktail (Thermo Fisher Scientific Pierce). The protein concentrations of the cell lysates were measured by Pierce BCA Assay. The samples were then prepared for loading onto the SDS-PAGE gel by mixing 1:1 with 2x Laemmli Sample Buffer and boiled for 5 min at 95 °C. 30 µg per well of each cell lysate (n=3) was loaded onto a 10%  
20 Tris-glycine readymade gel (Invitrogen Novex). A molecular weigh marker (Biorad) was used. The gel ran at 125V for 90 min. The protein was then transferred from the gel to 0.4 micron nitrocellulose membrane (BioRad) for 2 hrs at 25V at 4 °C. After the transfer, the nitrocellulose blot was stained to check the transfer efficiency (Thermo Fisher Scientific Pierce). Membrane was blocked with 5% BSA/TBST blocking solution  
25 for 1h, then washed for 5 min with TBST, incubated for 2h with goat anti-TLR2 pAb (Abcam) at 1/2000 dilution, 3X wash with TBST for 15 min each, incubated with rabbit anti-goat (Abcam) at 1/5000 dilution for 1 hr, 3X wash with TBST for 15 min each. The blot was then developed using ECL Western Blotting Detection Kit efficiency (Thermo Fisher Scientific Pierce). The developed blot was then stripped using a stripping buffer  
30 so that the B-actin loading control could be shown. After stripping the blot, the blot was again developed to show that it had been successfully stripped of the previous antibodies. Next, it was then blocked for 1 hr with 5% BSA/TBST, then washed for 5 min with TBST, incubated for 2 hrs with goat anti-B-Actin pAb (Abcam) at 1/1000 dilution, 3X

wash with TBST for 15 min each, incubated with rabbit anti-goat at 1/5000 dilution for 1 hr, 3X wash with TBST for 15 min each. The blot was then developed using ECL Western Blotting Detection Kit. The methods above were optimized conditions.

#### *In vitro TLR2 Functional Bioassay*

5           The *in vitro* TLR2 functional bioassay was developed and optimized for use in screening soluble compound libraries to identify both TLR2 agonists and antagonists. In this study, the TLR2 functional bioassay was used as a fast high throughput screening to identify TLR2 agonist ligands by measuring the inducing activity of NF- $\kappa$ B. HEK293/hTLR2 cells, highly overexpressing human TLR2, were used along with the  
10           parental HEK293, cells as a negative control. Cells were seeded at a density of 40,000 per well using a WellMate® Microplate dispenser (Thermo Fischer Scientific/ Matrix) in black 96-well plates with opaque white wells (Perkin Elmer Wallac, Waltham, MA) and then incubated at 37°C. On day 2, the cells were transiently transfected with pNifty-Luc (InvivoGen), an NF- $\kappa$ B inducible reporter plasmid expressing the luciferase reporter  
15           gene (Zuany-Amorim, C., J., et al. Nat Rev Drug Discov, 2002. 1(10):797-807), using an optimized 4:1 ratio by volume of Fugene® HD Transfection Reagent (Roche Applied Science, Indianapolis, IN) to pNifty-Luc plasmid DNA (1  $\mu$ g/mL). On day 3, the cells were stimulated with either test peptides or controls adjusted to a final concentration of 1  $\mu$ g/mL using a NanoDrop Spectrophotometer, ND1000 (Thermo Fisher Scientific). On  
20           day 4 after 24 hrs of peptide stimulation, luciferase induced activity by the induction of NF- $\kappa$ B was measured. Media was aspirated from the wells using an ELx405 Select plate washer (BioTek, Winooski, VT), 150  $\mu$ g/mL D-luciferin (Gold Biotechnology, St. Louis, MO) was dispensed using the microplate dispenser; the plates were incubated at 37 °C for 5 min. The luminescence intensity was measured using the standard luminescence  
25           protocol on a Victor™ X4 plate-reader equipped with a plate stacker for readout of multiple plates at a time (PerkinElmer, Waltham, MA). For each *in vitro* TLR2 bioassay, at least three different experiments were performed in triplicate (n=3+). Data were analyzed with GraphPad Prism software and curves were generated with the appropriate nonlinear fit regression analysis.

#### 30           *Statistical Analysis*

The results were represented as mean  $\pm$  s.d. and statistically evaluated by the Student's *t* test to determine statistical significance.

### Results

To identify TLR2 ligands with high activity and a built-in site for attachment of imaging contrast or therapeutic agents for the detection or treatment of pancreatic cancer, an *in vitro* high-throughput functional bioassay was developed to screen agonist ligand libraries for TLR2 activity. The assay was optimized prior to screening using the commercially available synthetic ligand Pam3CSK4, which induces TLR2 signaling to produce NF- $\kappa$ B. An expression vector containing the luciferase gene under control of an NF- $\kappa$ B activatable promoter was transfected into HEK293/hTLR2 cells. Optimal luciferase activity was observed 48h post transient transfection and 24 h post ligand stimulation (Figure 9). Luciferase activity was significantly greater (50 fold, n = 6, p<0.001 by t-test) in Pam3CSK4 ligand stimulated HEK293/hTLR2 cells relative to HEK293/hTLR2 cells incubated with no ligand; while the ligand stimulated HEK293 cells did not exhibit any significant NF- $\kappa$ B luciferase activity. Therefore, the measured luciferase activity via NF- $\kappa$ B induced activity is not due to non-specific interactions. Expression of human TLR2 in the HEK293/hTLR2 cells relative to the parental HEK293 cells was confirmed by RT-PCR and Western blot.

The TLR2 functional bioassay was used to screen a set of seven X-Dhp(Pam2)-peptide MALP2 compounds to identify TLR2 agonist ligands (Table 3). These X-Dhp(Pam2)-peptide MALP2 compounds (1-7 in Table 6; 357-363 in Table 3) are fully synthetic soluble compounds that were designed using the commercially available synthetic TLR2 agonist peptide ligand, Pam2CSK4 (Invivogen), as a template. Pam2CSK4 (S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-[R]-cysteinyl-[S]-seryl-[S]-lysyl-[S]-lysyl-[S]-lysyl-[S]-lysine) is a commercially available synthetic diacylated lipopeptide (LP). Typically, Pam2CSK4 and other diacylated LPs activate the formation of heterodimers between TLR2 and TLR6. Each compound in the set had the same scaffold, X-Dhp(Pam2)-peptide MALP2, where "X" represents an N-terminal manipulation for each compound. "X" represents the addition of: Palmitoyl (C16) for compound 1, Fluorescein for compound 2, Ac-PEGO20 for compound 3, Ac-Aha (C6) for compound 4, Adapaleneyl for compound 5, Ac-Aun (C11) for compound 6, and Tretinoyl for compound 7. Palmitoyl was chosen for 1 because palmitoyl groups are the most common type of lipid chain in bacterial lipoproteins (Belisle, J.T., et al. *J Bacteriol*, 1994. 176(8):2151-7; Mizuno, T., et al. *J Biochem*, 1979. 86(4):991-1000; Zlotnick,

G.W., et al. *J Biol Chem*, 1988. 263(20):9790-4; Braun, V., et al. *Biochim Biophys Acta*, 1975. 415(3):335-77).

Table 3. X-Dhp(Pam<sub>2</sub>)-peptide MALP2 derived synthetic compound library set

Compound	Structure	X Modification	Molecular Weight (g/mole)	TLR2 Agonist Activity
357	Pam-Dhc(Pam) <sub>2</sub> -Gly-Asn-Asn-Asp-Glu-Ser-Asn-Ile-Ser-Phe-Lys-Glu-Lys-NH <sub>2</sub> (SEQ ID NO:10)	Palmitoyl(C16)	2371.4	Yes
358	Fluorescein-Dhc(Pam) <sub>2</sub> -Gly-Asn-Asn-Asp-Glu-Ser-Asn-Ile-Ser-Phe-Lys-Glu-Lys-NH <sub>2</sub> (SEQ ID NO:10)	Fluorescein	2491.3	Yes
359	Ac-PEGO20-Dhc(Pam) <sub>2</sub> -Gly-Asn-Asn-Asp-Glu-Ser-Asn-Ile-Ser-Phe-Lys-Glu-Lys-NH <sub>2</sub> (SEQ ID NO:10)	Ac-PEGO20	2493.4	Yes
360	Ac-Aha-Dhc(Pam) <sub>2</sub> -Gly-Asn-Asn-Asp-Glu-Ser-Asn-Ile-Ser-Phe-Lys-Glu-Lys-NH <sub>2</sub> (SEQ ID NO:10)	Ac-Aha (C6)	2288.3	Yes
361	Adapalene-Dhc(Pam) <sub>2</sub> -Gly-Asn-Asn-Asp-Glu-Ser-Asn-Ile-Ser-Phe-Lys-Glu-Lys-NH <sub>2</sub> (SEQ ID NO:10)	Adapaleneyl	2526.4	Yes
362	Ac-Aun(C11)-Dhc(Pam) <sub>2</sub> -Gly-Asn-Asn-Asp-Glu-Ser-Asn-Ile-Ser-Phe-Lys-Glu-Lys-NH <sub>2</sub> (SEQ ID NO:10)	Ac-Aun (C11)	2358.4	Yes
363	Tretinoin-Dhc(Pam) <sub>2</sub> -Gly-Asn-Asn-Asp-Glu-Ser-Asn-Ile-Ser-Phe-Lys-Glu-Lys-NH <sub>2</sub> (SEQ ID NO:10)	Tretinoyl	2414.4	Yes

5           The structure activity relationships (SAR) of the compound set was investigated by manipulating the N-terminus portion of the peptide to enhance specificity, potency, and binding to TLR2 expressed on the cell surface. Synthetic LPs containing di- or tri-acylated cysteine groups are known mimic lipoprotein proinflammatory properties; indicating the acylated N-terminal cysteine is the most critical portion of the immune stimulatory motif (Bessler, W.G., et al. *J Immunol*, 1985. 135(3):1900-5; Berg, M., et al. *Am J Physiol*, 1994. 266(6 Pt 1):C1684-91; Seifert, R., et al. *Biochem J*, 1990. 267(3):795-802). Wu et al closely examined the roles of the highly conserved Cys residue and Cys-Ser dipeptide unit using a human TLR2 reporter gene assay (Takeda, K., et al. *Annu Rev Immunol*, 2003. 21:335-76) . They concluded that (R)-diacylthioglycerol analogues are maximally active. Others have reported that the Cys-Ser dipeptide unit is

the minimal structure for biological activity (Wu, W., et al. *J Med Chem.* 53(8):3198-213; Prass, W., et al. *Biochim Biophys Acta*, 1987. 900(1):116-28) and the thioether bridge between the diacyl and dipeptide units is crucial (Takeda, K., et al. *Annu Rev Immunol*, 2003. 21:335-76).

5 All seven of the compounds exhibited high levels of NF- $\kappa$ B induced luciferase activity when screened using the TLR2 functional bioassay comparable to the reference TLR2 agonist ligand controls, Pam2CSK4 and Pam3CSK4 (Figure 10). Typically, Pam2CSK4 and other diacylated LPs activate the formation of heterodimers between TLR2 and TLR6. However, TLR2 is also recognized by some diacylated LPs, such as  
10 Pam2CSK4, to induce signaling in a TLR6-independent manner according to murine model studies suggesting that both the lipid and peptide portion of the LP play a role in the recognition of TLR2 heterodimers (Buwitt-Beckmann, U., et al. *FEBS J*, 2005. 272(24):6354-64; Buwitt-Beckmann, U., et al. *Eur J Immunol*, 2005. 35(1):282-9). Pam3CSK4 (N-Palmitoyl-S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-[R]-cysteinyl-[S]-  
15 seryl-[S]-lysyl-[S]-lysyl-[S]-lysyl-[S]-lysine) is a synthetic tripalmitoylated LP that mimics the acylated amino terminus of bacterial LPs. It is a highly potent activator of NF- $\kappa$ B through induction of a signaling cascade by the recognition of the heterodimerization of TLR2 with TLR1 and also independently of TLR6 (Aliprantis, A.O., et al. *Science*, 1999. 285(5428):736-9; Ozinsky, A., et al. *Proc Natl Acad Sci U S A*, 2000. 97(25):13766-71; Takeuchi, O., et al. *Int Immunol*, 2001. 13(7):933-40; Takeuchi, O., et al. *J Immunol*, 2002. 169(1):10-4). In the screenings the positive agonist ligand controls, Pam2CSK4 and Pam3CSK4, did not exhibit significant NF- $\kappa$ B induced luciferase activity in the non-expressing TLR2 cell line, HEK293. This indicated that the NF- $\kappa$ B induced luciferase activity was specifically due to the TLR2 agonist ligand that  
20 specifically binds and activates TLR2s and was not due to non-specific interactions. Based on these results, all seven X-DhP(Pam2)-peptide MALP2 compounds exhibit TLR2 agonist activity when screened using the TLR2 bioassay at a 1  $\mu$ g/mL concentration.

30 A TLR2 agonist analog derived peptide library of soluble compounds designed to be more potent TLR2 agonists based on the SAR modifications was developed, synthesized, and screened (Table 4). This set of compounds are all fully synthetic, derived from different origins, and based on SAR modifications they should have more potential to be more acidic, hydrophilic, and more soluble than first library due to the

addition of PEGO groups, which are hydrophilic components. T-02 (Ac-PEGO-Dhc (Pam)<sub>2</sub>-Gly-Ser-PEGO-NH<sub>2</sub>) was derived from synthetic origin based on the scaffold of MALP2 with manipulation of N terminal PEGO. T-03 (Ac-PEGO-Dhc(Pam)<sub>2</sub>-Ser-Arg-Phe-Asp-Glu-Asp-Asp-Leu-Glu-NH<sub>2</sub>, SEQ ID NO:5) was derived from CD14 peptide origin manipulation of N-terminal PEGO. T-05 (Ac-PEGO-Dhc(Pam)<sub>2</sub>-Gly-Ser-Gln-Asn-Leu-Ala-Ser-Leu-Glu-Glu-NH<sub>2</sub>, SEQ ID NO:6) was derived from *S. aureus* peptide origin that should be more acidic or at least neutral compared to recently identified potent TLR2 agonist, SAA (serum amyloid A) by Cheng et al. (Jin, M.S., et al. *Immunity*, 2008. 29(2):182-91). The tested SAA was a recombinant human Apo-SAA1 (Peprotech) derived from *E. coli*. SAA is a major acute-phase protein that is considered to be a marker for inflammatory diseases even though its role is still not fully known. As shown in Figure 11, all three of the compounds exhibited high levels of luciferase activity when screened using the TLR2 functional bioassay (n = 4, p<0.001 by t-test). These levels were comparable to the Pam3CSK4 reference control and much more potent than SAA at both 1 µg/mL and 10 µg/mL. However, Cheng et al. did observe that heat-treated SAA (95°C for 30min) lost 95% of its activity in a similar type of NF-κB luciferase screening assay, thus indicating that SAA may be easily degraded by heat (Jin, M.S., et al. *Immunity*, 2008. 29(2):182-91). The low potency of SAA observed in the screening assay may be due to heat degradation because the cells were stimulated with ligand for 24 h at 37°C versus only 5 hours in the Cheng et al screening assay (Jin, M.S., et al. *Immunity*, 2008. 29(2):182-91). The higher potency of the X-Dhp(Pam<sub>2</sub>)-peptide MALP2 compound set may indicate that there is improved stability compared to SAA compound.

Table 4. TLR2 agonist analog synthetic compound library set

Compound	Structure	Origin	Molecular Weight (g/mole)
359	Ac-PEGO <sub>20</sub> -Dhc(Pam) <sub>2</sub> -Gly-Asn-Asn-Asp-Glu-Ser-Asn-Ile-Ser-Phe-Lys-Glu-Lys-NH <sub>2</sub> (SEQ ID NO:10)	Synthetic MALP2	2493.4
T-02	Ac-PEGO-Dhc (Pam) <sub>2</sub> -Gly-Ser-PEGO-NH <sub>2</sub>	Synthetic MALP2	1492.9
T-03	Ac-PEGO-Dhc(Pam) <sub>2</sub> -Ser-Arg-Phe-Asp-Glu-Asp-Asp-Leu-Glu-NH <sub>2</sub> (SEQ ID NO:5)	CD14	2137.2
T-05	Ac-PEGO-Dhc(Pam) <sub>2</sub> -Gly-Ser-Gln-Asn-Leu-Ala-Ser-Leu-Glu-Glu-NH <sub>2</sub> (SEQ ID NO:6)	<i>S. aureus</i>	2059.2
Pam2CSK4	S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-[R]-cysteinyl-[S]-seryl-[S]-lysyl-[S]-lysyl-[S]-lysyl-[S]-lysine (SEQ ID NO:11)	Synthetic	1271.85
Pam3CSK4	N-Palmitoyl-S-[2,3-bis(palmitoyloxy)-(2RS)-	Synthetic	1509.6

SAA (recombinant human apo-SAA1)	propyl]- [R]-cysteinyl-[S]-seryl-[S]-lysyl-[S]- lysyl-[S]-lysyl-[S]-lysine (SEQ ID NO:11) MRSFFSFLGE AFDGARDMWR AYSDMREANY IGSDKYFHAR GNYDAAKRGP GGVWAAEAS DRENIQRFFG HGAEDSLADQ AANEWGRSGK DPNHFRPAGL PEKY (SEQ ID NO:9)	<i>E. coli</i>	11.7
--	--	----------------	------

\* indicates reference peptide.

The potency of the second set of TLR2 agonist analog compounds (T-02, T-03, and T-05) were further characterized along with compound 359 from the first set, and Pam2CSK4, and Pam3CSK4 as reference compounds. The activity of each TLR2 agonist was measured using the *in vitro* TLR2 functional bioassay over a range of doses from 0.01 ng/mL to 1 µg/mL. Figures 12A-12F show the normalized dose-response curves generated by measuring the TLR2 agonistic activity for each compound over the range of concentrations.

EC<sub>50</sub> values were generated from the dose-response curves. The EC<sub>50</sub> of a dose response curve represents the concentration of an agonist where 50% of its maximal effect is observed. The EC<sub>50</sub> value of T-02 was the lowest at 20.09 nM concentration with a 95% confidence interval of 26.55 to 30.05 nM; while 3.66 nM and 22.54 nM are the EC<sub>50</sub> values for Pam2CSK4 and Pam3CSK4 respectively (Table 5). T-02 is also the smallest structure, with a molecular weight of 1492 g/mol, amongst the novel synthetic TLR2 agonists. Even though it is still in the low nanomolar concentration range, compound T-05 exhibited the highest EC<sub>50</sub> value, 78.41 nM in our TLR2 functional bioassay which was nearly 4 times higher concentration than T-02. Compound T-05 was not the largest of the peptides but was the only peptide that had a bacterial origin scaffold, while the origin of T-02 is the synthetic form of MALP-2. It is also worth noting that the curves for each ligand tested follow the typical sigmoidal shape that is expected of a receptor binding curve. Except for the curves of the 2 most potent TLR2 ligands, T-02 and T-03, NF-κB luciferase activity decreased at 1 µg/mL, the highest concentration. This decrease in NF-κB luciferase activity may be due to steric hindrance caused by over saturation of the ligand; which is supported by the fact these 2 ligands are nearly 2 to 4 times more potent compare than the other ligands. Based on these results, it was concluded that T-02, T-03, T-05, and 359 are highly potent activators of TLR2 with *in vitro* EC<sub>50</sub> concentrations in the low nanomolar range from 20.09 nM to 78.41 nM,

indicating that these fully synthetic agonists have high affinity and high efficacy for TLR2.

Table 5. EC<sub>50</sub> Values calculated from log(agonist) vs. normalized response

Compound	EC <sub>50</sub> (nM)	95% Confidence Interval (nM)	R Square Value
359	55.64	181.60 to 201.10	0.9989
T-02	20.09	26.55 to 30.05	0.9997
T-03	24.97	45.27 to 63.20	0.9979
T-05	78.41	118.80 to 130.40	0.9993
Pam2CSK4	3.66	1.08 to 4.91	0.9577
Pam3CSK4	22.54	17.70 to 102.30	0.9363

### Example 16: Evaluation of In Vivo Cellular Immune Responses

#### 5 Materials and Methods

##### *Animals*

All procedures were in compliance with the Guide for the Care and Use of laboratory Animal Resources (1996), National Research Council, and approved by the Institutional Animal Care and Use Committee, University of South Florida.

10 Immunocompromised mice were housed in a clean facility with special conditions that include HEPA filtered ventilated cage systems, autoclaved bedding, autoclaved housing, autoclaved water, irradiated food and special cage changing procedures. Mice were handled under aseptic conditions including the wearing of gloves, gowns and shoe coverings.

#### 15 *In Vivo Cellular Immune Response Assays*

To assess the efficacy of T-02 as an immune adjuvant, mice were immunized i.v. with a mixture of 100 µg optimized Trp<sub>1455/9M</sub> peptide (Guevara-Patino, J.A., et al. *J Clin Invest*, 2006. 116(5):1382-90), 50 µg anti-CD40 mAb (Clone; FGk-45.5), and 50 µg TLR-2 peptide (T-02, Pam2CSK4, or Pam3CSK4). When the Trp<sub>1455/9M</sub> peptide was  
 20 tested using the TLR2 functional bioassay, it was determined that it is not a TLR2 agonist. The response of tetramer<sup>+</sup> CD8 T cells in the blood was measured on day 7, 21, and 34 by tetramer staining. For tetramer staining, peripheral blood was taken from the submandibular vein and treated briefly with ammonium chloride buffer to lyse red blood cells. Blood cells were stained with FITC-conjugated anti-MHC class II, PerCP Cy5.5-  
 25 conjugated CD8a (both from eBioscience, San Diego, CA), and phycoerythrin-

conjugated Trp<sub>1455/9M</sub>/ H-2D<sup>b</sup> tetramers (provided by the NIH tetramer Facility, Emory University, Atlanta GA) for 40 min in ice. Fluorescence was evaluated using a FACSCalibur™ flow cytometer (BD Biosciences) and analyzed using FlowJo software.

## 5            Results

Using TLR agonists as vaccine adjuvants is a very promising application that has been highly explored to prevent and treat cancer as well as infectious diseases. The use of TLR agonists as immune adjuvants in peptide vaccination together with anti-CD40 monoclonal antibodies can increase the magnitude and duration of T-cell responses  
10            resulting from various types of immunizations including peptide vaccines (Cho, H.I., et al. *Cancer Res*, 2009. 69(23):9012-9; Celis, E., et al. *Cancer Res*, 2007. 67(17):7945-7).

Accordingly, the activity of T-02 as an immune adjuvant was selected to be evaluated *in vivo* and compared to the well-characterized commercially available synthetic TLR-2 agonists, Pam2CSK4 and Pam3CSK4. For these experiments, a peptide  
15            was selected from mouse tyrosinase-related protein-1 (Trp<sub>1455/9M</sub>) that serves as an epitope for CD8 T cells in the context of H-2D<sup>b</sup> (Guevara-Patino, J.A., et al. *J Clin Invest*, 2006. 116(5):1382-90). The Trp<sub>1455/9M</sub>-specific CD8 T cell responses were monitored in the blood on days 7, 21, 34 post-administration of immune adjuvants and analyzed by flow cytometry. No signs or symptoms of stress or toxicity were observed  
20            in the mice over the course of the experiment. Kimbrell et al. reported that LPs are extremely potent TLR2 agonists *in vivo* with no apparent toxicity in animal models (Kimbrell, M.R., et al. *Immunol Lett*, 2008. 118(2):132-41).

High fluorescence was observed on day 7 for the stained tetramer positive CD8 T cells for T-02, Pam2CSK4, and Pam3CSK4. The 100% response rate of the tetramer  
25            positive CD8 T cells using T-02 as immune adjuvant was observed on day 7 decreased to levels comparable to using either Pam2CSK4 or Pam3CSK4 on day 21 (Figure 13). These results indicate that the TLR-2 agonist T-02 exhibited similar *in vivo* activity comparable to the TLR-2 agonists, Pam2CSK4 and Pam3CSK4, for the generation and persistence of antigen-specific CD8 T cells. Therefore, T-02 ligand is a highly potent  
30            TLR2 agonist both *in vitro* and *in vivo* that is comparable to the reference TLR2 ligands Pam2CSK4 and Pam3CSK4.

### **Example 17: Binding assays**

#### Materials and Methods

*Time resolved fluorescence competitive and saturation binding assays*

TRF binding assays were performed as previously described (*see* Xu, L., et al. *Mol Cancer Ther.* 2009 8(8):2356-65).

### Results

Direct binding assays for TLR2 have not typically been used to determine  
5 biological activity, while SAR has been mostly determined by various reporter gene or  
functional cell-based assays (Kanzler, H., et al., et al. *Nat Med*, 2007. 13(5):552-9). A  
time-resolved fluorescence competitive and saturation binding assays was performed for  
the T-02 ligand and T-02 ligand conjugates. By competitive binding assay, T-02 bound  
with 25 nM Ki (Fig 15A). A version of the T-02 conjugated to the LiCor IRDye800CW  
10 (Fig. 14) bound with a comparable 10 nM Ki affinity (Fig. 15B). A version conjugated  
with a Eu-DTPA chelate bound with 30 nM Kd. The LiCor IRDye800CW/T-02  
conjugate (Fig. 14) was injected into an animal bearing a TLR2 expressing SU.86.86  
pancreatic cancer cell xenograft and was shown to be retained in the tumor at 24 h post  
injection while the agent had cleared from the animal except for the kidneys (Fig. 15C).  
15 The agent cleared from the kidney within days of the injection but was retained longer in  
the tumor. A time course demonstrated that a low 10 nmol/Kg dosage was retained in the  
SU.86.86 tumor for over 96 h (Fig. 15). The agent was also taken into and retained in  
orthotopic pancreatic tumor xenografts.

### **Example 18: Minimal Peptide TLR2 Ligands**

20 The discovery of ligands and small-molecular-mass synthetic compounds that  
specifically activate Toll-like receptor 2 (TLR2) has raised interest in this cell-surface  
receptor as a potential target for the development of new therapies, including the  
treatment of cancer.<sup>1</sup> TLR2 has a role in activation and regulation of the innate immune  
system and targeted stimulation of this receptor has been used to augment cancer  
25 immunotherapy.[1a, 2] Although TLR2 is predominantly expressed in tissues involved in  
immune function, the expression profile varies among tissues and cell types.[3] TLR2 is  
a type I transmembrane glycoprotein characterized by an external antigen recognition  
domain comprised of a highly conserved leucine-rich repeat motif, a transmembrane  
domain, and a cytoplasmic Toll/interleukin-1 (TIR) receptor homology signaling  
30 domain. Intracellular signaling is activated by agonist binding and is facilitated by the  
formation of the cytoplasmic TIR domain through heterodimerization with either TLR1  
or TLR6.[4, 5] TLR2 is a pattern recognition receptor with the ability to recognize  
pathogen-associated molecular patterns (PAMPs).[6] Stimulation by PAMPs initiates

signaling cascades that activate NF- $\kappa$ B transcription factors inducing the secretion of pro-inflammatory cytokines and effector cytokines directing the immune response.[6c]

The potential use of synthetic TLR2 agonists for the enhancement of cancer immunotherapy is an active area of research. There are four mechanisms by which TLR2 stimulation may produce significant antitumor activity: enhancement of the innate immunity, enhancement of T-cell immunity, enhancement of cytotoxic antibody function, and induction of apoptosis in TLR2-positive tumors.[1a] Examples include, the TLR2 induction of tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), increasing the production of nitric oxide synthase (iNOS) and thus inducing apoptosis of chemotherapy-resistant tumor cells;[7] reduction of bladder tumor growth by TLR2 agonist, SMP-105;[8] and TLR2 targeted induction of the immune system by the lipid-A derivative drug, OM-174, as a cancer vaccine adjuvant during immunotherapy.[9] We have developed the TriVax vaccine using TLR agonists as immune adjuvants in combination with peptide vaccination and anti-CD40 monoclonal antibodies, which can increase the magnitude and duration of vaccine-induced T-cell responses, eliciting potent protective antitumor immunity as well as remarkable therapeutic effects against melanoma.[10]

In an effort to improve the less than 6% 5 year survival rate for pancreatic cancer, TLR2 ligands are being studied for use in targeted pancreatic cancer imaging and treatment.[11] Improved survival rates are associated with the surgical resection of the primary tumor if the tumor tissue is completely removed at the margins.[12] However, it is a high risk procedure with a low success rate due to difficulty in clearly identifying tumor tissue from normal tissue, resulting in positive resection margins (R1).[13] The development of new intraoperative surgical methods employing fluorescence guided tumor detection could lead to increased negative resection margins (R<sub>0</sub>) resulting in improved survival rates. Recent clinical studies involving image-guided surgeries have demonstrated the potential of this approach.[14, 15] We have previously reported TLR2 as a bona fide cell surface marker for pancreatic cancer that is highly expressed in 70% of pancreatic tumors but is not highly expressed in surrounding normal pancreas tissue.[16] Fluorescence imaging probes developed using TLR2 specific ligands could be applied to the intraoperative detection of pancreatic tumor margins.

A variety of microbial component derived lipopeptides (LPs) are recognized as TLR2 ligands. For example, mycoplasma produce diacylated macrophage-activating lipopeptides 2-kDa (MALP-2), Cys(*S*-[2,3-bisacyloxy-(*R*)-propyl])-Gly-Asn-Asn-Asp-

Glu-Ser-Asn-Ile-Ser-Phe-Lys-Glu-Lys (SEQ ID NO:10), bind to the TLR2/TLR6 heterodimer.[17] The structure-activity relationships (SAR) of TLR2 binding and stimulation of the immune system for many synthetic LPs are well documented in the literature. Both the well-characterized synthetic di- and tri-acylated LP ligands, Pam<sub>2</sub>CSK<sub>4</sub> and Pam<sub>3</sub>CSK<sub>4</sub>, bind to internal protein pockets through hydrophilic interactions to selectively induce signaling via the TLR2/TLR6 and TLR2/TLR1 heterodimers, respectively.[5, 17c, 18] In addition to LPs, the serum amyloid A protein (SAA) was recently identified as a potent TLR2 agonist by Cheng *et al.*, and is a major acute-phase protein that is considered to be a marker for inflammatory diseases.[19]

TLR2 specific agonist ligands developed herein have potential for use in both the development of targeted agents for the imaging and treatment of pancreatic cancer, and as an adjuvant for cancer immunotherapy. In an effort to identify novel TLR2 ligands that are highly potent TLR2 agonists for use in immunotherapy, or ligands with high binding affinity for TLR2 with potential for attachment of imaging contrast and therapeutic agents, we have iteratively synthesized two sets of rationally designed synthetic compounds and investigated their SAR by functional bioassays, *in cyto* binding assays, *in vivo* immune system stimulation and molecular imaging studies demonstrating tumor specificity. Compound **10** had potent bioactivity (20 nM EC<sub>50</sub>), high affinity binding (24 nM K<sub>i</sub>) and effective immune system stimulation. After conjugation of a near-infrared fluorescent dye to **10** generating **13**, high bioactivity (34 nM EC<sub>50</sub>) and binding affinity (11 nM K<sub>i</sub>) were retained, and tumor specificity was observed *in vivo* by fluorescence imaging of mice bearing xenograft tumors. In addition, **10** has a greatly simplified synthesis strategy with improved solubility and a built-in attachment point for imaging contrast and/or a therapeutic moiety.

Toll-like receptor 2 (TLR2) is a target for immune system stimulation during cancer immunotherapy and a cell-surface marker for pancreatic cancer. To develop targeted agents for cancer imaging and therapy, we designed, synthesized and characterized thirteen novel, fully synthetic high affinity TLR2 agonists, based on known structure activity relationships. Analog **10** had the highest agonist activity (NF-κB functional assay, EC<sub>50</sub> = 20 nM) and binding affinity (competitive binding assay, K<sub>i</sub> = 25 nM). *In vivo* mouse studies determined that compound **10** stimulated the immune system by generation and persistence of antigen-specific CD8 T cells indicating its potential use in cancer immunotherapy. After conjugation of a near-infrared dye to **10**, agonist activity

(EC<sub>50</sub> = 34 nM) and binding affinity (K<sub>i</sub> = 11 nM) were retained in **13**. Compound **13** has the lowest mass (2729 MW), and highest binding affinity (11 nM K<sub>i</sub>) and agonist activity (34 nM EC<sub>50</sub>) (Figure 16A) retained after conjugation of the IR800CW NIR dye (Compound **13**: IRDye800CW-MPA-PEGO-dihydroxycysteine(palmitoyl)<sub>2</sub>-Gly-Ser-Ac-PEGO-NH<sub>2</sub>; Figure 25). Fluorescence signal was present in TLR2 expressing pancreatic tumor xenografts 24 h post-injection of **13**; while an excess of unlabeled ligand blocked **13** from binding to the tumor resulting in significantly decreased signal (p<0.001) demonstrating *in vivo* selectivity.

Improved survival rates for pancreatic cancer are associated with the complete surgical resection of tumor resulting in a tumor-free margin (R<sub>0</sub>). New methods employing intraoperative fluorescence (FL) guided tumor detection could lead to increased R<sub>0</sub> margins and improved survival. We have reported Toll-like receptor 2 (TLR2) as a bona fide cell-surface marker for pancreatic adenocarcinoma. We then developed a high-affinity TLR2 binding ligand conjugated to a near-infrared (NIR) fluorescent dye, IR800CW, as a targeted molecular imaging probe for the intraoperative detection of surgical margins. To evaluate the *in vivo* pharmacokinetics and biodistribution of compound **13**, FL imaging was performed on multiple optical imaging systems (PerkinElmer IVIS 200 and FMT2500XL, and ART Optix MX3) using TLR2 expressing pancreatic tumor xenograft mouse models (subcutaneous and orthotopic). Tumor specificity was observed, in which FL signal was retained in TLR2 expressing tumor xenografts up to 96 h post-injection while blocking with an excess of unlabeled competing ligand significantly decreased FL signal in the tumor at 24h (p<0.001) (Figure 16B). To investigate the possibility of achieving R<sub>0</sub> margins and improved survival rates using compound **13**, *in vivo* FL guided intraoperative surgical removal of orthotopic pancreatic tumors 24h post-injection was performed using a Diagnostic Instruments adapted LightTools system outfitted with an 800 nm filter set, cooled CCD camera and SPOT Advanced software (Figure 16D); and compared to mice that underwent surgical resection of tumors using normal light. We have previously demonstrated the feasibility of the intraoperative detection of tumors using a different well-characterized Cy5-labeled probe (Dmt-Tic-Cy5) that we also developed. The resected tumors from both groups were then FL imaged *ex vivo*. Prior to surgery, the orthotopic pancreatic tumor volumes were monitored weekly and measured *in vivo* by 3D ultrasound imaging. Mice underwent *in vivo* FL imaging up to 72 h post-surgery to confirm complete resection of

the tumors. The excised tumors and remaining normal pancreas underwent H&E staining, IHC for TLR2 expression and pathological evaluation of the margins. *In vivo* tumor selectivity and intraoperative detection of pancreatic cancer were demonstrated. This method will improve pancreatic cancer survival by increasing the percentage of R<sub>0</sub> margins.

## RESULTS

**TLR2 Ligand Library Design and Synthesis.** Thirteen novel fully synthetic compounds were designed and synthesized to discover novel TLR2 specific ligands with the desired properties of high specificity, high agonist activity, high binding affinity, solubility and built-in attachment points for conjugation of fluorescent dye and chelates. Initially, seven compounds (**1-7**) based on the structure of the bispalmitoylated MALP-2, Cys(*S*-[2,3-bis(palmitoyl)oxy-(*R*)-propyl])-Gly-Asn-Asn-Asp-Glu-Ser-Asn-Ile-Ser-Phe-Lys-Glu-Lys (SEQ ID NO:10), were synthesized. Each compound in the set was comprised of the same scaffold, X-Cys(*S*-[2,3-bis(palmitoyl)oxy-(*R*)-propyl])-Gly-Asn-Asn-Asp-Glu-Ser-Asn-Ile-Ser-Phe-Lys-Glu-Lys-NH<sub>2</sub> (SEQ ID NO:10), or X-MALP-2 where the X-group represents an N-terminal modification (Table 6, Figure 23).

After screening compounds **1-7** for bioactivity, a second set of three compound analogs (**8-10**) was designed based on SAR knowledge gained from the first set. The scaffold, Ac-PEGO-Cys(*S*-[2,3-bis(palmitoyl)oxy-(*R*)-propyl])-Y, was derived using compound **3**'s N-terminal modification of the MALP-2 LP that included an acetylated 20 atom ethylene glycol oligomer (PEGO) plus Y modifications at the C-terminus (Table 6).

Table 6. Synthesized Compounds.

#	Compounds (X, Y or Z Modifications)	MW
	X-Cys( <i>S</i> -[2,3-bis(palmitoyl)oxy-( <i>R</i> )-propyl])-Gly-Asn-Asn-Asp-Glu-Ser-Asn-Ile-Ser-Phe-Lys-Glu-Lys-NH <sub>2</sub> (SEQ ID NO:10)	
<b>1</b>	Palmitoyl	2371.4
<b>2</b>	Fluorescein-	2491.3
<b>3</b>	Ac-PEGO <sup>a</sup>	2493.4
<b>4</b>	Ac-Aha <sup>b</sup> -	2288.3
<b>5</b>	Adapalenoyl-	2526.4
<b>6</b>	Ac-Aun <sup>c</sup> -	2358.4
<b>7</b>	Tretinoyl-	2414.4

	Ac-PEGO-Cys( <i>S</i> -[2,3-bis(palmitoyl)oxy-( <i>R</i> )-propyl])- <b>Y</b>	
<b>8<sup>d</sup></b>	Ser-Arg-Phe-Asp-Glu-Asp-Asp-Leu- Glu-NH <sub>2</sub> (SEQ ID NO:5)	2137.2
<b>9</b>	Gly-Ser-Gln-Asn-Leu-Ala-Ser-Leu- Glu-Glu-NH <sub>2</sub> (SEQ ID NO:6)	2059.2
<b>10</b>	Gly-DSer-PEGO-NH <sub>2</sub>	1492.9
	<b>Z</b> -PEGO-Cys( <i>S</i> -[2,3-bis(palmitoyl)oxy-( <i>R</i> )-propyl])-Gly-DSer-PEGO-NH <sub>2</sub>	
<b>11</b>	Eu-DTPA <sup>e</sup> -	1975.4
<b>12</b>	Mpr <sup>f</sup> -	1538.9
<b>13</b>	IRDye800CW-Mpr-	2728.8

a PEGO denotes 20 atom ethylene glycol oligomer (the full structure is depicted in Figure 23); b Aha denotes 6-aminohexanoyl residue; c Aun denotes 11-aminoundecanoyl residue; d all amino-acid residues are D-configuration; e Eu-DTPA denotes Europium chelated in diethylenetriaminepentaacetic acid; f Mpr denotes 3-mercaptopropionyl residue.

Compound **8**'s Y-group modification was derived from a CD14 peptide known to induce the physical proximity of CD14, TLR2 and TLR1.[20] Compound **9**'s Y-group modification was derived from a *S. aureus* peptide that should be more acidic or at least neutral compared to the recently identified potent TLR2 agonist, serum amyloid A (SAA) by Cheng *et al.*[19a, 21] To test the importance of the peptide component of MALP-2 in terms of potency, compound **10**'s Y-group modification was derived from compound **3**'s structure with the peptide component reduced to a short Gly-DSer linker with a PEGO-NH<sub>2</sub> at the C-terminus to enhance solubility.

Since compound **10** was determined to have the most potent TLR2 bioactivity, three final compounds were designed and synthesized to incorporate at the N-terminus, in lieu of the acetyl group, a europium diethylenetriaminepentaacetic acid (Eu-DTPA) chelate (compound **11**), 3-mercaptopropionyl residue (Mpr) for attachment to thiol groups (compound **12**), and the near-infrared dye IRDye800CW (LI-COR, Lincoln, NE, USA) functionalized with Mpr for attachment (compound **13**) (Scheme 1 (Figure 24), Table 6). Compound **11** was used to determine TLR2 binding affinity via *in vitro* time-resolved fluorescence (TRF) binding assays. Compound **13** was used for *in vivo* fluorescence imaging to determine TLR2 specificity and binding.

***In Cyto Functional Bioassay.*** We developed a functional bioactivity assay to specifically detect intracellular signaling induced by agonist stimulation of the human TLR2 receptor at the cell-surface. This assay underwent optimization prior to starting our peptide screenings. Optimal NF- $\kappa$ B induced expression of luciferase led to observed luminescence 48 h post transient transfection and 24 h post ligand stimulation. Luminescence intensity was significantly greater (50-fold,  $n = 6$ ,  $p < 0.001$ ) in Pam<sub>3</sub>CSK<sub>4</sub> ligand stimulated HEK-293/hTLR2 cells relative to cells incubated with no ligand. The ligand-stimulated parental HEK-293 cells had no measurable luminescence. Hence, the measured luminescence is specifically induced by signaling of TLR2 agonists via the NF- $\kappa$ B pathway.

We initially screened the first set of seven MALP-2 derived compounds (**1-7**) with N-terminal modifications (Table 6) to determine TLR2 agonist activity. All seven of the compounds exhibited comparable levels of NF- $\kappa$ B induced luminescence relative to the reference TLR2 agonist ligand controls (Figure 16A). Based on these results, all seven compounds exhibit potent TLR2 agonist activity.

A second set of compound analogs (**8-10**) that retained the N-terminal modification of compound **3**, acetylated PEGO, with different C-terminal variations were screened for TLR2 agonist activity (Table 6). All three of the compounds exhibited significant luminescence intensity relative to the no-ligand control, comparable to the Pam<sub>3</sub>CSK<sub>4</sub> positive control and significantly more potent than SAA at both 1  $\mu$ g/mL and 10  $\mu$ g/mL ( $n = 4$ ,  $p < 0.001$ ) (Figure 16B). The fold of enhancement for **8**, **9**, and **10** vs SAA at 1  $\mu$ g/mL was 11, 13 and 14, respectively. The fold of enhancement for **8**, **9**, and **10** at 1  $\mu$ g/mL vs SAA at 10  $\mu$ g/mL was 4.2, 4.8 and 5.2, respectively.

The agonist potency of compounds **3**, **8-13**, Pam<sub>2</sub>CSK<sub>4</sub> and Pam<sub>3</sub>CSK<sub>4</sub> were further characterized over a range of concentrations (0.001 ng/mL to 10  $\mu$ g/mL) to determine EC<sub>50</sub> values. The resulting normalized dose-response curves generated by measuring the TLR2 agonistic activity for each compound and EC<sub>50</sub> values are reported in Table 7 ( $n=6$  assays for test compounds and  $n=3$  assays for control compounds,  $R^2$  values  $>0.94$ ). Test compounds (**3**, **8-10**) were potent TLR2 agonists with low nanomolar EC<sub>50</sub> values ranging from 20 to 78 nM. Compound **10** had the lowest EC<sub>50</sub> value (20 nM) (Figure 16C), which is comparable to the EC<sub>50</sub> values for Pam<sub>2</sub>CSK<sub>4</sub> (3.7 nM) and Pam<sub>3</sub>CSK<sub>4</sub> (23 nM) positive controls (Figures 20F and 20G). Compounds **11**, **12**, and **13** based on the structure of **10** with N-terminal attachments were determined to retain

nanomolar TLR2 agonist activity 204, 39 and 34 nM respectively (Table 7, Figure 16D, Figures 20D and 20E).

Table 7. TLR2 Agonist Activity ( $EC_{50}$  Values) Calculated From Dose-Response Curves.

Compd	$EC_{50}$		$R^2$ Value
	(nM)	Std. Error	
<b>3</b>	56	1.1	0.99
<b>8</b>	25	1.1	0.99
<b>9</b>	78	1.1	0.99
<b>10</b>	20	1.0	0.99
<b>11</b>	204	1.3	0.97
<b>12</b>	39	1.1	0.98
<b>13</b>	34	1.2	0.98
Pam <sub>2</sub> CSK <sub>4</sub>	3.7	1.4	0.96
Pam <sub>3</sub> CSK <sub>4</sub>	23	1.5	0.94

5 ***In Cyto Binding Assays.*** Lanthanide-based time-resolved fluorescence (TRF) saturation binding and competition binding assays were performed using TLR2  
 expressing cell lines. Saturation binding assays determined the  $K_d$  for the Eu-DTPA  
 chelate labeled compound **11** was 34, 74 and 78 nM and  $B_{max}$  was 114,271, 269,878  
 and 951,170 AFU for the HEK-293/hTLR2, SU.86.86, and Capan-I cells respectively  
 10 ( $n>3$  assays per cell line,  $R_2$  values  $>0.96$ ) (Table 8, Figure 17A and Figure 21).  
 Competitive binding assays using compound **11** as the competing ligand determined that  
 the  $K_i$  for compounds **10** and **13** is 25 and 11 nM in the HEK-293/hTLR2 cell line  
 respectively; and 91 and 67 nM in the SU.86.86 cell line ( $n>4$  assays,  $R_2 >0.78$ ) (Table  
 9, Figure 17B and C and Figures 22A and C). Compound **12** exhibited the highest  
 15 binding affinity in the SU.86.86 cell line with a  $K_i$  of 25 nM ( $n=4$  assays,  $R_2=0.90$ )  
 (Figure 22B).

Table 8. TLR2 Binding Affinity ( $K_d$ ) for Compound **11** Determined by Saturation Binding Assays.

TLR2 Expressing Cell line	$K_d$		$B_{max}$		$R^2$ Value
	(nM)	Std. Error	(AFU)	Std. Error	
HEK-	34	13	114,271	17,001	0.97

293/hTLR2					
SU.86.86	74	16	269,878	28,809	0.99
Capan-I	78	22	951,170	112,968	0.96

Table 9. TLR2 Binding Affinity ( $K_i$ ) Determined by Competition Binding Assays.

Compd	TLR2 Expressing Cell line	$K_i$ (nM)	Std. Error	$R^2$ Value
<b>10</b>	HEK-293/hTLR2	25	1.8	0.89
<b>10</b>	SU.86.86	91	1.4	0.95
<b>12</b>	SU.86.86	25	1.7	0.90
<b>13</b>	HEK-293/hTLR2	11	1.8	0.87
<b>13</b>	SU.86.86	67	2.3	0.78

***In Vivo Immune Response.*** Compound **10** was evaluated *in vivo* as an immune adjuvant and compared to the well-characterized commercially available synthetic TLR2 agonists, Pam<sub>2</sub>CSK<sub>4</sub> and Pam<sub>3</sub>CSK<sub>4</sub> in a peptide vaccine. The activity of each compound as an immune adjuvant was evaluated *in vivo* by measuring the Trp1455/9M-specific CD8 T cell responses in the blood on days 7, 21 and 34 post-immunization by flow cytometry analysis (n=3) (Figure 18). The maximum amount of fluorescently stained tetramer positive CD8 T cells for **10**, Pam<sub>2</sub>CSK<sub>4</sub> and Pam<sub>3</sub>CSK<sub>4</sub> observed on day 7 was 49.6%, 56.6% and 51.7% respectively. The 100% response rate of the tetramer positive CD8 T cells using **10** as immune adjuvant observed on day 7 decreased to an average of 25.7% on day 21 and 12.7% on day 34 which were comparable responses to using either Pam<sub>2</sub>CSK<sub>4</sub> or Pam<sub>3</sub>CSK<sub>4</sub> (Figure 18). Therefore these results indicate that compound **10** exhibited activity similar to the other known TLR2 agonists, Pam<sub>2</sub>CSK<sub>4</sub> and Pam<sub>3</sub>CSK<sub>4</sub>, for the generation and persistence of antigenspecific CD8 T cells. No signs or symptoms of stress or toxicity were observed in the mice over the course of the experiment.

***In Vivo Tumor Selectivity.*** Compound **13**, conjugated to a near-infrared fluorescent dye, IRDye800CW, was used to determine *in vivo* TLR2 binding and selectivity for TLR2 expressing tumor xenografts (SU.86.86 cells). At 24 h post-injection, *in vivo* fluorescence imaging detected retention of fluorescence signal in the tumor. To determine the *in vivo* selectivity of **13** for TLR2, a blocking study was performed. A significant reduction in the tumor fluorescence was observed 24 h post-

injection in the blocked group that received a 20-fold excess of Pam<sub>2</sub>CSK<sub>4</sub> co-injected with **13** compared to the unblocked group receiving only **13** ( $p < 0.001$ ,  $n = 8$ ). The mean unblocked tumor fluorescence was 1.94-fold higher than the blocked. *Ex vivo* imaging confirmed that the fluorescence was associated with the tumors and that the blocked tumors had decreased fluorescence compared to the unblocked tumors. IHC staining confirmed TLR2 expression in the tumors.

#### DISCUSSION AND CONCLUSIONS

We first investigated the SAR of a set of novel, fully synthetic compounds (**1-7**) through manipulation at the N-terminal portion of MALP-2 derived LPs to enhance TLR2 specificity, potency and binding affinity. Our TLR2 functional bioassay determined that these seven compounds had human TLR2 agonist activities comparable to the reference compounds, Pam<sub>2</sub>CSK<sub>4</sub> and Pam<sub>3</sub>CSK<sub>4</sub>. This result demonstrated that the addition of palmitoyl, fluorescein, Ac-PEGO, Ac-Aha, adapaleneoyl, Ac-Aun and tretinoyl groups on MALP-2 derived LPs did not inhibit agonist activity.

The novel TLR2 agonist analogs (**8-10**) of compound **3** were designed to alter the chemical properties of the parent compound in order to identify SAR that contributes to increased specificity and binding affinity. This set of compounds was derived from different origins with the goal of altering the compound properties to be more acidic, hydrophilic and soluble. Attachment of a modified CD14 peptide (**8**) or the linker Gly-D-Ser-PEGO-NH<sub>2</sub> (**10**) were both found to enhance the potency, with EC<sub>50</sub> values of 25 and 20 nM respectively, compared to **3** (EC<sub>50</sub> = 56 nM). The simplest and smallest compound (**10**), without inclusion of peptide, had the highest potency. Hence, the palmitoyl groups are the minimal binding/active component and the PEGO groups or peptides serve solely to increase solubility. The IRDye800CW fluorescent dye attachment (**13**) also exhibited a similar potency (EC<sub>50</sub> = 34 nM) to its unlabeled version (**10**) indicating that dye attachment did not significantly decrease TLR2 agonist activity. However the addition of Eu-DTPA chelate (**11**) resulted in a 10-fold decrease in potency (EC<sub>50</sub> = 204 nM). Compound **9** was synthesized by attachment of a *S. aureus* peptide to **3**, decreasing the potency (EC<sub>50</sub> = 78 nM). The *S. aureus* peptide was predicted to be more acidic or at least neutral compared to SAA, with potential to improve potency. Indeed, **9** was observed to have 13-fold higher potency compared to SAA. The SAR of novel TLR agonist compounds is typically explored using various reporter gene or functional cell-based assays.[22] In order to discover high affinity binding ligands for

development of TLR2 targeted agents, we developed a lanthanide-based TRF competition binding assay. We have previously been successful in the characterization of ligand binding affinities for other receptors using this method.[23] For this purpose, compound **11** was synthesized by attachment of Eu-DTPA chelate to the potent TLR2 agonist compound **10**. Saturation binding confirmed the high TLR2 binding affinity of **11** (<100 nM K<sub>d</sub>), which was then used as the competing ligand in competition binding assays that confirmed the high affinities of compounds **10**, **12** and **13** (<100 nM K<sub>i</sub>), which also correlated with high agonist potencies. Although **11** exhibited a 10-fold reduction in potency compared to **10**, high binding affinity was achieved.

In performing the saturation binding assays with **11**, we observed a difference in the K<sub>d</sub> values obtained in the HEK-293/hTLR2 cell line, which were genetically engineered to highly over express TLR2, compared to the 2 human pancreatic cells lines, SU.86.86 and Capan-1, that express lower endogenous levels of TLR2.[16] Similar results were also seen in the competition binding assays for both **10** and **13**, in which a reduction in binding affinity for SU.86.86 cells was observed compared to the engineered cell line. Since these TRF binding assays are performed using living cells and the ligand incubation step is longer than the time needed for receptor mediated uptake, off rates may be reduced in a receptor dependent manner and differences observed in the K<sub>d</sub> and K<sub>i</sub> values obtained from the different cell lines is likely due to the varying levels of TLR2 expression.

Using TLR agonists as vaccine adjuvants is a promising application that has been explored to prevent and treat cancer. We have previously reported that the use of TLR agonists as immune adjuvants in peptide vaccination together with anti-CD40 monoclonal antibodies can increase the magnitude and duration of T-cell responses resulting from various types of immunizations including peptide vaccines.[10a, b] Results herein show that compound **10** induced an *in vivo* immune response comparable to the currently available TLR2 synthetic agonists (Pam<sub>2</sub>- & Pam<sub>3</sub>CSK<sub>4</sub>) demonstrating that it can function as an immune adjuvant for use in cancer immunotherapy. Others have also reported that TLR2 agonistic LPs, based on the Pam<sub>2</sub>CS platform, have a potential role as vaccine adjuvants.[24] It is also worth noting that no signs or symptoms of stress or toxicity were observed in the mice over the course of the study. Kimbrell *et al.* reported that LPs are extremely potent TLR2 agonists *in vivo* with no apparent toxicity in animal models.[25]

The use of TLR2 agonist ligands in targeted pancreatic cancer imaging and treatment was explored. We demonstrated the tumor specific retention of the fluorescently labeled compound **13**, *in vivo*, using mice bearing TLR2 expressing xenografts (SU.86.86 cells). Since we previously identified TLR2 as a pancreatic cancer cell surface marker expressed in over 70% of pancreatic tumors but not in normal pancreas tissue, the TLR2 ligand compounds, especially compound **13**, can be used for intraoperative detection of pancreatic cancer leading to increased negative resection margins and increased pancreatic cancer survival.

#### EXPERIMENTAL SECTION

**Compound Synthesis, Acquisition and Preparation.** Compounds were prepared as previously published by solid-phase synthesis on Rink Amide Tentagel resin (0.23 mmol/g) using Fmoc/*t*Bu synthetic strategy and standard DIC-HOBt and HBTU or HCTU activations.[26] The synthesis was performed in fritted syringes using a Domino manual synthesizer obtained from Torviq (Niles, MI). For compound **3**, **8-13**, an Fmoc-protected version of PEGO (Novabiochem, San Diego, CA) was used and an Fmoc-protected derivative of Cys, Fmoc-Cys(*S*-[2,3-bisacyloxy-(*R*)-propyl])-OH (Fmoc-Dhc(Pam2)-OH) was synthesized as described in Example 19.[27] All compounds were fully deprotected and cleaved from the resin by treatment with 91% TFA (3% water, 3% EDT, and 3% TA) or 90% TFA (5% water, 5% TIS). After ether extraction of scavengers, compounds were purified by HPLC and/or size-exclusion chromatography (Sephadex G-25, 0.1 M acetic acid) to >95% purity. All compounds were analyzed for purity by analytical HPLC and MS by ESI or MALDI-TOF (synthetic details are in Example 19).

**Materials.**  $N\alpha$ -Fmoc protected amino acids, HBTU, and HOBt were purchased from SynPep (Dublin, CA) or from Novabiochem (San Diego, CA). Rink amide Tentagel S resin was acquired from Rapp Polymere (Tubingen, Germany). HOCT, DIC and DIEA were purchased from IRIS Biotech (Marktredwitz, Germany). The following side chain protecting groups were used for the amino acids: Arg( $N^{\xi}$ -Pbf); Asn( $N^{\text{am}}$ -Trt); Asp(*O**t*Bu); Glu(*O*-*t*Bu); His( $N^{\text{im}}$ -Trt); Ser(*t*Bu), DSer(*t*Bu), Lys( $N^{\epsilon}$ -Boc). An Fmoc-protected version of PEGO was purchased from Novabiochem. IRDye800CW maleimide was kindly provided by LI-COR (Lincoln, NE). Adapalene was purchased from AK Scientist (aksci.com). Peptide synthesis solvents, dry solvents, and solvents for HPLC (reagent grade), and trans-Retinoic acid, were acquired from VWR (West Chester, PA)

or Sigma-Aldrich (Milwaukee, WI), and were used without further purification unless otherwise noted. Compounds were manually assembled using 5 to 50 mL plastic syringe reactors equipped with a frit, and a Domino manual synthesizer obtained from Torviq (Niles, MI). The C-18 Sep-Pak™ Vac RC cartridges for solid phase extraction were  
5 purchased from Waters (Milford, MA).

**Peptide Synthesis.** Ligands were synthesized on Tentagel Rink amide resin (initial loading: 0.2 mmol/g) using N $\alpha$ -Fmoc protecting groups and a standard DIC/HOCT or HBTU/HOBt activation strategy. The resin was swollen in THF for an hour, washed with DMF, and the Fmoc protecting group removed with 20% piperidine in  
10 DMF (2 min + 20 min). The resin was washed with DMF (3X), DCM (3X), 0.2 M HOBt in DMF (2X), and finally with DMF (2X) and the first amino acid coupled using pre-activated 0.3 M HOCT ester in DMF (3 eq. of N $\alpha$ -Fmoc amino acid, 3 eq. of HOCT and 6 eq. of DIC). An on-resin test using Bromophenol Blue was used for qualitative and continuous monitoring of reaction progress. To avoid deletion sequences and slower  
15 coupling rate in longer sequences, the double coupling was performed at all steps with 3 eq. of amino acid, 3 eq. of HBTU and 6 eq. of DIEA in DMF. Wherever beads still tested Kaiser positive, a third coupling was performed using the symmetric anhydride method (2 eq. of amino acid and 1 eq. of DIC in dichloromethane). Any unreacted NH<sub>2</sub> groups on the resin thereafter were capped using an excess of 50% acetic anhydride in pyridine  
20 for 5 min. When the coupling reaction was finished, the resin was washed with DMF, and the same procedure was repeated for the next amino acid until all amino acids were coupled. Fmoc-PEGO, FmocAha, Fmoc-Aun, Tretinoic acid, Adapalene, and Fluorescein were attached to the resin as symmetrical anhydride (6 eq of acid and 3 eq of DIC in DCMDMF).

**Cleavage of Ligand from the Resin.** A cleavage cocktail (10 mL per 1 g of  
25 resin) of TFA (91%), water (3%), triisopropylsilane (3%), and 1,2-ethylenedithiol (3%) was injected into the resin and stirred for 4 h at room temperature. Alternatively, a cleavage cocktail of 90% trifluoroacetic acid (5% water, and 5% triisopropylsilane) was used. The crude ligand was isolated from the resin by filtration, the filtrate was reduced  
30 to low volume by evaporation using a stream of nitrogen, and the ligand was precipitated in ice-cold diethyl ether, washed several times with ether, dried, dissolved in water and lyophilized to give off-white solid powders that were stored at -20°C until purified. The crude compound was purified by size-exclusion chromatography.

**Synthesis of Compound 11, Eu-DTPA Labeled Ligand.** Attachment of DTPA to the N-terminus of was performed using preformed HOBt activation (3 equiv. of DTPA anhydride and 6 equiv. of HOBt, Scheme 1). DTPA was attached to H-PEGODhc(Pam<sub>2</sub>)-Gly-DSer-PEGO-resin as follows. Briefly, DTPA anhydride (3 equiv.) and HOBt (3 equiv.) in DMSO were heated until dissolved (60°C) then stirred for 30 minutes at room temperature. The preformed DTPA-OBt diester was injected into the free-amine H-PEGO-Dhc(Pam<sub>2</sub>)-Gly-DSer-PEGO-resin and stirred overnight. The resin was washed with DMSO, THF, 5% DIEA 5% water in THF (5 minutes), THF, and DCM. The compound was cleaved from the resin as described above and purified by HPLC. The purified peptide was dissolved in 0.1 M ammonium acetate buffer pH 8.0, 3.0 eq. Eu(III)Cl<sub>3</sub> was added and the reaction was stirred at room temperature overnight. The Eu-labeled peptide was separated using Solid-Phase Extraction (SPE) and lyophilized to yield an amorphous white powder. The final compound was characterized by HPLC (TEAA buffer pH 6.0), ESI-MS and/or FT-ICR.

**Synthesis of Compounds 12 and 13.** Attachment of Trt-Mpr-OH (*S*-trityl-3-mercaptopropionic acid) to the N-terminus H-PEGO-Dhc(Pam<sub>2</sub>)-Gly-DSer-PEGO-resin was performed using preformed HBTU activation (3 equiv. of Trt-Mpr-OH, 3 equiv. of HBTU and 6 equiv. of DIEA in DMF) (Scheme 1). The resin was washed with DMF and DCM. The compound **12** was cleaved from the resin as described above and purified by HPLC.

The compound **12** H-Mpr-PEGO-Dhc(Pam<sub>2</sub>)-Gly-DSer-PEGO-NH<sub>2</sub> (1 μmol) was dissolved in 1 mL DMF and reacted with 1 equiv. of IRDye800CW maleimide under argon atmosphere. The reaction was monitored by HPLC and additional aliquots (0.1 equiv.) of dye were added until the reaction complete. The compound was purified by HPLC.

**Purification and Analysis.** Purity of the peptides was ensured using analytical HPLC (Waters Alliance 2695 separation model with a dual wavelength detector Waters 2487) with a reverse-phase column (Waters Symmetry, 3.0· 75 mm, 3.5 μm; flow rate = 0.3 mL/min). (Conditions: HPLC pH 2, linear gradient from 10 to 90% B over 30 min, where A is 0.1% TFA and B is acetonitrile or THF, HPLC pH 6, linear gradient from 10 to 90% B over 30 min, where A is 0.1% TEAA and B is acetonitrile or THF). Size exclusion chromatography was performed on a borosilicate glass column (2.6 x 250 mm, Sigma, St. Louis, MO) filled with medium sized Sephadex G-25 or G-10. The

compounds were eluted with an isocratic flow of 1.0 M aqueous acetic acid. Solid-Phase Extraction (SPE) was employed where simple isolation of final compound was needed from excess salts and buffers for e.g., lanthaligand synthesis. For this purpose, C-18 Sep-Pak™ cartridges (100 mg or 500 mg) were used and pre-conditioned initially with 5  
5 column volumes (5 times the volume of packed column bed) each of acetonitrile, methanol, and water, in that order. After loading the compound, the column was washed several times with water, and then gradually with 5, 10, 20, 30, 50, and 70% of aqueous acetonitrile to elute the peptide. Structures were characterized by ESI (Finnigan, Thermoquest LCQ ion trap instrument), MALDI-TOF or FT-ICR mass spectrometry. An  
10 appropriate mixture of standard peptides was used for internal calibrations.

The test compounds (**1-13**) were dissolved in DMSO at a 1 mg/mL concentration as stock solutions stored at  $-20^{\circ}\text{C}$ . For biological experimental use, 10  $\mu\text{g/mL}$  working solutions of the compounds were prepared from stock solutions in sterilized, deionized water and used immediately.

15 Commercially available synthetic TLR2 agonists were used as references: Pam<sub>2</sub>CSK<sub>4</sub> and Pam<sub>3</sub>CSK<sub>4</sub> were purchased from InvivoGen (San Diego, CA) and recombinant human apo-SAA1 was purchased from PeproTech (Rocky Hill, NJ).

Trp<sub>1455/9M</sub> (TAPDNLGYM) is an H2 D<sup>b</sup>-optimized peptide for MHC class I binding[10c] was obtained from A&A Labs (San Diego, CA). Rat anti-mouse CD40  
20 monoclonal antibody was prepared from the FGK45.5 hybridoma culture supernatants.[10a] FITC-conjugated anti-MHC class II and PerCP Cy5.5-conjugated CD8a antibodies were both purchased from eBioscience (San Diego, CA). Phycoerythrin-conjugated Trp<sub>1455/9M</sub> / H-2D<sup>b</sup> tetramers were provided by the NIH Tetramer Facility, Emory University (Atlanta, GA).

25 **Cell Culture.** The parental HEK-293 cells (ATCC CRL-1573) and Capan-I cells (ATCC HTB-79) were cultured in DMEM/F12 media (Life Technologies Gibco) supplemented with 10% normal calf serum (NCS) (Atlanta Biologicals, Lawrenceville, GA) and 1% penicillin/streptomycin solution (Sigma). The HEK-293/hTLR2 cells (InvivoGen, San Diego, CA) were cultured in DMEM/F12 media supplemented with  
30 10% NCS, 1% penicillin/streptomycin solution, 10  $\mu\text{g/mL}$  blasticidin (InvivoGen). The SU.86.86 cells (ATCC CRL-1837) were grown in RPMI 1640 media (Life Technologies Gibco) supplemented with 10% NCS. All cells were grown at  $37^{\circ}\text{C}$  and 5% CO<sub>2</sub>.

The HEK-293/hTLR2 cells were genetically engineered to highly overexpress TLR2 by stable transfection of the parental HEK-293 cells with pUNO-hTLR2 plasmid expressing the human TLR2 gene.[28] The expression of human TLR2 in HEK-293/hTLR2 cells and absence in the parental HEK-293 cells was confirmed by RT-PCR and western blot analysis. RT-PCR and western blot expression of TLR2 on the cell surface of HEK-293/hTLR2 expressing cells with no expression in the parental HEK293 cells was tested. A band was observed at approximately 90 kDa. Optimal NF- $\kappa$ B induced expression of luciferase led to observed luminescence 48 h post transient transfection and 24 h post ligand stimulation. Luminescence intensity was significantly greater (50 fold, n = 6, p<0.001) in TLR2 ligand (Pam<sub>3</sub>CSK<sub>4</sub>) stimulated HEK293/hTLR2 cells relative to cells incubated with no ligand. No activity was observed with the HEK293 TLR2 negative expressing cells (n=3 assays with quadruplicate wells). The 2 human pancreatic cells lines used in our studies, SU.86.86 and Capan-I, express lower endogenous levels of TLR2.[16]

***In vitro* TLR2 Functional Bioassay.** The *in vitro* TLR2 functional bioassay was developed and optimized for use in high-throughput screening of soluble compound libraries to identify both TLR2 agonists and antagonists. The bioassay measures the induction of NF- $\kappa$ B signaling via TLR2 in HEK-293/hTLR2 cells and parental HEK-293 cells as a negative control. Cells were seeded at a density of 40,000 per well using a WellMate Microplate dispenser (Thermo Fisher Scientific/ Matrix) in black 96-well plates with opaque white wells (PerkinElmer, Waltham, MA) and then incubated at 37°C. On day 2, the cells were transiently transfected with pNifty-Luc (InvivoGen, San Diego, CA), an NF- $\kappa$ B inducible reporter plasmid expressing the luciferase reporter gene[28] using an optimized 4:1 ratio by volume of FugeneHD Transfection Reagent (Promega, Madison, WI) to pNifty-Luc plasmid DNA (1  $\mu$ g/mL). On day 3, the cells were stimulated with either test peptides or controls adjusted to a final concentration of 1  $\mu$ g/mL using a NanoDrop Spectrophotometer, ND1000 (Thermo Fisher Scientific). Synthetic di- and tri-acylated LP ligands, Pam<sub>2</sub>CSK<sub>4</sub> and Pam<sub>3</sub>CSK<sub>4</sub> (InvivoGen), were used as positive controls, TNF- $\alpha$  (InvivoGen) was also used as a transfection control that induces NF- $\kappa$ B independently of TLR2. On day 4 after 24 h of peptide stimulation, luciferase induced activity by the induction of NF- $\kappa$ B was measured. Media was aspirated from the wells using an ELx405 Select CW plate washer (BioTek, Winooski, VT), 150  $\mu$ g/mL D-luciferin (Gold Biotechnology, St. Louis, MO) was dispensed using

the microplate dispenser; the plates were incubated at 37°C for 5 min. The luminescence intensity was measured using the standard luminescence protocol on a Victor X4 Multilabel plate reader equipped with a plate stacker for readout of multiple plates at a time (PerkinElmer, Waltham, MA). For each *in vitro* TLR2 bioassay, at least three  
5 different experiments were performed in triplicate ( $n \geq 3$ ). Data were analyzed with GraphPad Prism software and curves were generated with the appropriate nonlinear fit regression analysis.

***In Cito Europium Time-Resolved Fluorescence Binding Assays.*** Europium TRF binding assays were performed as previously described with slight modifications  
10 using 3 cell lines that express TLR2: HEK-293/hTLR2, SU.86.86, and Capan-I.[23a, 23d, 29] The Capan-I and SU.86.86 cells were plated in 96-well black plates with white opaque wells (PerkinElmer); while the HEK-293/hTLR2 cells were plated on 96-well poly-D-lysine coated plates (Sigma-Aldrich) to aid in the attachment of these cells to the plate. Cells were grown in the 96-well plates for 2 days reaching approximately 80%  
15 confluency. Both types of plates were evaluated for nonspecific binding and background signal.

For saturation binding, increased concentrations of the labeled ligand, compound **11** (Table 8), were used to determine total binding to TLR2. Non-specific binding was determined in the presence of 1  $\mu\text{M}$  Pam<sub>2</sub>CSK<sub>4</sub>. On the day of the experiment the  
20 medium was aspirated. 50  $\mu\text{L}$  of binding buffer was added to the total binding wells and 50  $\mu\text{L}$  of Pam<sub>2</sub>CSK<sub>4</sub> was added to the non-specific wells and then allowed to incubate for 30m at 37°C. Next, 50  $\mu\text{L}$  of the serial dilutions of **10** were added and then allowed to incubate for 1 h at 37°C. Cells were washed three times to remove unbound ligand. Next, 100  $\mu\text{L}$  of DELFIA Enhancement Solution (PerkinElmer) was added to each well. Cells  
25 were incubated for 30 min at 37°C prior to reading. The plates were read on the VICTOR X4 Multilabel plate reader using the standard europium TRF protocol (340 nm excitation, 400  $\mu\text{s}$  delay and 400  $\mu\text{s}$  emission collection at 615 nm). To determine the mean  $K_d$ , statistical analysis was performed using GraphPad Prism software.

Competition binding assays were performed to test the TLR2 binding specificity  
30 of the test ligands using 2 cell lines: HEK-293/hTLR2 and SU.86.86. Cells were grown in 96-well plates for 2 days reaching approximately 80% confluency. On the day of the experiment, the cell culture media was aspirated and 50  $\mu\text{L}$  of non-labeled test ligand was added in a series of decreasing concentrations (1  $\mu\text{M}$  to 0.01 nM) followed by 50  $\mu\text{L}$

of the competing Eu-labeled ligand **10** at a fixed concentration of 90 nM. Cells were incubated with labeled and unlabeled ligands for 1 h at 37°C. Following incubation, cells were washed three times to remove unbound ligand. Next, 100 µL of DELFIA Enhancement Solution (PerkinElmer) was added to each well. Cells were incubated for 5 30 min at 37°C prior to reading. The plates were read on PerkinElmer VICTOR X4 Multilabel reader using the standard europium TRF protocol. To determine the mean  $K_i$ , statistical analysis was performed using GraphPad Prism software.

**Animal Studies.** All procedures were in compliance with the Guide for the Care and Use of Laboratory Animal Resources (1996), National Research Council, and 10 approved by the Institutional Animal Care and Use Committee, University of South Florida. Mice are housed in a clean facility with special conditions that include HEPA filtered ventilated cage systems, autoclaved bedding, autoclaved housing, autoclaved water, irradiated food and special cage changing procedures. Mice are handled under aseptic conditions including the wearing of gloves, gowns and shoe coverings.

15 ***In Vivo* Cellular Immune Response Assays.** C57BL/6 (B6) mice 6-8 weeks old were purchased from Charles River (Wilmington, MA). To assess the efficacy of **10** as an immune adjuvant, B6 mice were immunized i.v. with a mixture (in a volume of 200 µl) of 100 µg optimized Trp1455/9M peptide, [10c] 50 µg anti-CD40 monoclonal antibody (Clone; FGk-45.5), and 50 µg TLR2 agonist (**10**, Pam<sub>2</sub>CSK<sub>4</sub>, or Pam<sub>3</sub>CSK<sub>4</sub>). 20 The Trp<sub>1455/9M</sub> peptide was tested using the TLR2 functional bioassay, it was determined that it is not a TLR2 agonist. The response of tetramer positive CD8 T cells in the blood was measured on day 7, 21 and 34 by tetramer staining. For tetramer staining, peripheral blood was taken from the submandibular vein and treated briefly with ammonium chloride buffer to lyse red blood cells. Blood cells were stained with FITC-conjugated 25 anti-MHC class II, PerCP Cy5.5-conjugated CD8a, and phycoerythrin-conjugated Trp<sub>1455/9M</sub> / H-2D<sup>b</sup> tetramers for 40 min in ice. Fluorescence was evaluated using a FACSCalibur flow cytometer (BD Biosciences) and analyzed using FlowJo software.

***In Vivo* TLR2 Selectivity Experiment.** Female athymic nude mice 6-8 weeks old (Harlan) bearing human pancreatic tumor xenografts consisting of SU.86.86 cells on 30 the right flank were used for this study. Mouse weights and tumor volumes were determined using caliper measurements and the formula: volume (mm<sup>3</sup>) = (length x width<sup>2</sup>)/ 2. Images were acquired when the tumors reached an average size of 500 mm<sup>3</sup>. For the blocked group, a co-injection of 100 nmol/kg of the fluorescently labeled

compound **13** plus 2  $\mu\text{mol/kg}$  Pam<sub>2</sub>CSK<sub>4</sub> (a 20-fold excess) was administered via tail vein injection; for the unblocked group, 100 nmol/kg **13** was administered. Fluorescence images were acquired at time 0 and 24h using the Caliper Xenogen IVIS200 system (PerkinElmer) with the 710-760 nm excitation and 810-875 nm emission filter set. The fluorescence was quantified using Living Image software, in which the quantified signals were corrected for both instrument and mouse background subtractions. The quantified fluorescence was then plotted using GraphPad Prism software and underwent statistical analysis using Student's *t*-test.

For further confirmation of ligand **13** specificity for TLR2, *ex vivo* fluorescence imaging and histological analyses were performed on the tumors. For histological analyses the samples were fixed in 10% formalin solution, processed, embedded, sectioned and either H&E stained for the presence of tumor or underwent IHC staining using TLR2 antibody (Abcam #ab24192).

**Statistical Analysis.** The results are represented as mean  $\pm$  s.d. and statistically evaluated by Student's *t* test to determine statistical significance.


#### ABBREVIATIONS

Abbreviations used for amino acids and designation of peptides follow the rules of the IUPAC-IUB Commission of Biochemical Nomenclature in *J. Biol. Chem.* 1972, 247, 977-983. The following additional abbreviations are used: Boc, *tert*-butyloxycarbonyl; BB, bromophenol blue; *t*-Bu, *tert*-butyl; CH<sub>3</sub>CN, acetonitrile; DCM, dichloromethane; DI, de-ionized; DIPEA, diisopropylethylamine; Dhc, 2,3-dihydroxypropylcysteine or Cys(*S*-[2,3-hydroxy-(*R*)-propyl] residue; DMF, *N,N*-dimethylformamide; DIC, diisopropylcarbodiimide; DMEM, Dulbecco's Modified Eagle Medium; Eu-DTPA, europium diethylenetriaminepentaacetic acid; Fmoc, 9-fluorenylmethoxycarbonyl; FTICR, Fourier Transform-Ion Cyclotron Resonance; ESI-MS, Electrospray ionization mass spectrometry; EDT, 1,2-ethanedithiol; Et<sub>2</sub>O, Diethyl ether; HBSS, Hank's Balanced Saline Solution buffered with 25 mM Hepes; HCTU, *O*-[1H-6-chloro-benzotriazol-1-yl](dimethylamino) ethylene] uraniumhexafluorophosphate *N*-oxide; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; HOBt, *N*-hydroxybenzotriazole; HOCT, 6-chloro-1-hydroxybenzotriazole; LP, lipopeptide; MALDI-TOF, Matrix Assisted Laser Desorption Ionization-Time of Flight; MALP-2, macrophage-activating lipopeptide 2; Mpr, 3-mercaptopropionic residue; PAMP, pathogen-associated molecular patterns; Pbf,

2,2,4,6,7-pentamethyl-dihydrobenzofuran-5-sulfonyl; PEGO, 19-amino-5-oxo-3,10,13,16-tetraoxo-6-azanodecan-1-oic acid residue; PRR, pattern recognition receptor; SPPS, solid-phase peptide synthesis; RP-HPLC, reverse-phase high performance liquid chromatography; SAA, serum amyloid a; SAR, structure activity relationship; TA, thioanisole; THF, tetrahydrofuran; TIR, toll/interleukin receptor; TIS, triisopropylsilane; TFA, trifluoroacetic acid; TLR2, toll-like receptor 2; TNF- $\alpha$ , tumor necrosis factor  $\alpha$ ; TRF, time resolved fluorescence; Trt, trityl.

### Example 19: Synthesis

#### 10 Synthesis of *N*-Fluorenylmethoxycarbonyl-*S*-[2,3-bis(palmitoyloxy)-(2*R*)-propyl]-(*R*)-cysteine (**3R**) (Fmoc-Dhc(Pam<sub>2</sub>)-OH)




**Scheme 1.** (a) i) Zn, CH<sub>2</sub>Cl<sub>2</sub>, MeOH:HCl:H<sub>2</sub>SO<sub>4</sub> (100:7:1), r.t. 15 min. ii) Glycidol, 40 °C, 5 hr. (iii) KHSO<sub>4</sub>, 0 °C to r.t. 16 hr. (b) Palmitoyl chloride, DMAP, TEA, CH<sub>2</sub>Cl<sub>2</sub>:DMF (100:1), 0 °C to r.t. 3 hr. (c) TFA, r.t. 1 hr.

**General.** All reactions were conducted under Ar atmosphere using oven-dried  
 15 glassware. All chemicals were obtained from commercial sources and used without further purification. <sup>1</sup>H NMR spectra were recorded on Bruker-DRX-300 MHz instrument with chemical shifts reported relative to TMS (0.0 ppm) and residual DMSO (2.50 ppm). Proton-decoupled <sup>13</sup>C NMR spectra were referenced to CDCl<sub>3</sub> (77.0 ppm) as well as DMSO (39.51 ppm). Low resolution mass spectra were obtained on  
 20 AGILENT (HP) MDS 1100 using AP-ESI. High resolution mass spectra (HRMS) were

recorded on a Bruker FT-ICR MS 9.4T instrument. Melting points were measured using a Thomas Hoover capillary melting point apparatus and are uncorrected.


**Synthesis of *N*-Fluorenylmethoxycarbonyl-*S*-[2,3-dihydroxy-(2*RS*)-propyl]-(*R*)-cysteine *tert*-butyl ester (**1R/S**)**

5 To a solution of (Fmoc-Cys-O<sup>*t*</sup>Bu)<sub>2</sub> (1.91 g, 2.4 mmol) in dichloromethane (15 mL) was added Zn (1.10 g, 16.8 mmol). A freshly prepared mixture (8 mL) of MeOH:32 % HCl:concentrated H<sub>2</sub>SO<sub>4</sub> (100:7:1=v:v:v) was added under vigorous stirring at room temperature. After 15 minutes (±)-glycidol (1.78 g, 24 mmol) was added and the resulting mixture was stirred for 5 hours at 40°C. The mixture was concentrated to about  
10 half of the original volume and cooled to 0°C, then 5 % KHSO<sub>4</sub> aqueous solution (2 mL) was added and stirred for 16 hours with warming-up to room temperature slowly. The mixture was extracted with dichloromethane and the organic layer was washed with water, dried over anhydrous MgSO<sub>4</sub>, filtered and concentrated. The residue was purified  
15 by silica gel column chromatography using a mixture of dichloromethane and methanol (40:1 = v:v) to give *N*-Fluorenylmethoxycarbonyl-*S*-[2,3-dihydroxy-(2*RS*)-propyl]-(*R*)-cysteine *tert*-butyl ester (**1R/S**, 2.26 g) as colorless oil in 99 % isolated yield.



Colorless oil; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>), two *diastereoisomers* δ 1.50 (s, 9H), 2.04-2.14 (m, 1H), 2.59-3.20 (m, 5H), 3.48-3.59 (m, 1H), 3.65-3.85 (m, 2H), 4.24 (t, *J* = 6.98 Hz, 1H), 4.35-4.45 (m, 2H), 4.46-4.56 (m, 1H), 5.72-5.84 (m, 1H), 7.32 (t, *J* = 7.40 Hz, 2H), 7.41 (t, *J* = 7.41 Hz, 2H), 7.61 (d, *J* = 7.29 Hz, 2H), 7.77 (d, *J* = 7.37 Hz, 2H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) two *diastereoisomers* δ 28.0, (35.7, 35.8), (36.6, 36.7), 47.0, 54.4, (65.0, 65.2), (67.16, 67.19), (70.3, 70.5), 83.2, 120.0, 125.1, 127.0, 127.7, 141.2, 143.66, 143.72, 25 (156.0, 156.07), (169.62, 169.65); LRMS (ESI) *m/z* Calcd for C<sub>25</sub>H<sub>31</sub>NO<sub>6</sub>SNa (M+Na)<sup>+</sup> 496.2, obsd 496.0.

**Synthesis of *N*-Fluorenylmethoxycarbonyl-*S*-[2,3-dihydroxy-(2*R*)-propyl]-(*R*)-cysteine *tert*-butyl ester (**1R**)<sup>1-2</sup>**




The title compound was synthesized according to the procedure described for compound (**1R/S**) starting from (Fmoc-Cys-O<sup>*t*</sup>Bu)<sub>2</sub> (5.74 g, 7.2 mmol) and R-(+)-glycidol (5.33 g, 72 mmol). *N*-Fluorenylmethoxycarbonyl-*S*-[2,3-dihydroxy-(2*R*)-propyl]-(*R*)-cysteine *tert*-butyl ester (**1R**, 5.70 g) was obtained as a viscous oil in 84 % isolated yield.

Colorless oil;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  1.49 (s, 9H), 2.39 (t,  $J = 5.94$  Hz, 1H), 2.63 (dd,  $J = 13.7, 8.40$  Hz, 1H), 2.75-2.82 (m, 1H), 2.93 (dd,  $J = 14.0, 6.10$  Hz, 1H), 3.03 (dd,  $J = 14.0, 4.60$  Hz, 1H), 3.33 (d,  $J = 3.63$  Hz, 1H), 3.48-3.55 (m, 1H), 3.64-3.72 (m, 1H), 3.75-3.84 (m, 1H), 4.23 (t,  $J = 7.07$  Hz, 1H), 4.39 (d,  $J = 7.07$  Hz, 2H), 4.49-4.55 (m, 1H), 5.87 (d,  $J = 7.97$  Hz, 1H), 7.31 (t,  $J = 7.40$  Hz, 2H), 7.41 (t,  $J = 7.36$  Hz, 2H), 7.61 (d,  $J = 7.29$  Hz, 2H), 7.77 (d,  $J = 7.44$  Hz, 2H);  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  28.0, 35.8, 36.8, 47.0, 54.4, 65.2, 67.2, 70.5, 83.2, 120.0, 125.1, 127.1, 127.7, 141.3, 143.66, 143.75, 156.0, 169.7; LRMS (ESI)  $m/z$  Calcd for  $\text{C}_{25}\text{H}_{31}\text{NO}_6\text{SNa}$  ( $\text{M}+\text{Na}$ ) $^+$  496.2, obsd 496.0.

10            **Synthesis of *N*-Fluorenylmethoxycarbonyl-*S*-[2,3-bis(palmitoyloxy)-(2*RS*)-propyl]-(*R*)-cysteine *tert*-butyl ester (2*R/S*) $^{1-2}$**


To a mixture of compound **1*R/S*** (1.56 g, 3.28 mmol) and palmitoyl chloride (2.71 g, 9.85 mmol) in a mixture (35 mL) of  $\text{CH}_2\text{Cl}_2$  and DMF (100:1=v:v) was added triethylamine (997 mg, 9.85 mmol), followed by DMAP (80.3 mg, 0.657 mmol) at  $0^\circ\text{C}$ .  
 15 The resulting mixture was stirred at  $0^\circ\text{C}$  for 30 minutes and at room temperature for 3 hours. The reaction was quenched by an addition of saturated NaCl aqueous solution and extracted with dichloromethane. The organic layer was washed with water, dried over anhydrous  $\text{MgSO}_4$ , filtered and concentrated. The residue was purified by silica gel column chromatography using a mixture of hexanes and ethyl acetate (9:1 = v:v) to give  
 20 *N*-Fluorenylmethoxycarbonyl-*S*-[2,3-bis(palmitoyloxy)-(2*RS*)-propyl]-(*R*)-cysteine *tert*-butyl ester (**2*R/S***, 2.60 g) as white solid in 83 % isolated yield.

 White solid, mp =  $52-54^\circ\text{C}$  (lit. $^2$   $38-42^\circ\text{C}$ );  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ), two *diastereoisomers*  $\delta$  0.879 (t,  $J = 6.88$  Hz, 6H), 1.25 (br, 48H), 1.49 (s, 9H), 1.55-1.64 (br, 4H), 2.26-2.33 (m, 4H), 2.77 (d,  $J = 6.39$  Hz, 2H), 3.00-3.13 (m, 2H), 4.12-4.18 (m, 1H), 4.22-4.40 (m, 4H), 4.48-4.55 (m, 1H), 5.10-5.20 (m, 1H), 5.69 (t,  $J = 6.34$  Hz, 1H), 7.29-7.34 (m, 2H), 7.40 (t,  $J = 7.39$  Hz, 2H), 7.62 (d,  $J = 7.47$  Hz, 2H), 7.77 (d,  $J = 7.47$  Hz, 2H);  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ ) two *diastereoisomers*  $\delta$  14.1, 22.7, 24.85, 24.87, 28.0, 29.1, 29.3, 29.4, 29.5, 29.66, 29.70, 31.9, (33.17, 33.24), 34.1, 34.2, (35.33, 35.38), 47.1, (54.26, 54.29), (63.40, 63.43), 67.2, (70.19, 70.26), 83.0, 120.0, 125.2, 127.1, 127.7, 141.3, 143.8, (155.66, 155.69), 169.5, (173.0, 173.04), 173.3; LRMS (ESI)  $m/z$  Calcd for  $\text{C}_{57}\text{H}_{91}\text{NO}_8\text{SNa}$  ( $\text{M}+\text{Na}$ ) $^+$  972.6, obsd 972.5.

**Synthesis of *N*-Fluorenylmethoxycarbonyl-*S*-[2,3-bis(palmitoyloxy)-(2*R*)-propyl]-(*R*)-cysteine *tert*-butyl ester (**2R**)<sup>1-2</sup>**

The title compound was synthesized according to the same procedure described for compound (**2R/S**) starting from compound **1R** (3.62 g, 7.64 mmol). *N*-


5 Fluorenylmethoxycarbonyl-*S*-[2,3-bis(palmitoyloxy)-(2*R*)-propyl]-(*R*)-cysteine *tert*-butyl ester (**2R**, 5.12 g) was obtained as white solid in 71 % isolated yield.



White solid, mp = 56-57°C (lit.<sup>2</sup> 45 °C); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 0.878 (t, *J* = 6.93 Hz, 6H), 1.25 (br, 48H), 1.49 (s, 9H), 1.55-1.63 (br, 4H), 2.26-2.33 (m, 4H), 2.77 (d, *J* = 6.40 Hz, 2H), 3.02 (dd, *J* = 13.8, 5.24 Hz, 1H), 3.09 (dd, *J* = 13.8, 4.64 Hz, 1H), 4.15 (dd, *J* = 11.9, 5.90 Hz, 1H), 4.21-4.40 (m, 4H), 4.49-4.54 (m, 1H), 5.14-5.18 (m, 1H), 5.71 (d, *J* = 7.60 Hz, 1H), 7.32 (t, *J* = 7.39 Hz, 2H), 7.40 (t, *J* = 7.31 Hz, 2H), 7.62 (d, *J* = 7.44 Hz, 2H), 7.77 (d, *J* = 7.44 Hz, 2H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 14.1, 22.7, 24.81, 24.83, 27.9, 29.1, 29.2, 29.3, 29.4, 29.62, 29.66, 31.9, 33.2, 34.0, 34.2, 35.3, 47.0, 54.3, 63.4, 67.1, 70.2, 82.9, 119.9, 125.08, 125.13, 127.0, 127.6, 141.2, 143.7, 155.7, 169.4, 173.0, 173.3; LRMS (ESI) *m/z* Calcd for C<sub>57</sub>H<sub>91</sub>NO<sub>8</sub>SNa (M+Na)<sup>+</sup> 972.6, obsd 972.8.

**Synthesis of *N*-Fluorenylmethoxycarbonyl-*S*-[2,3-bis(palmitoyloxy)-(2*RS*)-propyl]-(*R*)-cysteine (**3R/S**)<sup>1-2</sup>**

Compound **2R/S** (1.0 g, 1.05 mmol) was dissolved in trifluoroacetic acid (20 mL) and the resulting mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure and the resulting oily residue was coevaporated from toluene (30 mL) and dichloromethane (30 mL). The residue was lyophilized from *tert*-butyl alcohol to give *N*-Fluorenylmethoxycarbonyl-*S*-[2,3-bis(palmitoyloxy)-(2*RS*)-propyl]-(*R*)-cysteine (**3R/S**, 750 mg) as white solid in 84 % isolated yield.




White solid, mp = 82-84 °C (lit.<sup>2</sup> 64-65°C); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>), two *diastereoisomers* δ 0.878 (t, *J* = 6.88 Hz, 6H), 1.25 (br, 48H), 1.55-1.65 (br, 4H), 2.27-2.38 (m, 4H), 2.70-2.80 (m, 2H), 3.06-3.21 (m, 2H), 4.10-4.41 (m, 5H), 4.61-4.72 (m, 1H), 5.11-5.22 (m, 1H), 5.78 (d, *J* = 7.81 Hz, 1H), 7.31 (td, *J* = 7.44, 1.10 Hz, 2H), 7.40 (t, *J* = 7.34 Hz, 2H), 7.61 (d, *J* = 7.29 Hz, 2H), 7.76 (d, *J* = 7.44 Hz, 2H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) two *diastereoisomers* δ 14.1, 22.7, 24.84, 24.87, 29.0, 29.09, 29.11, 29.24, 29.29, 29.36, 29.44, 29.50, 29.66, 29.70, 31.9 (32.79, 32.92), 34.1, 34.3, (34.59, 34.74), 47.0, (53.48, 53.61), (63.51 63.56), 67.4, 70.2, 120.0,

125.1, 127.1, 127.7, 141.3, 143.64, 143.68, (155.89, 155.95), (173.41, 173.46), (173.55, 173.62), (174.20, 174.30) LRMS (ESI)  $m/z$  Calcd for  $C_{53}H_{84}NO_8S$  (M+H)<sup>+</sup> 894.6, obsd 894.5.

5 **Synthesis of *N*-Fluorenylmethoxycarbonyl-*S*-[2,3-bis(palmitoyloxy)-(2*R*)-propyl]-(*R*)-cysteine (3*R*)**


The title compound was synthesized according to the same procedure described for compound (3*R*/*S*) starting from compound 2*R* (1.50 g, 1.58 mmol) and trifluoroacetic acid (30 mL). *N*-Fluorenylmethoxycarbonyl-*S*-[2,3-bis(palmitoyloxy)-(2*R*)-propyl]-(*R*)-cysteine (3*R*, 1.34 g) was obtained as white solid in 95 % isolated yield.



White solid, mp = 84-85 °C (lit.<sup>2</sup> 61°C); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 0.877 (t, *J* = 6.91 Hz, 6H), 1.25 (br, 48H), 1.55-1.65 (br, 4H), 2.27-2.34 (m, 4H), 2.77 (d, *J* = 6.33 Hz, 2H), 3.06 (dd, *J* = 13.7, 6.13 Hz, 1H), 3.17 (dd, *J* = 14.0, 4.61 Hz, 1H), 4.13-4.19 (m, 1H), 4.21-4.41 (m, 4H), 4.64-4.70 (m, 1H), 5.16-5.19 (m, 1H), 5.79 (d, *J* = 7.86 Hz, 1H), 7.33 (td, *J* = 7.45, 0.95 Hz, 2H), 7.40 (t, *J* = 7.30 Hz, 2H), 7.61 (d, *J* = 7.34 Hz, 2H), 7.76 (d, *J* = 7.45 Hz, 2H), 10.0 (brs, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 14.1, 22.7, 24.81, 24.85, 29.07, 29.09, 29.26, 29.34, 29.5, 29.64, 29.68, 31.9, 32.9, 34.0, 34.2, 34.6, 47.0, 53.6, 63.5, 67.4, 70.2, 120.0, 125.1, 127.0, 127.7, 141.2, 143.61, 143.65, 156.0, 173.45, 173.55, 174.6; HRMS (ESI)  $m/z$  Calcd for  $C_{53}H_{84}NO_8S$  (M+H)<sup>+</sup> 894.5912, obsd 894.5900.

20 **Synthesis of *N*-Fluorenylmethoxycarbonyl-*S*-[2,3-dihydroxy-(2*R*)-propyl]-(*R*)-cysteine (4*R*)**

Compound 1*R* (3.15 g, 6.65 mmol) was dissolved in trifluoroacetic acid (70 mL) and the resulting mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure and the resulting oily residue was coevaporated from toluene (50 mL) and dichloromethane (50 mL). The residue was purified by silica gel column chromatography using a mixture of dichloromethane and methanol (9:1 = v:v) to give *N*-Fluorenylmethoxycarbonyl-*S*-[2,3-dihydroxy-(2*R*)-propyl]-(*R*)-cysteine (4*R*, 1.80 g) as white solid in 65 % isolated yield.



White solid, mp = 54-56 °C; <sup>1</sup>H NMR (300 MHz, DMSO-*d*<sub>6</sub>) δ 2.49 (dd, *J* = 13.2, 7.05 Hz, 1H), 2.69 (dd, *J* = 13.5, 4.63 Hz, 1H), 2.78 (dd, *J* = 13.5, 9.69 Hz, 1H), 2.98 (dd, *J* = 13.6, 4.54 Hz, 1H), 3.29-3.39 (m, 2H), 3.54-3.61 (m, 1H), 4.10-4.17 (m, 1H), 4.21-4.30 (m, 3H), 4.50-5.20

(br, 2H), 7.33 (t,  $J = 7.32$  Hz, 2H), 7.42 (t,  $J = 7.31$  Hz, 2H), 7.73-7.78 (m, 3H), 7.89 (d,  $J = 7.44$  Hz, 2H);  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  34.9, 35.5, 46.9, 53.8, 64.9, 67.3, 71.1, 120.0, 125.1, 127.1, 127.7, 141.2, 143.47, 143.63, 156.5, 173.7; HRMS (ESI)  $m/z$  Calcd for  $\text{C}_{21}\text{H}_{23}\text{NO}_6\text{SNa}$  ( $\text{M}+\text{Na}$ ) $^+$  440.1138, obsd 440.1133.

5

## REFERENCES

1. (a) Kanzler et al., *Nat Med* **2007**, *13*(5), 552-9; (b) Zuany-Amorim et al., *Nat Rev Drug Discov* **2002**, *1* (10), 797-807.
2. (a) Jarnicki et al., *Journal of immunology* **2008**, *180* (6), 3797-806; (b) Marshall et al., *Cancer research* **2012**, *72* (3), 581-91; (c) Adams, *Immunotherapy* **2009**, *1* (6), 949-64.
3. (a) Akira and Takeda, *Nat Rev Immunol* **2004**, *4*(7), 499-511; (b) West et al., *Annu Rev Cell Dev Biol* **2006**, *22*, 409-37.
4. Jin and Lee, *Immunity* **2008**, *29* (2), 182-91.
5. Ozinsky et al., *Proc Natl Acad Sci U S A* **2000**, *97* (25), 13766-71.
6. (a) Janeway and Medzhitov, *Annu Rev Immunol* **2002**, *20*, 197-216; (b) Akira et al., *Nat Immunol* **2001**, *2* (8), 675-80; (c) Kawai and Akira, *Nat Immunol* *11* (5), 373-84.
7. Hennessy et al., *Nat Rev Drug Discov* *9* (4), 293-307.
8. (a) Simons et al., *Urol Oncol* **2008**, *26* (4), 341-5; (b) Murata, *Cancer Sci* **2008**, *99* (7), 1435-40.
9. (a) D'Agostini et al., *Int Immunopharmacol* **2005**, *5* (7-8), 1205-12; (b) Garay et al., *Eur J Pharmacol* **2007**, *563* (1-3), 1-17; (c) De Ridder et al., *Int J Radiat Oncol Biol Phys* **2006**, *66* (5), 1473-80.
10. (a) Cho and Celis, *Cancer Res* **2009**, *69* (23), 9012-9; (b) Celis, *Cancer Res* **2007**, *67* (17), 7945-7; (c) Guevara-Patino et al., *J Clin Invest* **2006**, *116* (5), 1382-90.
11. American Cancer Society. Cancer facts & figures-2012, p. v.
12. (a) Ferrone et al., *J Gastrointest Surg* **2008**, *12* (4), 701-6; (b) Howard et al., *J Gastrointest Surg* **2006**, *10* (10), 1338-45; discussion 1345-6.
13. (a) Angst and Kim-Fuchs, *J Gastrointest Surg* **2012**, *16* (3), 673; (b) Esposito et al., *Ann Surg Oncol* **2008**, *15* (6), 1651-60; (c) Campbell et al., *Histopathology* **2009**, *55* (3), 277-83.

14. (a) van Dam et al., *Nature medicine* **2011**, *17* (10), 1315-9; (b) Sevick-Muraca et al., *Radiology* **2008**, *246* (3), 734-41; (c) Tagaya et al., *Am J Surg* **2008**, *195* (6), 850-3; (d) Stummer et al., *Lancet Oncol* **2006**, *7* (5), 392-401; (e) Hadjipanayis et al., *Semin Oncol* **2011**, *38* (1), 109-18; (f) Keereweer et al., *Curr Pharm Biotechnol* **2012**; (g) Ntziachristos et al., *J Biomed Opt* *15* (6), 066024.
15. (a) Nguyen et al., *Proc Natl Acad Sci U S A* **2010**, *107* (9), 4317-22; (b) Ntziachristos et al., *Journal of biomedical optics* **2010**, *15* (6), 066024.
16. Morse et al., *Biochem Pharmacol* *80* (5), 748-54.
17. (a) Muhlradt et al., *The Journal of experimental medicine* **1997**, *185* (11), 1951-8; (b) Muhlradt et al., *Infect Immun* **1998**, *66* (10), 4804-10; (c) Takeuchi et al., *Int Immunol* **2001**, *13* (7), 933-40.
18. (a) Alexopoulou et al., *Nature medicine* **2002**, *8* (8), 878-84; (b) Morr et al., *European journal of immunology* **2002**, *32* (12), 3337-47; (c) Takeuchi et al., *J Immunol* **2002**, *169* (1), 10-4; (d) Jin et al., *Cell* **2007**, *130* (6), 1071-82; (e) Manavalan et al., *Front Physiol* **2011**, *2*, 41; (f) Kang et al., *Immunity* **2009**, *31* (6), 873-84; (g) Buwitt-Beckmann et al., *Gastroenterol Res Pract* *2010*, 240365.
19. (a) Cheng et al., *J Immunol* **2008**, *181* (1), 22-6; (b) Uhlar and Whitehead, *Eur J Biochem* **1999**, *265* (2), 501-23.
20. Manukyan et al., *European journal of immunology* **2005**, *35* (3), 911-21.
21. Fujimoto et al., *Chembiochem* **2009**, *10* (14), 2311-5.
22. Czarniecki, *J Med Chem* **2008**, *51* (21), 6621-6.
23. (a) Handl et al., *Anal Biochem* **2005**, *343* (2), 299-307; (b) Xu et al., *Mol Cancer Ther* **2009**, *8* (8), 2356-65; (c) Barkey et al., *Journal of medicinal chemistry* **2011**, *54* (23), 8078-84; (d) Josan et al., *Org Lett* **2009**, *11* (12), 2479-82.
24. (a) Agnihotri et al., *Journal of medicinal chemistry* **2011**, *54* (23), 8148-60; (b) Salunke et al., *Journal of medicinal chemistry* **2012**.
25. Kimbrell et al., *Immunol Lett* **2008**, *118* (2), 132-41.
26. (a) Vagner et al., *Angew Chem Int Ed Engl* **2008**, *47* (9), 1685-8; (b) Krchnak et al., *Int J Pept Protein Res* **1988**, *32* (5), 415-6; (c) Krchnak and Vagner, *Pept Res* **1990**, *3* (4), 182-93.
27. (a) Metzger et al., *Int J Pept Protein Res* **1991**, *38* (6), 545-54; (b) Reichel et al., *J Am Chem Soc* **1999**, *121* (35), 7989-7997.
28. Schindler and Baichwal, *Mol Cell Biol* **1994**, *14* (9), 5820-31.


29. Handl et al., *Anal Biochem* **2004**, 330 (2), 242-50.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of skill in the art to which the disclosed  
5 invention belongs. Publications cited herein and the materials for which they are cited are specifically incorporated by reference.

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following  
10 claims.

We claim:

1. A non-invasive method for *in vivo* detection of cancer cells in a subject, the method comprising:  
administering to the subject a targeted imaging probe that specifically binds a cellular target, wherein the cellular target is Toll-like Receptor 2 (TLR2); and  
imaging the subject with a molecular imaging device to detect the targeted imaging probe in the subject, wherein detection of the targeted imaging probe in an organ of a subject is an indication of cancer cells in the organ.
2. The method of claim 1, wherein the molecular imaging device comprises a gamma radiation detector.
3. The method of claim 1, wherein the molecular imaging device comprises a positron emission detector.
4. The method of claim 1, wherein the targeted imaging probe comprises a TLR2 ligand linked to a detectable label.
5. The method of claim 4, wherein the targeted imaging probe comprises **X**-Cys(*S*-[2,3-bis(palmitoyl)oxy-(*R*)-propyl])-**Y**, wherein **X** is a moiety coupled to the amino group of the cysteine, wherein the moiety comprises the label, and wherein **Y** is a peptide group.
6. The method of claim 5, wherein  
**X** is acetyl-PEGO- (Ac-PEGO), palmitoyl-, fluorescein-, acetyl-6-aminohexanoyl- (Ac-Aha), adapalenoil-, acetyl-11-aminoundecanoyl- (Ac-Aun), or tretinoyl-; and  
**Y** is -Gly-DSer-PEGO-NH<sub>2</sub>, -Gly-DSer-NH<sub>2</sub>, -Cys-Ser-(Lys)<sub>4</sub>-NH<sub>2</sub>, -Gly-Asn-Asn-Asp-Glu-Ser-Asn-Ile-Ser-Phe-Lys-Glu-Lys-NH<sub>2</sub>, -Ser-Arg-Phe-Asp-Glu-Asp-Asp-Leu-Glu-NH<sub>2</sub>, or -Gly-Ser-Gln-Asn-Leu-Ala-Ser-Leu-Glu-Glu-NH<sub>2</sub>.
7. The method of claim 4, wherein the targeted imaging probe has the structure



wherein R<sub>1</sub> is -CO-R<sub>6</sub> or H, wherein R<sub>6</sub> is C<sub>12</sub> to C<sub>18</sub> alkyl or alkenyl;  
wherein R<sub>2</sub> is -CH<sub>2</sub>-O-CO-R<sub>7</sub>, -CH<sub>2</sub>-OH, or -H, wherein R<sub>7</sub> is any C<sub>12</sub> to C<sub>18</sub> alkyl, alkenyl, amine, alkyl amine, alkenyl amine, alkyl ether, polyether, wherein R<sub>7</sub> is

optionally substituted with one or more functional group(s) selected from the group consisting of alkyl, alkenyl, ether, polyether, or alkyl amine;

wherein R<sub>3</sub> is R<sub>8</sub>-label, wherein R<sub>8</sub> is acetyl-PEGO- (Ac-PEGO), palmitoyl-, fluorescein-, acetyl-6-aminohexanoyl- (Ac-Aha), adapalenoil-, acetyl-11-aminoundecanoyl- (Ac-Aun), or tretinoyl-;


wherein R<sub>4</sub> is -Gly-D<sub>2</sub>Ser-PEGO-NH<sub>2</sub>, -Gly-D<sub>2</sub>Ser-NH<sub>2</sub>, -Cys-Ser-(Lys)<sub>4</sub>-NH<sub>2</sub>, -Gly-Asn-Asn-Asp-Glu-Ser-Asn-Ile-Ser-Phe-Lys-Glu-Lys-NH<sub>2</sub>, -Ser-Arg-Phe-Asp-Glu-Asp-Asp-Leu-Glu-NH<sub>2</sub>, -Gly-Ser-Gln-Asn-Leu-Ala-Ser-Leu-Glu-Glu-NH<sub>2</sub>, or – serine methyl ester;

wherein R<sub>5</sub> is –S- or –Se-; and

wherein if R<sub>1</sub> is H, then R<sub>2</sub> is –CH<sub>2</sub>-O-CO-R<sub>7</sub> wherein R<sub>7</sub> is any C<sub>12</sub> to C<sub>18</sub> alkyl or alkenyl.

8. The method of claim 7, wherein R<sub>1</sub> is –CO-R<sub>6</sub>, wherein R<sub>6</sub> is C<sub>12</sub> to C<sub>18</sub> alkyl; wherein R<sub>2</sub> is –CH<sub>2</sub>-O-CO-R<sub>7</sub>, wherein R<sub>7</sub> is any C<sub>12</sub> to C<sub>18</sub> alkyl; wherein R<sub>3</sub> is R<sub>8</sub>-label, wherein R<sub>8</sub> is acetyl-PEGO- (Ac-PEGO), palmitoyl-, fluorescein-, acetyl-6-aminohexanoyl- (Ac-Aha), adapalenoil-, acetyl-11-aminoundecanoyl- (Ac-Aun), or tretinoyl-; wherein R<sub>4</sub> is -Gly-D<sub>2</sub>Ser-PEGO-NH<sub>2</sub>, -Gly-D<sub>2</sub>Ser-NH<sub>2</sub>, -Cys-Ser-(Lys)<sub>4</sub>-NH<sub>2</sub>, -Gly-Asn-Asn-Asp-Glu-Ser-Asn-Ile-Ser-Phe-Lys-Glu-Lys-NH<sub>2</sub>, -Ser-Arg-Phe-Asp-Glu-Asp-Asp-Leu-Glu-NH<sub>2</sub>, -Gly-Ser-Gln-Asn-Leu-Ala-Ser-Leu-Glu-Glu-NH<sub>2</sub>, or – serine methyl ester; and wherein R<sub>5</sub> is –S-.
9. The method of claim 4, wherein the targeted imaging probe comprises Dhp(Pam<sub>2</sub>)-peptide MALP2.
10. The method of claim 4, wherein the targeted imaging probe comprises dipalmitoyl-S-glyceryl-L-Cys-Ser-(Lys)<sub>4</sub> (Pam<sub>2</sub>CSK<sub>4</sub>).
11. The method of claim 4, wherein the targeted imaging probe comprises tripalmitoyl-S-glyceryl-L-Cys-Ser-Lys-Lys-Lys-Lys (Pam<sub>3</sub>CSK<sub>4</sub>).
12. The method of claim 4, wherein the targeted imaging probe comprises the lipolanthionine peptide (2R,6R)-Pam<sub>2</sub>LanHda-Ser-(Lys)<sub>4</sub>-NH<sub>2</sub> (lipolan).
13. The method of claim 4, wherein the targeted imaging probe comprises Ac-PEGO-Dhc (Pam)<sub>2</sub>-Gly-Ser-PEGO-NH<sub>2</sub> (T-02).

14. The method of claim 4, wherein the targeted imaging probe comprises Ac-PEGO-Dhc(Pam)<sub>2</sub>-Ser-Arg-Phe-Asp-Glu-Asp-Asp-Leu-Glu-NH<sub>2</sub> (T-03; SEQ ID NO:5).
15. The method of claim 4, wherein the targeted imaging probe comprises Ac-PEGO-Dhc(Pam)<sub>2</sub>-Gly-Ser-Gln-Asn-Leu-Ala-Ser-Leu-Glu-Glu-NH<sub>2</sub> (T-05; SEQ ID NO:6).
16. The method of any one of claims 4 to 15, wherein the detectable label is a near-infrared (NIR) fluorophore.
17. The method of any one of claims 1 to 16, wherein the cancer cells are metastasized cancer cells.
18. The method of any one of claims 1 to 17, wherein the cancer cells are pancreatic cancer cells.
19. A composition comprising a targeted imaging probe, wherein the targeted imaging probe comprises a TLR2 ligand linked to a detectable label.
20. The composition of claim 19, wherein the targeted imaging probe has the structure



wherein R<sub>1</sub> is -CO-R<sub>6</sub>, wherein R<sub>6</sub> is C<sub>12</sub> to C<sub>18</sub> alkyl;

wherein R<sub>2</sub> is -CH<sub>2</sub>-O-CO-R<sub>7</sub>, wherein R<sub>7</sub> is any C<sub>12</sub> to C<sub>18</sub> alkyl;

wherein R<sub>3</sub> is R<sub>8</sub>-label, wherein R<sub>8</sub> is acetyl-PEGO- (Ac-PEGO), palmitoyl-, fluorescein-, acetyl-6-aminohexanoyl- (Ac-Aha), adapalenoil-, acetyl-11-aminoundecanoyl- (Ac-Aun), or tretinoyl-;

wherein R<sub>4</sub> is -Gly-D<sub>2</sub>Ser-PEGO-NH<sub>2</sub>, -Gly-D<sub>2</sub>Ser-NH<sub>2</sub>, -Cys-Ser-(Lys)<sub>4</sub>-NH<sub>2</sub>, -Gly-Asn-Asn-Asp-Glu-Ser-Asn-Ile-Ser-Phe-Lys-Glu-Lys-NH<sub>2</sub>, -Ser-Arg-Phe-Asp-Glu-Asp-Asp-Leu-Glu-NH<sub>2</sub>, -Gly-Ser-Gln-Asn-Leu-Ala-Ser-Leu-Glu-Glu-NH<sub>2</sub>, or -serine methyl ester; and

wherein R<sub>5</sub> is -S-.

21. The composition of claim 19, wherein the targeted imaging probe comprises dipalmitoyl-S-glyceryl-L-Cys-Ser-(Lys)<sub>4</sub> (Pam<sub>2</sub>CSK<sub>4</sub>).
22. The composition of claim 19, wherein the targeted imaging probe comprises tripalmitoyl-S-glyceryl-L-Cys-Ser-Lys-Lys-Lys-Lys (Pam<sub>3</sub>CSK<sub>4</sub>).
23. The composition of claim 19, wherein the targeted imaging probe comprises the lipolanthionine peptide (2R,6R)-Pam<sub>2</sub>LanHda-Ser-(Lys)<sub>4</sub>-NH<sub>2</sub> (lipolan).

24. The composition of claim 19, wherein the targeted imaging probe comprises Ac-PEGO-Dhc(Pam)<sub>2</sub>-Gly-Ser-PEGO-NH<sub>2</sub> (T-02).
25. The composition of claim 19, wherein the targeted imaging probe comprises Ac-PEGO-Dhc(Pam)<sub>2</sub>-Ser-Arg-Phe-Asp-Glu-Asp-Asp-Leu-Glu-NH<sub>2</sub> (T-03; SEQ ID NO:5).
26. The composition of claim 19, wherein the targeted imaging probe comprises Ac-PEGO-Dhc(Pam)<sub>2</sub>-Gly-Ser-Gln-Asn-Leu-Ala-Ser-Leu-Glu-Glu-NH<sub>2</sub> (T-05; SEQ ID NO:6).
27. A kit comprising two or more targeted imaging probe in two or more containers, wherein at least one the targeted imaging probe comprises a TLR2 ligand linked to a detectable label, wherein the detectable label is a near-infrared (NIR) fluorophore.
28. A composition for stimulating an immune response, the composition comprising an adjuvant, wherein the adjuvant comprises a TLR2 ligand.

Figure 1A




Figure 1B




Figure 2A




Figure 2B




Figure 2C




Figure 2D




Figure 3A




Figure 3B




Figure 3C




Figure 3D




Figure 4A




Figure 4B




Figure 4C





Figure 4D



8/25

Figure 5A





Figure 5B



9/25

Figure 6




Figure 7A






Figure 7B



10a/ 25


Figure 8A Bioluminescence



10b/25

Figure 8B

### Fluorescence



11/25

Figure 9





Figure 10



12/25

Figure 11




Figure 12A




Figure 12B





Figure 12C



14/25

Figure 12D




Figure 12E




Figure 12F





Figure 13A



16/25

Figure 13B




Figure 14





Figure 15A



18/25

Figure 15B




Figure 15C




Figure 16A




Figure 16B




Figure 16C




Figure 16D




Figure 17A




Figure 17B





Figure 17C



20a / 25

Figure 18





Figure 19



21a / 25

Figure 20A




Figure 20B




Figure 20C





Figure 20D



21b / 25

Figure 20E




Figure 20F




Figure 20G




Figure 21A





Figure 21B



22a / 25

Figure 22A




Figure 22B




Figure 22C




Figure 23




Figure 24




Figure 25

